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Summary 
Polymers are becoming preferred materials in biomedical applications 
because of their vast diversity of properties, functionalities and applications. 
Properties as mechanical strength, stability against degradation, 
biocompatibility and biodegradability, among others, have been attractive 
for different medical applications. One of the most interesting applications 
of these materials is drug delivery systems. Biodegradable polymers and 
copolymers are the preferred materials for the manufacture of a variety of 
devices for temporal applications in medicine and pharmacology; these 
biodegradable polymers can be chemically synthesized or biologically 
produced. Biotechnological polymers have attracted much attention because 
two main advantages; first, they are produced from renewable resources; 
and second, as they are biologically produced they are biocompatible, 
biodegradable and bioresorbable materials. Thus, modification of 
biotechnological polymers to obtain specific properties or functionalities is a 
good strategy for the development of promising biomedical materials. 
In this Thesis the water soluble biotechnological polymer         
poly(β,L-malic acid) (PMLA) was modified to change its hydrophilic 
character to produce non water-soluble polymers capable of forming 
particulate systems for drug encapsulation and controlled release. PMLA is 
a polyester-3 with a pendant carboxylic group; it is biocompatible, 
biodegradable and bioresorbable. The carboxylic side group can be 
substituted in order to modify the properties of the polymer. The polymer as 
polyelectrolyte, is also water-soluble. 
Different strategies were used for polymer derivatization: direct 
esterification and amidation through the activation of the carboxylic side 
groups with carbodiimides; ionic complex formation with a cationic drug 
(Doxorubicin); and esterification with aliphatic long chains by a two step 
method employing thiol-ene click reactions. Obtained PMLA derivatives 
resulted in hydrophobic or amphiphilic polymers, which were appropriated 
for nanoparticle formation, either by emulsion solvent evaporation or by 
precipitation dialysis techniques. 
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Derivatives physicochemical characterization was made by 1H and 13C 
nuclear magnetic resonance (NMR) spectroscopy, gel permeation 
chromatography (GPC) and differential scanning calorimetry. Hydrolytic 
degradation was followed by GPC and 1H NMR, while particles were 
observed by scanning electron microscopy and their size and surface charge 
characterized by dynamic light scattering and ζ-potential measurement. 
Assays of drug encapsulation and release were also performed and 
cytotoxicity tests were done on cancer cell lines. 
Nanoparticles (100-300 nm aprox.) were obtained from all PMLA 
derivatives, except for the ionic complex which formed microparticles. 
Nanoparticles showed potential as drug delivery systems since they were 
able to encapsulate the anticancer drugs Temozolomide and Doxorubicin, as 
well as the model drugs Theophylline and Carbamazepine. Drug release 
was assessed under physiological conditions; the release rate was found to 
depend on encapsulation method, drug and polymer derivative.  
Hydrolytic degradation assays showed that free malic acid and the 
organic compound derived from the reagent used for modification were the 
last products of aqueous degradation of PMLA derivatives. Cytotoxicity 
tests demonstrated the low toxicity of the synthesized derivatives. 
Results generated in this Thesis suggest that the biotechnological 
polymer PMLA is a material of interest as a platform for the design and 
development of biodegradable drug delivery systems with potential in the 
therapy of diseases considered today challenging for pharmacologic 
treatment. 
 
 
Key words: Poly(malic acid), biotechnological polymer, drug delivery system, 
biodegradable, biocompatible, nanoparticle, polymer modification, drug 
encapsulation, cancer, Temozolomide, Doxorubicin. 
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Resum 
Els polímers s'han convertit en els materials preferits per a ús 
biomèdic degut la gran diversitat de propietats, funcionalitats i aplicacions 
que tenen. Propietats com resistència mecànica, estabilitat en front de la 
degradació, biocompatibilitat i biodegradabilitat, entre d’altres, són 
atractives per a diverses aplicacions mèdiques. Una de les aplicacions més 
interessants d'aquests materials és com a sistemes d'alliberament controlat 
de fàrmacs. Els polímers i copolímers biodegradables són els materials 
predilectes per a la fabricació d'una varietat de dispositius per a aplicacions 
temporals en medicina i farmacologia; aquests polímers biodegradables 
poden ser sintetitzats químicament o produïts biològicament. Els polímers 
biotecnològics han captat l’atenció per dues raons principals; primer, 
s’obtenen a partir de fonts renovables; i segon, que en ser produïts 
biològicament són materials biodegradables, biocompatibles i 
bioassimilables. Per això, la modificació de polímers biotecnològics per 
obtenir propietats o funcionalitats específiques és una bona estratègia per al 
desenvolupament d'un material biomèdic prometedor. 
En la present Tesi el polímer biotecnològic, soluble en aigua,  àcid 
poli(β,L-màlic) (PMLA) s’ha modificat per canviar el seu caràcter hidrofílic 
per tal de produir polímers insolubles en aigua capaços de formar sistemes 
de partícules per a l’encapsulació i l’alliberament controlat de fàrmacs. El 
PMLA és un polièster-3 amb un grup carboxílic lateral; és biocompatible, 
biodegradable i bioassimilable. El grup carboxílic lateral pot ser substituït 
per tal de modificar les propietats del polímer. El polímer com a 
polielectròlit, és també soluble en aigua.  
En aquest treball s’han utilitzat diferents estratègies per a la 
derivatització del polímer: l’esterificació i l’amidació directes, mitjançant 
l'activació dels grups carboxílics laterals amb carbodiimides; la formació de 
complexos iònics amb un fàrmac catiònic (Doxorrubicina); i l’esterificació 
amb cadenes alifàtiques llargues, utilitzant un mètode en dos passos 
mitjançant reaccions clic tiol-è. Els derivats de PMLA obtinguts van resultar 
ser polímers hidrofòbics o anfifílics, apropiats per a la formació de 
nanopartícules, ja sigui pel mètode d'emulsió evaporació de solvent o per la 
tècnica de precipitació diàlisi. 
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La caracterització físico-química dels derivats es va realitzar mitjançat 
espectroscòpia de ressonància magnètica nuclear (RMN) de 1H i 13C, 
cromatografia de permeació en gel (GPC) i calorimetria diferencial de 
rastreig. El seguiment de la degradació hidrolítica es va fer mitjançant GPC i 
1H RMN, mentre que les partícules van a ser observades amb microscòpia 
electrònica de rastreig i la seva mida i càrrega superficial caracteritzades 
mitjançant dispersió de llum i mesurament del potencial-ζ. En van realitzar 
estudis sobre l’encapsulació de fàrmacs i el seu alliberament, així com 
assajos de citotoxicitat sobre línies de cèl·lules canceroses. 
En van obtenir nanopartícules (100-300 nm aprox.) amb tots els 
derivats, excepte en el cas dels complexos iònics que formen micropartícules. 
Les nanopartícules van mostrar potencial com a sistemes d’alliberament 
controlat ja que va ser possible l'encapsulació dels fàrmacs anticàncer 
Temozolomida i Doxorrubicina, així com dels fàrmacs models Teofilina i 
Carbamazepina. L'alliberament de fàrmacs es va avaluar en condicions 
fisiològiques; la taxa d'alliberament es va trobar dependent del mètode 
d'encapsulació, del fàrmac i del derivat polimèric utilitzat.  
Els assajos de degradació hidrolítica mostren que l'àcid màlic i la 
molècula orgànica derivada del compost utilitzat per a la modificació són els 
últims productes de la degradació hidrolítica dels derivats de PMLA. Les 
proves de citotoxicitat demostren la baixa toxicitat dels derivats sintetitzats. 
Els resultats generats en aquesta Tesi suggereixen que el polímer 
biotecnològic PMLA és un material d’interès com a plataforma per al 
disseny i desenvolupament de sistemes biodegradables d'alliberament 
controlat de fàrmacs amb potencial en la teràpia de malalties considerades 
avui dia un  repte per el tractament farmacològic. 
 
Paraules clau: Àcid polimàlic, polímer biotecnològic, sistema d'alliberament 
controlat, biodegradable, biocompatible, nanopartícula, modificació de polímers, 
encapsulació de fàrmacs, càncer, Temozolomide, Doxorrubicina. 
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Resumen 
Los polímeros se han convertido en los materiales preferidos para 
usos biomédicos debido a la gran diversidad de propiedades, 
funcionalidades y aplicaciones que poseen. Propiedades como resistencia 
mecánica, estabilidad a la degradación, biocompatibilidad y 
biodegradabilidad, entre otras, son atractivas para diversas aplicaciones 
médicas. Una de las aplicaciones más interesantes de estos materiales son los 
sistemas de liberación controlada de fármacos. Los polímeros y copolímeros 
biodegradables son los materiales predilectos para la fabricación de una 
variedad de dispositivos de uso temporal en medicina y farmacología; estos 
polímeros biodegradables pueden ser sintetizados químicamente o 
producidos biológicamente. Los polímeros biotecnológicos han captado gran 
atención por dos razones principales; primero, son obtenidos a partir de 
recursos renovables; y segundo, que al ser biológicamente producidos, estos 
son biodegradables, biocompatibles y bioasimilables. Por esto, la 
modificación de polímeros biotecnológicos para la obtención de propiedades 
o funcionalidades específicas es una buena estrategia para el desarrollo de 
un material biomédico prometedor. 
En la presente Tesis el polímero biotecnológico, soluble en agua,  
acido poli(β,L-málico) (PMLA) se modificó para cambiar su carácter 
hidrofílico para producir polímeros insolubles en agua capaces de formar 
sistemas particulados para la encapsulación y liberación controlada de 
fármacos. El PMLA es un poliéster-3 con un grupo carboxílico lateral; es 
biocompatible, biodegradable y bioasimilable. El grupo carboxílico lateral 
puede ser substituido para modificar las propiedades del polímero. El 
polímero como polielectrolito, es también soluble en agua. 
En este trabajo se utilizaron diferentes estrategias para la 
derivatización del polímero: la esterificación y amidación directas, mediante 
la activación de los grupos carboxílicos laterales con carbodiimidas; la 
formación de complejos iónicos con un fármaco catiónico (Doxorrubicina); y 
la esterificación con cadenas alifáticas largas, utilizando un método de dos 
pasos mediante reacciones click tiol-eno. Los derivados de PMLA obtenidos 
resultaron ser polímeros hidrofóbicos o anfifílicos, apropiados para la 
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formación de nanopartículas, ya sea por el método de emulsión evaporación 
de solvente o por la técnica de precipitación diálisis. 
La caracterización fisicoquímica de los derivados se realizó mediante 
espectroscopia de resonancia magnética nuclear (RMN) de 1H y 13C, 
cromatografía de permeación en gel (GPC) y por calorimetría diferencial de 
barrido. La degradación hidrolítica fue monitoreada mediante GPC y 1H 
RMN, mientras que las partículas fueron observadas con microscopía 
electrónica de barrido y su tamaño y carga superficial caracterizadas 
mediante dispersión de luz y medición del potencial-ζ. Estudios sobre la 
encapsulación de fármacos y su liberación fueron realizados, así como 
ensayos de citotoxicidad sobre líneas de células cancerígenas. 
Se obtuvieron nanopartículas (100-300 nm aprox.) con todos los 
derivados, excepto para el complejo iónico que formaron micropartículas. 
Las nanopartículas mostraron potencial como sistemas de liberación 
controlada ya que fue posible la encapsulación de los fármacos 
anticanerígenos Temozolomida y Doxorrubicina, así como de los fármacos 
modelos Teofilina y Carbamazepina. La liberación de fármacos se evaluó en 
condiciones fisiológicas; la tasa de liberación se encontró dependiente del 
método de encapsulación, el fármaco y el derivado polimérico utilizado.  
Los ensayos de degradación hidrolítica muestran que el ácido málico 
y la molécula orgánica derivada del compuesto utilizado para la 
modificación son los últimos productos de la degradación hidrolítica de los 
derivados de PMLA. Las pruebas de citotoxicidad demostraron la baja 
toxicidad de los derivados sintetizados. 
Los resultados generados en esta Tesis sugieren que el polímero 
biotecnológico PMLA es un material de interés como plataforma para el 
diseño y desarrollo de sistemas biodegradables de liberación controlada de 
fármacos con potencial en la terapia de enfermedades consideradas hoy día 
un reto para el tratamiento farmacológico. 
 
Palabras clave: Acido polimálico, polímero biotecnológico, sistema de liberación 
controlada, biodegradable, biocompatible, nanopartículas, modificación de 
polímeros, encapsulación de fármacos, cáncer, Temozolomide, Doxorrubicina. 
vii 
 
Index 
 
 Pag. 
Summary i 
  
Acronyms xii 
  
1. Introduction  1 
1.1. General objective 3 
1.2. Specific objectives 3 
1.3. Outline 4 
  
2. Biodegradable Polymers for Drug Delivery Systems 6 
2.1. Introduction 6 
2.2. Biotechnological polymers: poly(β,L-malic acid) 13 
2.2.1. Chemical structure and physicochemical 
properties 
13 
2.2.2. Biological synthesis 15 
2.2.3. Chemical synthesis 17 
2.2.4. Degradability 18 
2.2.5. PMLA modification 19 
2.2.6. Biomedical applications 21 
2.2.7. Critical aspects of PMLA 22 
2.3. Biotechnological polymers: poly(γ-glutamic acid) 23 
2.4. Polymer derivatization 27 
2.4.1. Esterification 30 
2.4.2. Amidation 31 
viii 
 
2.4.3. Ionic coupling 32 
2.4.4. Thiol-ene click reaction 33 
2.5. Nanoparticles for drug delivery systems 36 
2.5.1. Emulsion solvent evaporation technique 39 
2.5.2. Nanoprecipitation: self-assembled structures  41 
2.5.3. Drug encapsulation and release 43 
  
3. Materials and Methods 46 
3.1. Materials 46 
3.2. Synthesis of poly(β,L-malic acid) derivatives 47 
3.3. Hydrolytic degradation 47 
3.4. Nanoparticles preparation and drug encapsulation 49 
3.5. Drug loaded films 52 
3.6. In vitro drug release 52 
3.7. Cell lines and culture media 54 
3.8. Cytotoxicity tests and nanoparticles cellular uptake 54 
3.9. Measurements 56 
  
4. Poly(methyl malate) Nanoparticles: Formation, 
Degradation, and Encapsulation of Anticancer Drugs 
59 
4.1. Introduction 61 
4.2. Results and discussion 63 
4.2.1. Synthesis and characterization of PAALM-1 63 
4.2.2. Nanoparticles formation and characterization 63 
4.2.3. Hydrolytic degradation 67 
4.2.4. Cytotoxicity 71 
4.2.5. Drug encapsulation and in vitro release 72 
4.3. Conclusions 75 
  
ix 
 
5. Nanoparticles of Esterified Polymalic Acid for Controlled 
Anticancer Drug Release 
76 
5.1. Introduction 78 
5.2. Experimental 80 
5.2.1. PMLA esterification with ethanol and 1-butanol 80 
5.3. Results and discussion 80 
5.3.1. Synthesis and characterization 80 
5.3.2. Hydrolytic degradation 83 
5.3.3. Nanoparticle formation  88 
5.3.4. Drug encapsulation and in vitro release 91 
5.3.5. Cell viability and nanoparticles cellular uptake 93 
5.4. Conclusions 97 
  
6. Modification of Microbial Polymalic Acid With 
Hydrophobic Amino Acids for Drug-Releasing 
Nanoparticles 
98 
6.1. Introduction 100 
6.2. Experimental 101 
6.2.1. Synthesis of poly(β,L-malic acid)-graft-AA 101 
6.3. Results and discussion 102 
6.3.1. Amino acid grafting on PMLA 102 
6.3.2. Hydrolytic degradation 105 
6.3.3. Nanoparticle formation  109 
6.3.4. Nanoparticle cytotoxicity 111 
6.3.5. Drug encapsulation and in vitro release 112 
6.4. Conclusions 115 
  
 
 
 
  
x 
 
7. Self-Assembled of Ionic Complexes from Poly(β,L-Malic 
Acid) for Drug Delivery 
116 
7.1. Introduction 118 
7.2. Experimental 120 
7.2.1. PMLA/Doxorubicin ionic complexes synthesis 120 
7.3. Results and discussion 120 
7.3.1. Synthesis and characterization 120 
7.3.2. Thermal characterization 125 
7.3.3. Particles formation and characterization 127 
7.3.4. Hydrolytic degradation mechanism 130 
7.3.5. In vitro drug release 132 
7.4. Conclusions 136 
  
8. Modification of Biotechnological Polymers by Thiol-Ene 
Click Reaction: Nanoparticle Formation and Drug 
Encapsulation 
137 
8.1. Introduction 139 
8.2. Experimental 141 
8.2.1. Esterification reactions 141 
8.2.2. Thiol-ene click reactions 142 
8.3. Results and discussion 142 
8.3.1. Comb-like polymers synthesis  142 
8.3.2. Thermal characterization 148 
8.3.3. Nanoparticles formation and characterization 150 
8.3.4. Hydrolytic degradation 153 
8.3.5. Drug encapsulation and in vitro release 157 
8.4. Conclusions 
 
 
 
162 
xi 
 
9. General Conclusions  163 
  
Appendix: Support Information  167 
  
References 174 
  
Acknowledgments 183 
  
About the Author 185 
  
Publications and Communications 186 
 
xii 
 
Acronyms 
 
°C Celsius degrees 
AA   Amino acid 
Abs Absorbance 
AIC 5-aminoimidazole-4-carboxamide 
AGAUR Agency for administration of university and 
research grants (by its Spanish initials) 
ATCC American type culture collection 
ATR   Attenuated total reflectance 
BBB Blood brain barrier 
CBZ Carbamazepine 
cm  Centimetre 
CONACyT National science and technology council (by 
its Spanish initials) 
coPGGA-AlxHy coPoly(α-allyl-β,L-glutamate-co-glutamic acid) 
coPGGA-PrSOcxHy coPoly(α-3-octylthio-propyl-β,L-glutamate-co-
glutamic acid) 
coPGGA-PrSdoDxHy coPoly(α-3-dodecylthio-propyl-β,L- 
glutamate-co-glutamic acid) 
coPGGA-PrShxDxHy coPoly(α-3-hexadecylthio-propyl-β,L- 
glutamate-co-glutamic acid) 
coPMLA-AlxHy coPoly(α-allyl-β,L-malate-co-malic acid) 
coPMLA-BuxHy coPoly(α-butyl-β,L-malate-co-malic acid) 
coPMLA-EtxHy coPoly(α-ethyl-β,L-malate-co-malic acid) 
coPMLA-PrSOcxHy coPoly(α-3-octylthio-propyl-β,L-malate-co-
malic acid) 
coPMLA-PrSdoDxHy coPoly(α-3-dodecylthio-propyl-β,L-malate-co-
malic acid) 
coPMLA-PrShxDxHy coPoly(α-3-hexadecylthio-propyl-β,L-malate-
co-malic acid) 
Da Dalton 
xiii 
 
DAPI  4',6-diamidino-2-phenylindole 
DCC Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DCU Dicyclohexylurea 
DDS Drug delivery system 
DLS Dynamic light scattering 
DMPA  2,2-Dimethoxy-2-phenylacetophenone 
DMSO Dimethylsulfoxyde 
D2O Deuterated water 
DOX Doxorubicin 
DSC Differential scanning calorimetry 
EE Encapsulation efficiency 
Et Ethyl 
EPR  Enhanced permeation retention 
F Phenylalanine 
FDA  Food and drug administration 
FT-IR  Fourier transform infrared spectroscopy 
GPC  Gel permeation chromatography 
GRAS   Generally regarded as safe 
h Hour 
HPLC  High performance liquid chromatography 
HFIP Hexafluoro-2-propanol 
I Ionic strength 
L Leucine 
Leu Leucine 
MHz  Megahertz 
k Kilo (103) 
μg Microgram 
μm Micrometre 
μM Micromolar 
M Molar 
MATGAS  Materials and Gases 
Me Methyl 
xiv 
 
MEM Minimum essential medium 
mg Milligram 
MICINN Science and innovation ministry (by its 
Spanish initials) 
min Minute 
mL Milliliter 
MLABn Benzyl malolactonate 
mm Millimetre 
mM Millimolar 
mmol   Millimol 
ms Millisecond 
mV  Millivolt 
Mw Molecular weight (weight average) 
MWCO Molecular weight cut-off 
MTS Yellow [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt] 
NEAA  Non essential amino acids 
NIH National institutes of health 
nm Nanometre 
NMP   N-methyl-pyrrolidone 
NP Nanoparticle 
NMR Nuclear magnetic resonance 
O/W Oil/water 
PAALM-1 Poly(α-methyl-β,L-malate) 
PAALM-L-X coPoly(α-leucine ethyl ester-β,L-malate-co-
malic acid) 
PAALM-F-X coPoly(α-phenylalanine methyl ester-β,L-
malate-co-malic acid) 
PB Phosphate buffer 
PC Poly(ε-caprolactone) 
Pd. Polydispersity 
PEG Polyethylene glycol 
xv 
 
PGA Poly(glycolic) acid 
PGGA Poly(γ-glutamic) acid 
pH Potential of hydrogen 
PHA Poly(hydroxyalkanoate) 
Phe  Phenylalanine 
pKa Acid dissociation constant 
PLA Poly(lactic acid) 
PLG Poly(lactide-co-glycolide) 
PLGA Poly(lactic-co-glycolic acid) 
PMLA Poly(β,L-malic acid) 
PMLA-Bn Poly(α-benzyl-β,L-malate) 
PMLA-Bu Poly(α-butyl-β,L-malate) 
PMLA-Et Poly(α-ethyl-β,L-malate) 
PMLA-NHS Poly(α-N-hydroxysuccinimidyl-β,L-malate) 
ppm Parts per million 
PVA  Poly(vinyl alcohol) 
ROP Ring opening polymerization 
RT Room temperature 
s Second 
SEM Scanning electron microscopy 
TEA Triethylamine 
TEO Theophylline 
Tg Glass transition temperature 
TCA Tricarboxylic acid 
TGA Thermogravimetric analysis 
THF Tetrahydrofuran 
TMZ Temozolomide 
UV-Vis Ultraviolete-visible 
v Volume 
w Weight 
W Watt 
  
1 
 
1 
 
Introduction  
Knowledge concerning how to obtain, process and use materials 
over time has been a key element for the civilization progress. At the 
beginning, there was the rock era in where the first tools were 
developed; later the metal era which allowed more sophisticated 
instruments and afterward the industrial revolution. Now we are 
witnessing the era of synthetic materials that is predominated by 
polymeric materials which are going beyond traditional materials with 
the possibility of creating smart materials. 
 Polymers are becoming preferred materials because of their vast 
diversity of properties, functionalities and applications. A relevant area 
that has put a lot of interest in polymeric materials is the medic field; 
properties as mechanical strength, stability against degradation, 
biocompatibility and biodegradability, among others, have been 
attractive for different medical applications. One of the more interesting 
applications is drug delivery systems, which in the last decades have 
presented a fast expansion because of the progress in our knowledge in 
different areas like molecular biology, biotechnology, nanotechnology, 
pharmacology and material science. The design and development of new 
biodegradable materials with specific functionalities is in the scope of 
researchers to achieve an effective and efficient system for controlled 
drug release.  
Among these new polymeric materials we can make a two major 
class subdivision, those chemically synthesized and those from 
Chapter 1 
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biological origin which are produced biotechnologically. The last ones 
have two main advantages; first they are produced from renewable 
resources; and second, because they are biologically produced they are 
biocompatible, biodegradable and bioresorbable materials. Thus, 
modification of biotechnological polymers to obtain specific properties 
or functionalities is a good strategy for the development of a promising 
biomedical material. 
One of these promising biotechnological polymers is poly(β,L-
malic acid) (PMLA), which has been recently under research for 
biomedical applications as it has been classified as biocompatible, non-
immunogenic and bioresorbable material. For drug delivery systems the 
most prominent system has been developed as a soluble conjugate, 
Polycefin, which consist in a multifunctional macromolecule with PMLA 
as a backbone and different pendant functional moieties (i.e. PEG chains, 
monoclonal antibodies, fluorescents probes, bioactive compounds, 
membrane disrupting groups) for the treatment of brain and breast 
cancer. In our group we have been working in the development of solid 
particulate delivery systems; first works were made with methylated 
PMLA which evidenced the potential of PMLA for particle formation; 
nevertheless, methanol released from this derivative could result in cell 
toxicity. The main focus of this Thesis is the generation of low cytotoxic 
derivatives, from the modification of biotechnologically produced 
PMLA, and the exploration of a post-polymerization modification 
technique which could allow multi-functional derivatization of PMLA 
for solid nanoparticulated systems for controlled drug delivery. 
 
 
 
 
 
 
                           Introduction 
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1.1. General objective  
 
Modification of the biotechnological polymer poly(β,L-malic acid), 
by the shifting of its hydrophilic/hydrophobic character, for preparation 
of nanoparticles capable of drug encapsulation with potential as drug 
delivery systems. 
 
1.2. Specific objectives 
 
i. Formation and characterization of poly(α-methyl β,L-malate) 
nanoparticles for Temozolomide and Doxorubicin encapsulation. 
 
ii. Synthesis and characterization of poly(α-ethyl β,L-malate) and 
poly(α-butyl β,L-malate) 50 and 100 % modified, nanoparticle 
formation by two different methods for Temozolomide and 
Doxorubicin encapsulation. 
 
iii. Grafting of leucine ethyl ester and phenylalanine methyl ester on 
poly(β,L-malic acid), characterization and nanoparticle formation 
for Temozolomide and Doxorubicin encapsulation. 
 
iv. Ionic complex formation and characterization between poly(β,L-
malic acid) and Doxorubicin, for a pH dependent drug release 
system. 
 
v. Synthesis and characterization of comb-like polymers by grafting 
long aliphatic chains through thiol-ene click reactions on poly(β,L-
malic acid), nanoparticle formation and drug encapsulation. A 
comparative study with poly(γ-glutamic acid). 
 
 
Chapter 1 
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1.3. Outline 
In this Thesis the water soluble biotechnological polymer, poly(β,L-
malic acid), was modified to shift its hydrophilic character to produce a 
non water-soluble polymer capable of forming particulate systems for 
drug encapsulation and controlled release.  The present work is divided 
in nine chapters as follows: 
Chapter 1- The current chapter presents a general introduction, 
aims and organization of the Thesis. 
Chapter 2- This chapter attends to a review of the polymers and 
techniques used in this Thesis with special focus on PMLA and its 
derivatization for biomedical applications.  
Chapter 3- In this section the general materials and methods used 
for the research are summarized.  
Results of the Thesis are divided in chapters which correspond to 
different modification strategies, as follows: 
Chapter 4- This chapter presents a study of nanoparticle formation 
by emulsion solvent-evaporation method of poly(α-methyl β-malate) 
with different surfactants. PMLA was previously methylated with 
diazomethane, hydrolytic degradation and cytotoxicity were studied and 
Temozolomide and Doxorubicin encapsulated. 
Chapter 5- This part treats about the esterification of PMLA with 
ethanol and 1-butanol to obtain hydrophobic homopolymers and 
amphiphilic copolymers. Polymers characterizations, hydrolytic 
degradation, nanoparticles formation by two different methods, drug 
encapsulation and release are presented, as well as cytotoxicities and 
cellular uptake assays are discussed.  
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Chapter 6- This chapter deals with the modification of PMLA with 
hydrophobic amino acids with the aim of making amphiphilic molecules 
capable of self-assembling into nanoparticles for drug encapsulation. 
Results include polymer characterization, hydrolytic degradation, 
particle formation, drug encapsulation and cytotoxicity studies.  
Chapter 7- This section makes reference to the ionic complexation 
of PMLA with the cationic drug Doxorubicin. The change of 
hydrophilicity for particle formation is directly driven by the drug 
complexation on the polymer. Characterization of the complex, 
hydrolytic degradation and drug release are presented. 
Chapter 8- This chapter presents the synthesis of comb-like 
copolymers of PMLA and PGGA as a comparative study, through the 
grafting of aliphatic long lateral chains by thiol-ene click reactions. 
Amphiphilic copolymers are able to self-assemble in particles for 
encapsulation of drug models. Characterization, hydrolytic degradation, 
particle formation and drug encapsulation/release studies are presented.  
Chapter 9- Last chapter summarize the general conclusions of the 
performed research. 
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2 
 
Biodegradable Polymers for  
Drug Delivery Systems 
 
 
2.1. Introduction 
The history of materials in medicine goes far into the past time to 
the Egyptian culture, which used linen sutures to close large wounds. 
Nowadays, material and medical sciences have evolved into a new age 
of medical materials or biomaterials. There are two main kinds of 
materials that are going to be introduced in a body, those for prosthetic 
purposes and those whose contribution is required for a limited period 
of time (Figure 2.1). For many years, stable materials were used without 
distinction between permanent and time-limited applications. Polymers 
became interesting materials for biomedical applications because their 
mechanical properties and diverse functionalities. Long time ago, 
compounds derived from biopolymers like animal sinews were used, but 
the discovery of fiber forming and hydrolysability of poly(glycolic acid) 
(PGA) was the first step towards the development of a synthetic 
biodegradable and bioresorbable polymer for time-limited applications.1  
The history of synthetic degradable and biodegradable polymers 
started in 1960s when Schmitt and Polestina, at Davis & Geck, 
synthesized and patented poly(glycolic acid) for use it as biodegradable 
suture. Ethicon added lactic acid to the composition to make the 
biodegradable poly(lactic-co-glycolic acid) (PLGA).2 It was realized that 
the water sensitive aliphatic polyesters derived from glycolyde and 
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lactide could be of interest to process therapeutic aids having lifetimes 
comparable with the healing time of injured soft and hard tissues with 
great potential for a variety of medical applications.3 Around the 70s 
years the polymers evaluated as biomaterials had increased rapidly 
(Table 2.1), however the number of compounds that have reached 
commercial application is still small.4 
 
Permanent Temporal
a
b
c d e
f
 
Figure 2.1. Permanent and temporal medical applications of polymers: a) bond 
prosthesis, b) joint prosthesis, c) tissue regeneration scaffolds, d) drug delivery 
systems, e) chirurgical sutures and f) arterial stents. 
 
Within the last decades a variety of natural and synthetic materials 
has been extensively studied for possible biomedical applications, such 
as bone or joint prosthesis, artificial blood vessels and surgical sutures, 
among others. However, one of the most attractive potential uses of 
these polymers is in the formulation of novel drug delivery systems for 
parenteral administration.5 Here, the polymeric material is an essential 
part of a therapeutic system which is designed to achieve either control 
over drug delivery rate, temporal control, or for a selective delivery at a 
specific site of action, spatial control.6  
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Table 2.1. Polymers in biomedicine and their applications.
Polymer family Origen
Degradation
products
Applications
Polyesters:
(Poly: lactic acid, glycolic 
acid, malic acid, hydroxy 
acids, caprolactone)
Chemical/natual 
Lactic acid
Glycolic acid
Malic acid
Hydroxy acids
Sutures, Stents
Drug delivery
Tissue scaffolds
Polysaccharides: 
(Chitosan, Alginates)
Chemistry on chitin Unknow
Drug delivery
Hydrogels
Polyamides:
(Poly: glutamic acid, 
lysine, aspartic acid)
Chemical/natural Glutamic acid
Drug delivery
Hydrogels
Sutures
Polyanhydrides Chemical Chemicals
Surgery and 
pharmacology
Poly(orthoesters) Chemical Chemicals Drug delivery
Poly(methyl 
methacrylate)
Chemical
Non-
biodegradable
Drug delivery
Prosthesis
Contact lenses
Fracture fixation
Polytetrafluoroethylene Chemical
Non-
biodegradable
Heart valves
Vascular grafts
Nerve repair
 
 
Conventional pharmacotherapy involves the use of drugs whose 
absorption and therefore bioavailability depends on many factors, such 
as solubility, pKa, molecular weight and chemical stability. In general, 
especially their low molecular weights, confers them the capacity to 
cross various body compartments and access numerous cell types and 
subcellular organelles. However, this form of indiscriminate distribution 
leads to the occurrence of side effects and the need of higher doses of the 
drug to achieve a satisfactory pharmacological response. Thus, the 
success of medical treatments not only depends on the therapeutic agent, 
but also in its bioavailability in the site of action inside the body.7 DDS 
seeks to improve the pharmacological activity of drugs by enhancing 
absorption, distribution, metabolism and excretion (bioavailability); they 
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are usually high molecular weight carriers such as nano and micro 
particles, capsules, capsosomes, micelles and dendrimers, in which the 
drug is embedded or covalently bound.8 These systems have been used 
for the transport and delivery of macromolecules like peptides and 
proteins,9,10 gens,11,12 vaccines13,14 and drugs of low molecular weight.6  
Drug delivery systems start to develop in the late 60s, Dupont 
researchers’ added peptide drugs to PLA and fabricated microparticles 
and pellets for DDS; other laboratories were making clinical tests on 
PLGA microencapsulated steroids for a contraceptive method. First 
commercialized DDS were macroscopic devices, like the ophthalmic 
insert called the Ocusert® that released the anti-glaucoma drug 
pilocarpine or the different contraceptive subcutaneous implants.2 The 
pioneer work of Langer and Folkman, who showed that proteins could 
be released from non-degradable polymers matrices15 may have 
stimulated to think about other ways to delivery such drugs, such as by 
loading them in biodegradable polymers. Other biodegradable polymers 
started to be developed like poly(ethylene glycol terephtalate), 
polyorthoesters, polyanhydrides and block copolymers of PLGA-PEG.  
In the late 70s the concept of polymer-drug conjugate or nano-
therapeutics became on the table. Three concepts were key factors for the 
development of nano-therapeutics. First, the concept of PEGylation, 
which refers to poly(ethylene glycol) conjugated with drugs or vehicles 
to enhance blood circulation times; second, the concept of active 
targeting by the use of cell recognition molecules in the DDS; and third, 
the enhanced permeation retention (EPR), where nano-scale carriers are 
entrapped in solid tumors due to the leaky vasculature of the fast 
growing tumor, which is also called passive targeting.2,16 Since then a lot 
of formulations have been designed and tested, micelles, liposomes, 
nanoparticles, conjugates, for the transport and delivery of hydrophilic 
and hydrophobic drugs. It is possible to classify two types of polymeric 
carriers, macromolecular-conjugates carriers, where the drug is 
covalently linked to a macromolecule soluble in body fluid; and colloidal 
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carriers, where the active compound is entrapped in a solid matrix 
formed from a macromolecule.5 The first clinically approved injectable 
degradable microparticulate DDS was Decapeptyl® LP, a treatment for 
prostate cancer, launched in 1986 in Europe and still in the market.2  At 
nanoscale, only some drug-loaded liposomes like Doxil® had reached its 
application. Figure 2.2 shows the time line of DDS development. 
Nanotechnology and drug controlled release have become 
important since the USA initiative in the year 2000, in which they 
dedicated more than 20 research centers to these topics. Five of them 
were designated to the development of what some ones consider the 
future of the pharmaceutical industry, and that the prognostics see the 
technology for drug controlled release at nano level as reality in 2020. 
But the development of nanotechnology has brought considerable 
attention to the problem of toxicity of nanomaterials, because of its 
unique physicochemical properties. A crucial feature of these systems is 
the mechanism by which they are removed from the body; they may be 
excreted directly via renal clearance or biodegraded and metabolized. 
The problem has been addressed in many cases by the development of 
biodegradable polymers, optimization of chemical composition, surface 
modification and other approaches.17  
1950 1960 1970 1980 1990 2000 2010
PGGA
PGA
PLA
First report
PMLA biosynthesis
Chitosan
Alginate
PMLA
synthesis
Polymer‐drugs
conjugates
Nanomedicine
impulse
PLA microparticles
peptidedrugs
Ocusert®
(macro DDS)
Decapeptyl®
(microparticles)
Polycefin®
(multifunctional
PMLA conjugate)
Drug delivery
patches
Osmotic pump
capsules
Hydrogel
systems
Targeted
delivery
Doxyl®
(nanoparticles‐
liposomes)  
Figure 2.2. Time line of DDS development.  
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Nowadays, biodegradation and absorption of any high molecular 
weight material which is to be introduced in the body for a limited 
period of time must be considered as a prerequisite for applications in 
human therapy;18 considering this, biodegradable polymers and 
copolymers are the preferred materials for the manufacture of a variety 
of devices that are today widely applied in medicine and 
pharmacology;19 specifically they have become increasingly important in 
the development of DDS, for which they must meet very specific 
requirements: a) biocompatibility of the polymer and its degradation 
products, b) sufficient mechanical strength to meet the needs of specific 
applications, c) degradation kinetics matching the biological process,     
d) solubility in various solvents, e) chemical, structural and application 
versatility, f) economically acceptable shelf life and g) approval of the 
European Medicine Evaluation Agency or from the Food and Drug 
Administration (USA).20 
We must differentiate among the terms bioabsorbable, 
biodegradable and bioresorbable (bioassimilable); bioabsorbable refers to 
a polymeric material or device that can dissolve in body fluids without 
any molecular mass decrease. Biodegradable is used for polymer 
materials which break down to macromolecule degradation but no proof 
of elimination from the body. And last bioresorbable, in which is 
assumed the complete elimination of the initial foreign material and of 
degradation products with no residual effects.4 
Latest advances in DDS are based on the use of biopolymers or 
biodegradable synthetic polymers, which allow repeated human 
treatment without deposition and storage diseases. This has stimulated 
the modification of naturally occurring biopolymers and the 
development of new synthetic ones.20,21 In general, research and 
production of biopolymers and metabolite-based polymers have 
captured great interest by the elucidation of its potential in the 
biomedical field, because of their biological origin they are a priori 
considered as a biodegradable and bioresorbable by the human body.22 
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The most studied and used polymeric materials in biomedicine are 
the polyesters poly(lactic acid), poly(glycolic acid), polycaprolactone 
(PC) and their copolymers.7 Other new biodegradable polymers have 
been studied like polyamides, polyanhydrides, polyorthoesters and 
biotechnological polymers; among these there are two biopolymers that 
present great advantage over PLA and PGA, poly(β-malic acid) (PMLA) 
and poly(γ-glutamic acid) (PGGA). It is the functionality that the lateral 
carboxylic group confers to them, which allows their relatively easy and 
direct chemical modification, to modulate properties like their solubility, 
degradation rate, targeting molecules insertion, stability and release of 
encapsulated drugs, among others. 
Even though significant advances have been made in the field of 
micro and nano DDS, there are still many challenges in this field, like 
standardized evaluation methods and newer site directed polymers.23 
There is an interconnection between the development of DDS in the 
future and the increment of our knowledge in biology; the better we 
know how the live systems work, the easier it will be to design nano-
scale DDS that are serum stable, efficiently taken by specific cells, able to 
escape the endosomes and target specific sites or pathways inside the 
cell. Polymer based DDS are an attractive area with innumerable 
opportunities for further research and development; however, the 
success in these areas depends on the intense efforts of scientists from 
different disciplines such as biology, pharmacy and polymer science 
(Figure 2.3).7 
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Figure 2.3. Disciplines involved in drug delivery systems development. 
 
 
2.2. Biotechnological polymers: poly(β,L-malic acid) 
2.2.1. Chemical structure and physicochemical properties 
Poly(β,L-malic acid) belongs to the polyester family, it is derived 
from malic acid (α-hydroxy succinic acid), a chiral hydroxy acid whose L 
enantiomer is a natural bioorganic compound present in a great variety 
of fruits and vegetables and a mammal metabolite of the tricarboxylic 
acid cycle (TCA). It is linked by ester bonds which are formed between 
the hydroxyl group and the carboxyl group located at the β position 
(polyester 3); in difference with most of the polyesters it has a lateral 
carboxylic group pendant from the repetitive unit α-carbon, giving an 
asymmetric character to this carbon which is naturally found as stereo- 
and regio- regular polymer only in L configuration; thus it is an optically 
active polymer. PMLA can be produced by microorganism 
fermentation24 and also chemically synthesized by direct 
polycondensation or by ring opening polymerization making possible to 
obtain poly(α,L-malic acid) or poly(β,L-malic acid) or a copolymer of both 
(Figure 2.4).20 
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PMLA is highly hygroscopic and water soluble, in both its acid 
and salt forms. Particularly, PMLA from Physarum polycephalum is 
obtained as a white semi-crystalline powder, soluble in most polar 
solvents. It is a semi-crystalline polymer with a melt temperature around 
210 °C and a thermal decomposition close to the melting of the polymer 
which evolves by an unzipping depolymeraziton mechanism with 
generation of fumaric acid.25  It is a weak acid with a pKa between 3 and 
4 depending in its origin. All carboxylic groups are ionized at neutral 
pH, thus the polymer is highly charged under physiological conditions.26 
The lateral carboxylic group of PMLA gives it a polyelectrolyte character, 
which ionizes readily in water and makes it different from other natural 
polyesters like poly(hydroxyalkanoates);4 due to the reactivity of these 
groups the chemical modification or derivatization to obtain different 
materials with specific physicochemical properties is possible. The 
charge repulsion of the ionized polymer provokes that an extended 
conformation is preferred by PMLA, moreover, the polyanion has a high 
degree of conformational freedom in aqueous solution so it does not 
display higher-ordered structures in water.24  
 
 
O
O
COOH
O
COOH O
Poly(α,L‐malic acid) Poly(β,L‐malic acid)  
Figure 2.4. Chemical structure of poly (malic acid) stereoisomers. 
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2.2.2. Biological synthesis 
The first published work on natural PMLA is about low molecular 
PMLA production from Penicillium cyclopium in 1969,27 however the 
chemical synthesis from the corresponding lactones28 was done before 
the biological synthesis was recognized.29 Since then low and high 
molecular weight PMLA have been obtained from various myxomycetes 
and several mitosporic fungi like Physarum polycephalum (Table 2.2). 
PMLA biosynthesis has been related to DNA replication regulatory 
system, because it forms specific complexes with DNA polymerases to 
inhibit their activity.30 Biological systems only synthesizes enantiomeric 
pure PMLA, with β structure and L configuration,31 result of the 
esterification between the hydroxyl group and the β-carboxyl from the 
malic acid monomeric unit. PMLA architecture can be linear or branched 
depending upon the microorganism that produce it.24 Polymer 
production depends on several factors such as the composition of the 
growth medium, the time of harvest and the particular stage of the life-
cycle of the organism under consideration. PMLA from Physarum 
polycephalum varies widely in molecular mass (10-300 kDa) while that 
from mitosporic fungi is considerably smaller (5-9 kDa).32  
 
Table 2.2. PMLA producing microorganisms. 
Organism Polymer contenta 
(mg·L-1) 
Mw   
(kDa) 
Db 
Aureobasidium sp.33,34 7.8 – 62.2 x 103 5 – 11 1.1 
Physarum polycephalum33 400 – 2.7  x 103 10 – 300 1.2 – 3.7 
Penicillium cyclopium24 5.7 x 103 5  
Cladosporium sp.24 24 – 350    
a PMLA concentration in the culture medium. 
b Molecular weight dispersity of the polymer (Mw/Mn). 
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Of the various forms of cells in the fungi life cycle only the 
plasmodium produce PMLA, neither the amoebae nor spherules nor 
spores do contain PMLA (Figure 2.5). Polymer is first produced in the 
cell nuclei for a later release into the growth medium via the cytosol. 
PMLA is produced from D-glucose involving the citric acid cycle for the 
production of precursors; the amount of polymer released to the 
medium is proportional to the content of D-glucose in the culture 
medium.24 It has been shown that CaCO3 strongly stimulate PMLA 
production, and that this production it is not cell-growth dependant but 
competitive for glucose as carbon source.32 
 
Germinating
spore
Amoeboid
cell
Flagellated
cell
Zygote
Feeding
plasmodium
Mature
plasmodium
Gamete
Sporangium
development
 
Figure 2.5. Life cycle of the myxomycete Physarum polycephalum. Drawing by Margret 
LaFarge.35. 
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2.2.3. Chemical synthesis 
On another hand, chemical synthesis of PMLA is also possible. In 
fact, it has been the synthetic PMLA which has been used in most of the 
research about this polymer, because it is possible to control its 
molecular weight. PMLA has been synthesized in several steps from 
bromosuccinic acid,36 aspartic acid37 and malic acid enantiomers.38 
Chemical synthesis can be done by two different routes, 
polycondensation of L-malic acid (Figure 2.6a) which leads to a low 
molecular weight polymer39 and ring opening polymerization (ROP) of 
substituted β-lactonates20,28,31 (Figure 2.6b) which allows configuration 
control and high molecular weight polymers. The first high molecular 
weight PMLA synthesis was made by ROP by Vert and Lenz in 1979 
after the successful synthesis of the β-substituted β-malolactones, such as 
benzyl β-malolactonate.28 The biochemical reactivity of synthetic PMLA 
has been indistinguishable from natural polymer.40  
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Figure 2.6. Chemical polymerization of poly(malic acid): a) L-Malic acid 
polycondensation and b) ring opening polymerization of β-malolactonate (MLABn) 
for racemic PMLA synthesis. 
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2.2.4. Degradability 
Because of the PMLA potential as material for biomedical 
applications PMLA and its derivatives hydrolytic degradation have been 
extensively studied. PMLA hydrolytic degradation happens 
spontaneously or by enzymatic hydrolysis,24 and depending on the pH  
degradation can be substantial due to the autocatalytic degradation, 
which results in a non-random cleavage of the main chain.5,26 The rate of 
hydrolysis has its minimum in phosphate buffered neutral solutions, 
which should be used for the purification and storage of polymalate 
salts. Hydrolytic degradation of the polymer sodium salt at pH 7.0 and 
37 °C results in a random cleavage of the polymer, the molecular mass 
decrease by 50 % after a period of 10 h.41 The end product of PMLA 
hydrolytic degradation is L-malic acid one of the metabolites of the 
tricarboxylic acid cycle (Figure 2.7), thus it is considered a bioresorbable 
(bioassimilable) polymer.4 In respect to its derivatives, alkyl esters, 
previous studies have shown that degradation rate is in function of 
polymer composition, as more hydrophobic groups are substituted on 
the polymer the lower the degradation rate is.42 In a different work 
Martínez-Barbosa et al. studied the hydrolytic degradation on synthetic 
PMLA derivatives, concluding that degradation rate is directly related to 
material hydrophilicity.21 Nevertheless, degradation mechanisms in 
biological systems are very different, since there are a lot of enzymes 
involved,43 where degradation rate will significantly depend on the 
concentration and activity of those biocatalyzers. PMLA biodegradation 
and bioassimilation has been also studied in vivo through radio-labeling, 
founding that its blood clearness is fast and that the major part is 
excreted via urinary in small oligomers form.44 Moreover, citotoxicity 
tests have been done to a wide variety of derivatives founding that most 
of them are well tolerated by the tested cell lines.21,45-47 Due to these 
characteristics and because PMLA hydrolytic degradation product is 
malic acid, PMLA is considered as biodegradable, non-immunogenic, 
non-toxic and bioresorbable material for mammals and humans.4,26 
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Figure 2.7. Malic acid: PMLA hydrolytic degradation product and a metabolite of 
mammals’ tricarboxylic acid cycle. 
 
2.2.5. PMLA modification 
PMLA main chain bears lateral carboxylic groups and a terminal 
hydroxyl and carboxyl groups which can be substituted, allowing the 
modulation of the overall polymer hydrophobicity21,48 or the 
introduction of bioactive ligands to give specific properties to the 
polymer.49,50 PMLA has three groups for modification: A) carboxyl 
groups can be reacted in the presence of carbodiimides as coupling 
reagents, B) the terminal hydroxyl group via the reaction of 
isothiocyanates, and C) the β-carboxyl of the main chain by the attack of 
a nucleophile, such as primary amines and diamines, leading to 
simultaneous chain scission (Figure 2.8).26 The high hygroscopicity and 
susceptibility to hydrolysis of PMLA has motivated the search of new 
derivatives with better stability and lower degradation rates, as well as 
derivatives that can be useful for nanoparticle formation and drug 
encapsulation. Esterification of the carboxyl side group of PMLA results 
in polymers with a dramatic change in its original properties. Our group 
had previously reported the methylation of biological PMLA by reaction 
with diazomethane,51 resulting in a highly crystalline and highly 
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hydrophobic polymer in difference with the hydrophilic PMLA; and the 
formulation of microparticles for erythromycin delivery in which 
methylated PMLA particles are considered promising devices for 
controlled delivery of several drugs.48,52  
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Figure 2.8. PMLA groups susceptible to modification. A) carboxyl groups with 
carbodiimides as coupling reagents; B) terminal hydroxyl group via isothiocyanates; 
C) ester group by the attack of a nucleophile (to yield two shortened polymer 
molecules and a substitution at the terminal carboxyl group of one of them). 
 
Other derivatives have been studied, but these are not prepared by 
postpolymerization modification techniques. Instead, they are obtained 
directly by ROP polymerization of different modified β-malolactones 
and the partial or total hydrogenolysis of copolymers with poly(β-benzyl 
malate). With this technique derivatives like poly(β-benzyl malate), 
poly(β-butyl malate), poly(β-hexyl malate), and copolymers have been 
obtained.21,53 Furthermore, the copolymerization of malic units with 
lactic units has been performed by ROP in the presence of stannous 
octoate, these has allowed the functionalization of PLA while its 
hydrophilicity increases.54 
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2.2.6. Biomedical applications 
PMLA and its derivatives has been used as platform in the 
synthesis of nanocarriers for drug delivery systems in which the active 
compound has been covalently attached18,55 or physically 
entrapped;21,48,53,56 water insoluble PMLA-Bn and other hydrophobic 
derivatives has been used to prepare various solid devices, including 
compression molded pellets, films, microparticles and nanoparticles but 
none of these have yet led to concrete therapeutic application.20,57 Also 
PMLA has been investigated as a constituent for macromolecular 
conjugates bearing several functionalities to treat human brain and 
breast tumors in mouse models.50,58,59 In all of these investigations it has 
been concluded that PMLA is a promising building block for the design 
of efficient drug delivery systems.  
Most prominent PMLA formulations are clofazimine 
encapsulation for intravenous treatment of tuberculosis,60 and Polycefin, 
from Cedars-Sinai Medical Center research group, a biopolymeric 
nanoconjugate for breast and brain cancer treatment with effective 
targeting delivery by conjugation of tumor targeting antibodies;61 which 
has been also conjugated with  Temozolomide,62 Doxorubicin55 and 
antisense oligonucleotides50,59 as active anticancer compounds. It has 
been shown in vivo that the nanoconjugate can effectively reach the 
tumor tissue and reduce tumor growth in rats (Figure 2.9). 
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Figure 2.9. An MDA-MB-468 subcutaneous breast tumor-bearing mouse was 
administered intravenously with a PMLA conjugate (Polycefin). 24 hours later, the 
animal showed drug distribution mostly in the tumor, as well as in kidney and liver 
(drug clearing organs).63 
 
2.2.7. Critical aspects of PMLA 
Today, up to my knowledge, there are other three groups working 
with PMLA, two in France (Dr. M. Vert and Dra. S. Cammas) which 
perform their research with synthetic PMLA; and one in the USA (Dra. J. 
Ljubimova with Dr. E. Holler) which works with biotechnological 
PMLA, who kindly provide us with biosynthetic PMLA. There are very 
few works dealing with PMLA modification and application in 
biomedicine, and moreover treating with biologically produced polymer; 
one of the main reasons is because it is not commercially available. 
PMLA may be considered to a certain extent as a member of the 
PHAs family, which is wide-spread in many bacterial species, and it is 
available in relatively large quantities by fermentation. Production cost 
can be relatively low for PHAs, and some of the polyesters are eligible as 
raw materials for manufacturing plastics. In difference, PMLA is not 
competitive, since its production costs are still high and the biosynthesis 
has not been completely understood; furthermore, the high susceptibility 
of PMLA to hydrolysis makes difficult to obtain considerable amounts of 
material with an appropriate molecular weight, because prolonged 
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fermentation times results in the degradation of the all ready excreted 
polymer in the medium.24 Same problem is expected for the post-
polymerization modification, which must be done under soft conditions 
to avoid possible scission of the main chain. 
PMLA is extremely water-soluble and therefore it is of 
complementary nature to PHAs which are water insoluble and limited to 
non-aqueous applications systems. Aside qualifying as raw material for 
the manufacture of water-soluble plastics or tissue, the polyanionic 
nature allows several other applications, some of which probably justify 
the relatively high productions costs. Those applications should be of 
value in the field of pharmacology, medicine and agriculture because 
ensures safe and healthy bioresorbability as it is a metabolite derived 
polymer. The main property that we explode in this work is the 
functionality of PMLA which makes possible the derivatization of the 
polymer, differentiating it from the most common and used 
biodegradable polymers in medicine. As more producing organisms are 
discovered, a diversity in structure and composition may become 
available that will render this material even more interesting.24  
 
2.3. Biotechnological polymers: poly(γ-glutamic acid) 
Poly(γ-glutamic acid) (PGGA) is one of the homo-poly(amino 
acid)s known to be present in nature produced by microorganisms;64 it is 
a nylon 4 with a carboxylic group substitution pendant on the α-carbon. 
Poly(γ-glutamic acid) presents its peptide bond between the amino 
group of one monomer and the carboxylic group in γ position of the 
other monomer. It can be produced either by biological fermentation or 
by chemical synthesis. Like PMLA it has an stereoisomer, poly(α-
glutamic acid) (Figure 2.10), which has been extensively studied by its 
biochemical incidence.  
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Figure 2.10. Chemical structure of poly(glutamic acid) stereoisomers.  
 
PGGA natural presence was discovered in 1937 in the capside of 
Bacillus anthracis.65 Later it was found to be the main product of the 
aerobic fermentation of Bacillus subtilis; but it was not until 1954 when 
Thorne and coworkers made the first research on PGGA biosynthesis 
and the optimization of the factors influencing biopolymer production.66 
Nevertheless the biochemical incidence of poly(α-glutamic acid), after 
some years of controversy now is known that biological PGGA is 
essentially constituted by γ bonds.67 Regarding to its configuration, 
despite that the L-glutamic acid enantiomer is more abundant in nature, 
it is the D pair which predominates in PGGA biosynthesis, nevertheless 
its D:L enantiomeric composition varies largely depending upon the used 
bacterial strain and fermentations conditions.68 In the decade of the 70s, 
Murao and coworkers studied PGGA production by Bacillus subtilis E5 
on a culture medium with glucose and glutamic acid; they found that 
PGGA yields were higher than the quantities of acid administrated, so 
later they found that PGGA could be produced on a media only with 
urea and glucose.69 Since then several works have been conducted to 
understand the biosynthetic pathways to increase PGGA productivity by 
different bacterial strains.70-72 
In the same way as PMLA, PGGA can be chemically synthesized, 
either by polycondensation (Figure 2.11a) or by ROP (Figure 2.11b). First 
chemical synthesis was done by glutamic acid polycondensation, being 
necessary the α-carboxyl protection and γ-carboxyl activation and the 
preparation of the proper dimer to avoid undesired secondary reactions. 
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Polymer obtained by this method can be D or L homopolymers as well as 
stereocopolymers D/L, depending on the initial glutamic acid 
configuration; nevertheless these polymers resulted with low molecular 
weights.73 With ROP technique, good yields and controlled molecular 
weights can be obtained from 3-(2,5-dioxo-1,3-oxazolidin-4-il)propionic 
acid a glutamic acid derivative. However, this synthetic route can be 
complicated because of the γ-N-carboxyanhydride instability which is 
formed during the process; thus molecular weight only reaches a few 
thousands because the decomposition products can limit the molecular 
weight.74 
In difference with nylon 4, which is a conventional polyamide, 
PGGA is a highly hydrophilic polyamide due to its lateral carboxylic 
group with properties characteristic of a degradable material because of 
its susceptibility to hydrolysis in acidic and basic conditions. It is a 
polyacid with a pKa ~2.27 that ionizes at increasing pH, considered as 
well as a polyelectrolyte,75 it can be obtained in its acid or salt form 
depending on the ionization state. PGGA is obtained as a white semi-
crystalline powder polymer but it melts with decomposition, so can be 
classified as a thermostable polymer with a melting temperature around 
210 °C. Also, it is water soluble and its solubility strongly depends on the 
ionization degree and in its secondary structure. It is able to form α-helix 
and β-sheets; in the last case, the formation of hydrogen bonds limits its 
solubility. As a polyamide, it is susceptible to chemical hydrolysis, 
because the lateral carboxylic group increases its hydrophilicity and the 
water access to the polymer main chain. Degradation in water at ambient 
temperature is important, it increases notably with higher temperature 
and is accelerated under both acid and basic conditions.76  
The γ peptide bond of PGGA differentiates it from proteins which 
have a peptide linkages formed between the α-amino and the                  
α-carboxylic acid groups; the pendant free carboxylic group produces an 
asymmetric carbon in the structure and this functionality makes its 
derivatization feasible so the overall hydrophobicity of the polymer 
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could be modulated,77 bioactive ligands can be introduced 78,79 or might 
associate with drugs;80,81 thus PGGA has a countless number of 
possibilities without parallel in the field of conventional polyamides.82  
PGGA and its derivatives are considered promising biocompatible 
materials that could display functional properties of biomedical interest 
like drug delivery systems.  
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Figure 2.11. Chemical synthesis of poly(α-alkyl-γ-glutamate): a) poly-condensation. 
G* activated carboxylic group; and b) ring opening polymerization. 
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PGGA is object of current interest because of its natural origin, 
biodegradability, biocompatibility and bioresorbability, since it degrades 
into glutamic acid which is an essential substance to human.82 PGGA 
biodegradation, as well as PMLA, depends in most part to enzymatic 
activity. Glutamic acid as a natural occurring amino acid is perfectly 
assimilable by the body. PGGA is edible and due to its biological 
properties as non-toxic and non-immunogenic material it is proper for 
biomedical applications as a drug delivery system,81  bioadhesives,83 
material for tissue engineering 84 and hydrogels.85 Several authors have 
investigated PGGA and its copolymers use in DDS for protein 
encapsulation,86 cancer treatment,81 as inmunoestimulant against viral 
and tumoral infections87 among others; nevertheless, biomedical 
applications of PGGA remain as potential and poor studied. Up to day, 
as classified as GRAS (Generally Regarded As Safe) by the US Food and 
Drug Administration the main application of PGGA is in the food 
industry as flocculant and gelling compound.88 
 
2.4. Polymer derivatization  
Developments of original devices in the biomedical field are 
nowadays based on the use of biopolymers or biodegradable synthetic 
polymers answering to very strict conditions of applications. This has 
stimulated the modification of existing polymers or the development of 
new ones.21 Moreover, current advances in the understanding of cellular 
and molecular biology have provoked an increasing need for materials 
with specific and better defined structures or functionalities; however, 
the preparation of such materials imposes major synthetic challenges.89 
In the drug delivery field, it should be noted that distinct mechanisms of 
drug controlled release require different polymers with a variety of 
physiochemical properties. Most of the polymers used in the 
development of DDS are designed with the capacity to form 
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supramolecular structures (matrices or capsules), which are suitable to 
retain therapeutic agents and deliver them under certain conditions.8 
PMLA and PGGA have a great advantage for modification over 
the most used biodegradable polymers in biomedicine, i.e. PLA and 
PGA; because their inherent functionality that provides them very 
specific characteristics like their high hydrophilicity, and in consequence 
their susceptibility to hydrolysis. This functionality had caused great 
interest for the synthesis of new derivatives from these polymers which 
present better stability to degradation or show other specific 
functionalities, so the field of applications can be increased. But, at the 
same time, hydrolysis susceptibility restricts the modification methods 
that can be applied for direct derivatization. With the exception of 
certain ionic coupling reactions that have been recently reported,90-92 
most of the chemical modifications carried out on the carboxylic side 
group involve the covalent attachment of organic compounds.51,53,58,77,93 
The most common modification is the lateral carboxylic group 
esterification or amidation, which is used with the aim of modulate their 
hydrophobicity in accordance to the type, conversion degree and 
substitution distributions or to introduce bioactive ligands that will give 
specific properties to the polymer. 
With respect to biomedical applications, hydrophobic character 
modulation is of great importance; as more hydrophobic is the conjugate, 
easier is the penetration into the cell by membranolysis.46 Also it has 
been shown that hydrophobization of PMLA conjugates carriers 
promoted cell penetration.18 In the case of brain tumors treatment, it is 
necessary that the systems be able to penetrate de blood brain barrier 
(BBB). This membrane is extremely permioselective, avoiding the 
penetration of hydrophilic compounds that could be in the blood stream 
and that can damage the brain, and in the same way is a limiting barrier 
for DDSs.  
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The carboxylic side groups of the polyacids may serve as excellent 
points to build graft copolymers by either attaching polymeric side 
chains (grafting-on) or initiating the growth of polymeric branches 
(grafting-from).82 In addition to the random copolymers formed by direct 
modification of the pendant carboxylic groups, block- copolymers 
containing long homogeneous sequences of PMLA or PGGA linked to 
other homopolymeric segments of different properties have been 
developed by synthetic methods for their self-assembling properties and 
potential application in biomedicine.53 A terpolymer from PMLA 
derivatives units have been prepared by ROP to mimic heparin sulfates 
in order to enhance bond and tissue repair.45  
The most advanced case for application of a PMLA derivative is 
Polycefin, a multifunctional nanoconjugated that use PMLA as a 
backbone. The ability of Polycefin to go through the blood brain barrier 
depends on the hydrophobic character of the molecule, which is 
determined by the different nature of the grafted moieties;50 also a 
tandem of recognition molecules have been added for an efficient 
targeting delivery,94 and with capability for carrying chemotherapeutic 
agents62 or gene therapy (Figure 2.12).50 These have been achieved by the 
activation of the carboxyl groups and the posterior grafting of the 
different functional moieties.   
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Figure 2.12. Cartoon of PMLA-based multifunctional nanoconjugate: Polycefin.59 
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2.4.1. Esterification 
PMLA modification presents a big challenge because the labile 
nature of the main chain ester bond; this make mandatory to perform 
specific reactions under smooth conditions if the molecular weight is to 
be conserved. Thus, condensation methods for esterification are 
practically unviable because of the main chain scission that occurs 
during this process. For this reason, most of the PMLA derivatives have 
been obtained by chemical synthesis (ROP) with the appropriate 
monomers.5,53 Recently in our group, Fernandez and coworkers made 
the esterification of biologically produced PMLA with diazomethane 
(Figure 2.13) obtaining poly(α-methyl β,L-malate) 100% esterified 
without reduction in the molecular weight, but this method is limited to 
methyl derivatives.51 The same method was used for the production of 
fully and partially methylated PMLA for the production of micro- and 
nano- spheres for antibiotic and proteins encapsulation, respectively.48,95 
 
Poly(β‐malic acid) Poly(α‐methyl‐β‐malate)
O
COOH O
H2C N N+ O
O
OO
Me
+  N2
 
Figure 2.13. PMLA methyl esterification with diazomethane. 
 
In the case of PGGA other esterification methodologies can be 
applied since the amide bond in the main chain confers more stability to 
more aggressive reaction conditions. The first and most frequent method 
for PGGA esterification is based on the reaction with alkyl bromides in 
the presence of sodium hydrogen carbonate using an organic solvent as 
DMSO or NMP (Figure 2.14).96 This methodology has been extensively 
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applied by different authors who introduced more or less important 
modifications in the reaction conditions in order to improve yields and 
conversions.77,97 In recent years, a new procedure for the esterification of 
PGGA has been developed; which consist of two steps; first, ethylation 
with ethyl bromide followed by transesterification with alcohols in the 
presence of titanium tetrabutoxide.98 
 
Poly(γ‐glutamic acid) Poly(α‐alkyl‐γ‐glutamate)
N
H
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Figure 2.14. PGGA esterification with alkyl bromides. 
 
2.4.2. Amidation 
In addition to the esterification reactions, amidation is another 
option for direct modification on the polycarboxilates like PMLA and 
PGGA. PMLA amidation has been done in the development of Polycefin, 
it has been achieved by the activation of the carboxylic groups by          
N-hydroxysuccinimide and a posteriori amidation by nucleophylic 
attack by primary amines on the activated polymer (Figure 2.15). By this 
technique PMLA has been amidated with NH2-poly(ethylen glycol), 
membrane disrupting peptides, drugs attached through pH sensitive 
hidrazide linkages, antibody targeting molecules and fluorescent 
probes.50 
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Figure 2.15. PMLA amidation through carboxyl group activation with                        
N-hydroxysuccinimide. 
 
The carboxylic group of PGGA is susceptible to being amidated 
with a variety of amino compounds; reaction is assisted by a convenient 
activating agent such as a carbodiimide. Although different amino 
compounds have been covalently attached to PGGA, conjugation with 
naturally occurring amino acids is among preferred grafting approach. 
Nontoxic hydrophobic esters of amino acids, in particular the ethyl ester 
of L-phenylalanine, have been extensively explored for producing 
amphiphilic PGGA derivatives able to self-organize in structured 
nanoparticles. The degree of amidation determines the type of molecular 
association that operates in the building of the particle and is therefore 
critical in establishing its size.84 
 
2.4.3. Ionic coupling 
The capacity of polyelectrolytes to form more or less stable 
complexes upon coupling with opposite charged ionic compounds is 
well known. In the case of the counter ion has a noticeable 
hydrophobicity, the water solubility of the original polyelectrolyte is lost 
and the complexes become soluble in organic solvents. Furthermore, the 
complexes usually display a pattern of physical properties largely 
dissimilar to those of the parent polyelectrolyte, which is in many cases 
the objective of their preparation.  
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PMLA and PGGA are able to form stoichiometric ionic complexes 
with alkyltrimethylammonium surfactants and with a precise 
composition and satisfactory stability creating comb-like nanostructured 
polymers.90,91,99 As polyelectrolytes, these macromolecules are sensible to 
pH, this character has been used for pH responsive systems in the 
biomedical field. An example of the application of PGGA to the design of 
pH sensitive DDS is the production of nanoparticles through the ionic 
interaction of the negative charged PGGA with the polycation chitosan 
for encapsulation of heparin, a fibroblast grow factor, with a pH 
dependent  release100 or the PGGA complexation with DOX and a 
cationic lipid which results in nanometric particles with potential for 
targeted delivery in solid tumors.101  
A different strategy that could bring much interest because of its 
simplicity is the direct ionic complex formation between a polyion and 
an opposite charge ionic drug; this strategy has been directed for drug-
loading on polymers more than for modification. The simplicity and 
interest of this type of complexes reside in the fact that they are formed 
in aqueous solutions without the need of organic solvents and without 
secondary products. A ionic complex between polyaspartic acid and the 
cationic drug diminazene, a model drug, had been done, the study 
revealed that ionic interactions and hydrogen bonds were present.102 
PGGA ionic complex with the cationic drug Doxorubicin, a cancer 
chemotherapeutic, had been also studied; this complexation leads to the 
formation of nanoparticles which shows a pH dependent drug release.103 
 
2.4.4. Thiol-ene click reaction 
To address the gap between the sophisticated functionality that is 
required for future advances in bio- and nano- technology and the 
limited chemical control offered by many of the synthetic processes that 
are currently available, we are now witnessing an increasing application 
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of synthetic organic chemistry concepts into material science.89 The 
concept of postpolymerization functionalization strategies introduces a 
number of major challenges, such as efficiency and orthogonality, which 
must be overcome.104 
An excellent example of the power of postpolymerization 
strategies is the wide range of functional materials that have been 
prepared using Cu-catalyzed azide-alkyne click chemistry; but for 
biomedical applications an alternative without metallic catalyst is 
preferred, like thiol-ene reactions (Figure 2.16).105 Click chemistry has 
been shown to be synthetically efficient,106 specifically, radical-mediated 
thiol-ene reaction as a facile and convenient tool for the 
postpolymerization modification of well-defined reactive polymers and 
for the construction of complex macromolecules. While only recently 
recognized and exploited as a click process, the thiol-ene reaction, in 
both, its radical and base/nucleophilic forms, has already been 
demonstrated to be a powerful and versatile method for site specific 
functionalization and as a convenient conjugation tool.107 There are 
several features associated with the thiol-ene reaction that make it a 
particularly attractive, facile and versatile process; the reactions must:     
i) result in a stable linkage, ii) exhibit minimal cross-reactivity with other 
functional groups, iii) react to completion, iv) be free of appreciable 
amounts of side products, and v) proceed under benign reaction 
conditions.108 Click chemistry provides alternatives to conventional 
strategies used for postmodification of side chains for PGGA esters; a 
two step modification is possible under the mild conditions used in 
modern click conjugation strategies.88,109 Furthermore, the vast array of 
commercially available molecules and biomolecules with either thiol or 
ene functionality makes this a powerful technique to introduce 
functional groups.  
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Figure 2.16. Click reaction forms: a) copper catalized azide-alkyne, b) base-catalyzed 
thiol-ene and c) radical photoinitiated thiol-ene. 
 
Thiol-ene photopolymerization for biomedical applications was 
recently presented as a novel mechanism for cross-linking and hydrogel 
formation. This technique has been exploited to fabricate protein 
delivery vehicles capable of enzyme-responsive drug release.110 Also, 
thiol-ene reactions had been used for the stabilization and 
functionalization of polymer multilayer-coated particles and capsules for 
a new generation of particulate delivery systems and microreactors.111 
For functionalization, covalent attachment of biomolecules to polymers 
have been performed like the site-selective conjugation of peptides and 
proteins using the disulfide bridge when it is not essential for bioactivity 
retention,112 or polymer functionalization with cysteamine which 
provides a spot for Doxorubicin conjugation onto the polymer through a 
pH-sensitive hydrazone bond.113 For more complex architectures click 
reactions also were successfully applied for the synthesis of dendrimers 
as a possible drug delivery vehicle with the conjugation with cisplatin.114  
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2.5. Nanoparticles for drug delivery systems 
Application of nanotechnology in medicine is known as 
nanomedicine and it is attempted to improve life quality of human 
beings, fighting against diseases in an innovative way. Most of the 
effectiveness of an oral drug is lost when it is metabolized by the leaver 
or digested in the digestive track. Pharmaceutics solution to this is to 
increase the drug amount in each tablet, taking in account how much is 
going to be lost during the administration.  Employing different routes of 
administration, like intravenous or intramuscular injections, has resulted 
in a reduction of losses. The use of nanoparticles goes further because it 
allows the penetration of cell membranes to introduce chemical, 
biological or genetic therapeutic material in determined cells. This 
nanodelivery promises revolutionary treatments for incurable diseases 
up today.115 
In the last decades, nanotechnology has focused on formulating 
therapeutic agents as biocompatible nanocomposites such as 
nanoparticles, nanocapsules, micellar systems and conjugates (Figure 
2.17); were drugs are entrapped, encapsulated, dissolved or attached to a 
polymer matrix. Polymers able to delivery active agents are becoming 
more popular since they are less immunogenic than viral vectors50 and 
offer some advantages over liposomes, like better stability protection for 
drugs and proteins and better properties for controlled release.6 For 
these, a great variety of polymers have been tested for DDS and they can 
effectively deliver a drug to a target site increasing the therapeutic 
benefit, while minimizing toxicity and side effects; but it is 
biodegradable nanoparticles which have taken great attention as 
effective carrying devices, because they possess useful controlled release 
properties and do not accumulate in the body.116 
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Figure 2.17. Types of drug delivery systems: a) particles, b) capsules, c) micelles and 
d) conjugates.  
 
DDS systems based on polymer particles, either nanoparticles or 
microparticles, are clearly advantageous because: a) particle size and 
surface can be engineered to achieve passive or active drug targeting,     
b) drugs can be incorporated without chemical reaction, c) drug activity 
is optimally preserved during its transportation to the site of action,       
d) site-specific targeting can be achieved by attaching targeting ligands, 
e) formulation can be delivered through different routes of 
administration,  f) toxicity of active compounds is reduced by controlling 
its delivery g) controlled and sustained drug release can be achieved, and 
h) particle degradation can be modulated by polymer matrix 
choose.2,6,80,116,117 
Microparticles were among the first controlled delivery systems, 
administration could be subcutaneous, intramuscular, or intraperitonial; 
but because of their size they are not able to circulate through the 
capillary vessels. To overcome this, nanoparticles are now the focus of 
research, they are defined as particulate dispersion or solid particles with 
a size in the range of 10-1000 nm and they offer several advantages over 
microparticles like deep penetration into tissues through capilars, pass 
through the epithelial membrane and better uptake by cells.118 
Regardless, nanoparticles do have limitations; for example, their small 
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size and large surface area can lead to particle aggregation, making 
physical handling difficult; in addition, same factor results in limited 
drug loading, an initial burst release and the recognition and fast 
clearness by the body immune system.116 
Nanoparticles in medicine have been used not only as a DDS, but 
also for fluorescence, magnetic resonance and X-ray imaging. 
Nevertheless, most of the works deals with drug delivery, especially in 
cancer therapy. In chemotherapy DDS has spread out rapidly because 
their use can reduce systemic toxicity and minimize the side effects on 
normal cells while drug concentration at specific sites increases by 
administering the drug directly to cancer cells; besides, some systems 
offer the possibility of crossing the blood brain barrier, a permoselective 
membrane that protects the brain. For example, one of the main 
challenges in cancer chemotherapy is drug formulation, which normally 
involves toxic excipients. Nanoparticle-based DDS provide an alternative 
over the use of toxic adjuvants by encapsulating the drug.80 Non-toxic 
drug formulations must be used for the treatment of tumor cells because 
it is toxicity of normal cells that constrains dose and frequency, both 
important factors in cancer chemotherapy treatment.119 
To achieve an efficient DDS we must to consider the 
physicochemical properties of the main three components involved in 
the DDS application; the vehicle (i.e. polymer matrix), the active 
compound to be delivered and the target compartment (organ or cells). 
As it is not possible to modify the properties of the target compartment 
and limited in the modification of the active compound, the challenge is 
to determine the optimal physicochemical properties of the polymer to 
confer drug loading efficiency, long circulation times, site recognition 
targeting and controlled drug release. 
Conventionally, nanoparticle preparation methods could be split 
in two mayor classes: i) from an existing polymer; and ii) during 
polymerization process. In the first case, several methods have been 
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proposed for dispersing preformed polymers like PLA, PGA, PLGA and 
PC: emulsion-solvent evaporation, spontaneous emulsification/solvent 
diffusion, salting out/emulsification-diffusion, adaptations of these 
methods with the use of supercritical fluids, nanoprecipitation, ionic 
gelation, coacervation of hydrophilic polymers and spray drying.116,120 
Through the 70s and 80s, most degradable drug-loaded microparticles 
were formed either by solvent evaporation from emulsion or by phase 
separation techniques.2 
 
2.5.1. Emulsion solvent evaporation technique 
Microparticles and nanoparticles can be formed by emulsion 
solvent evaporation method, it have been widely applied in the last 
decades either with synthetic or natural polymers for the preparation of 
a large diversity of formulations with different applications, from 
biomedical science to the textile and shoe industry. 
The solvent evaporation method is a two-step process; first, the 
polymer is dissolved in an organic solvent like dichloromethane, 
chloroform or ethyl acetate, the solution is then emulsified into an 
aqueous solution of a surfactant (i.e. gelatin, PVA, polysorbate-80) to 
form an oil in water emulsion (O/W) by shear stress produced either by 
agitation, homogenization or sonication. Second step, after the formation 
of a stable emulsion, is solvent removal which can be achieved by 
evaporation or liquid extraction; in the first case, volatile solvent from 
the polymer dispersion is removed by increasing the temperature or 
reducing the pressure under agitation; while the liquid extraction is done 
by the addition of continuous phase or additional extraction agents 
which absorb the entire solvent leaching from the solidifying particles 
(Figure 2.18).120 This method is good for a laboratory scale, but for larger 
scales alternative methods are used.6 For drug encapsulation the drug is 
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dispersed or dissolved into the preformed organic polymer solution 
before the emulsion formation. 
Particle size and size distribution will be mainly determined by the 
size of the droplet of the emulsion disperse phase, which is determined 
by phases’ viscosities, energy applied for emulsion generation, and 
interfacial interaction of both phases.121,122 Fast solvent removal from 
emulsion also increased the control on particle size and distribution 
without physical aggregation.123 Particle size may affect drug release 
rate, drug encapsulation efficiency, product syringeability, in vivo fate in 
terms of uptake by phagocytic cells and biodistribution of the particles 
after administration.120,124 
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Figure 2.18. Particle formation by emulsion-solvent evaporation technique.125 
 
To prevent coalescence of the drug/matrix dispersion droplets, a 
surface active or viscosity enhancer stabilizer as PVA is generally added 
to the continuous phase, drug encapsulation efficiency can be improved 
by controlling the molecular weight of PVA as surfactant.123 Another 
emulsifying agent that is used for the production of particles by solvent 
evaporation is PEG which also renders to the nanoparticles mask 
characteristics against reticulo-endothelial system recognition.126 Since 
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the emulsion stabilizer stays at the oil/water interface during solvent 
evaporation, there is a possibility of adsorption of the stabilizer; binding 
of surfactant on the particles may alter the physicochemical surface 
properties.127 
Normally, the O/W emulsion is applied for hydrophobic 
molecules encapsulation, but there is a variation of this method which 
employs a double emulsion technique for the encapsulation of 
hydrophilic drugs. The drug is first dissolved in aqueous media (W1) and 
emulsionated in an organic polymeric phase (O), the stable emulsion 
(W1/O) is then emulsionated again in the aqueous continuous phase 
(W2) forming a double emulsion system (W1/O/W2), which leads to 
particle formation after solvent removal.124 
 
2.5.2. Nanoprecipitation: self-assembled structures  
Self-assembly is an important driving force in the formation of a 
variety of highly ordered structures for polymeric macromolecules that 
are useful for different applications. The most commonly used 
interactions include electrostatic and hydrogen bonding, as well as 
amphiphilic forces.128 Amphiphilic block or graft copolymers consisting 
of hydrophilic and hydrophobic segments are self assembling materials 
capable of forming polymeric associates in aqueous solutions due to the 
intra- or inter- molecular hydrophobic interactions.129  
This method basically consists in the change of solubility 
conditions of the polymer solution, so the polymer will self-arrange in a 
defined structure depending on chemical structure and solubilization-
precipitation conditions. Under selective solvent conditions, the 
copolymers adopt various organized structures; multimolecular 
spherical core-shell nanoparticles, having an inner-core made up by the 
insoluble blocks and an outer-shell built by the soluble blocks, represent 
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the most frequent structure and belong to the family of colloidal 
polymers (Figure 2.19).53 
 
a)
b)
 
Figure 2.19. Self-assembled particles from amphiphilic polymers: a) block copolymer 
and b) graft copolymer. 
 
The parameters which influence the self-assembly of molecules in 
solution include the temperature and solvent quality. Mixing two 
solvents is the most common and flexible way to achieve a large and 
rapid change in solvent quality. The critical attribute that drives 
micellization, such as solvent quality or temperature, should be rapidly 
passed to yield an initial supersaturation ratio. To impart colloidal 
stability and avoid fusion, the copolymers should contain a soluble 
portion of sufficient size for steric or electrostatic repulsion.130 
Grafting of hydrophobic amino acids or peptides on water-soluble 
polymers has been done with the aim of giving an amphiphilic character 
to the polymer so it could form nanoparticles.93 The hydrophobic inner 
core of the structure acts as an incorporation site for therapeutic agents, 
especially hydrophobic drugs. These systems can be used to provide 
targeted cellular delivery of drugs, to avoid toxic effects, and to protect 
the active compound against biodegradation.84 Degradable 
macromolecular micelles based on amphiphilic synthetic block 
copolymers of PMLA and PMLA alkyl esters have been produced for 
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drug carriers53 and also nanoparticles form amphiphilic graft copolymers 
by partial methylation of biological PMLA for protein encapsulation and 
delivery95 or partial esterification with alkyl chains of PGGA for 
erythromycin and protein delivery.86 The success of most advanced drug 
delivery strategies requires development of sophisticated new site-
specific carriers.  Thermoresponsive131 and pH-sensitive113,132 micellar 
DDS have been developed form block and graft copolymers by dialysis 
techniques. An advantage of the precipitation dialysis method over 
emulsion evaporation is the elimination of the use of high stress devices 
like sonicators or homogenizers avoiding potential damage.133 
 
2.5.3. Drug encapsulation and release 
Micro- and nano- particles are systems of great interest as drug 
delivery systems of high and low molecular weight active compounds. 
Biopolymer particles-based drug delivery systems provide an ideal 
alternative for drug encapsulation since the activity, solubility, cell 
permeability, and stability of drugs can be manipulated by using 
polymers with different chemical and physical properties;103 being able 
to convert poorly soluble, poorly absorbable and biologically labile 
active substances into promising deliverable drugs.  
Drug can be dissolved, dispersed, encapsulated or attached to the 
polymeric matrix; and depending upon the preparation method, 
nanoparticles or nanocapsules can be obtained. Nanocapsules are 
vesicular systems in which the drug is confined into a cavity surrounded 
by a polymeric membrane; while nanoparticles are matrix systems in 
which the drug is uniformly dispersed.6 Covalent bonds used for drug-
polymer conjugation can be pH79,134,135 or Redox136 sensitive to address a 
site specific delivery. Nevertheless, active compounds can also be linked 
through non-covalent interactions like hydrogen bonds or ionic and 
hydrophobic interactions.103,137 But in general, like for cancer treatment, 
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free drug release from the polymer is a prerequisite for the activity of 
most of the active agents. To achieve an effective drug release and 
therapeutic effect a proper choice of the type of linkage between drug 
and carrier is relevant138 so the association between both components 
could be broken for a successful time- or site- delivery. 
The literature describes three main mechanisms for drug release 
from polymeric particles systems, which primarily differ in the role that 
the carrier plays in controlling the release. One is controlled release by 
swelling; in which polymer hydration causes a volume increase of the 
polymeric structure and the resulted pore size increase allows diffusion 
of the aqueous medium within the polymeric matrix and thus the drug 
release. Another mechanism is by polymer degradation; hydration of the 
polymer results in hydrolytic degradation with release of its contents, 
release and degradation depends on the stability of the polymer 
linkages. And finally, there is drug release by pure diffusion; where the 
compound diffuses through the voids of the polymeric device (Figure 
2.20).8 If the diffusion of the drug is faster than matrix degradation, then 
the mechanism of drug release occurs mainly by diffusion. However, in 
biodegradable polymers release generally occurs by a combination of the 
three mechanisms. The characteristics of each particle differ in terms of 
drug loading capacity, particle and drug stability, drug release rates, and 
targeted delivery ability.119 
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Swelling
Erosion Diffusion  
Figure 2.20. Drug release mechanisms from polymeric particulated delivery 
systems.139 
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3 
 
Materials and Methods 
 
3.1. Materials 
Poly(β,L-malic acid) (PMLA) sample used in this work was provided by 
Dr. Portilla (Cedars-Sinai, Los Angeles, USA). It was biotechnologically 
produced by aerobic cultivation of Physarum polycephalum and isolated 
and purified as described elsewhere.24 Purity of the sample was 
ascertained by 300 MHz 1H NMR, and it had a weight-averaged 
molecular weight between 25-34 kDa with a dispersity of 1.08-1.2 as 
determined by GPC. PAALM-1 was prepared by methylation of PMLA 
with diazomethane in dry acetone as previously described in detail.51 
Poly(γ,glutamic acid) (PGGA) sample used in this work was kindly 
supplied by Dr. Kubota of Meji Co. (Japan). It was produced by 
fermentation of Bacillus licheniformis, with a weight-average molecular 
weight approximately of 30 kDa and a nearly racemic composition.        
L-Leucine ethyl ester, L-phenylalanine methyl ester, allyl alcohol, allyl 
bromide, 1-octanothiol, 1-dodecanothiol, 1-hexadecanothiol, 2,2-
dimethoxy-2-phenylacetophenone (DMPA), dicyclocarbodiimide (DCC)  
and Theophylline (1,3-dimethylxanthine) (TEO) were purchased from 
Sigma-Aldrich. Temozolomide (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-
d]-as-tetrazine-8-carboxamide) (TMZ); Doxorubicin ((7S,9S)-7-
[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-
trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-
5,12-dione) (DOX) and Carbamazepine (5H-dibenz[b,f]azepine-5-
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carboxamide) (CBZ) were obtained from AKSci (Union City, CA, USA). 
All organic solvents were either analytical or HPLC grade and they were 
used without further purification. 
 
3.2. Synthesis of poly(β,L-malic acid) derivatives 
The synthesis of each derivative is presented in the corresponding 
chapter; Table 3.1 shows the synthesized PMLA derivatives, their 
acronyms and the chapter number of the correspondent results and 
discussions. 
 
3.3. Hydrolitic degradation 
Hydrolytic degradation rate of PMLA derivatives was evaluated 
by following the change in molecular weight as function of time from 
samples incubated in aqueous buffers. For this, series of polymer 
nanoparticle or powder samples of about 2 mg each were immersed in 
citrate buffer pH 5.0 or phosphate buffer pH 7.4 at 37 °C, and collected at 
scheduled times for GPC analysis.  
For the assessment of the hydrolytic degradation mechanism,       
10 mg of polymer were placed in NMR tubes containing 1 mL of 
deuterated water or buffered solution, incubated at 60 °C and analyzed 
by 1H NMR at scheduled times; soluble degradation products released to 
the incubation medium were identified and their relative amounts 
monitored at different time points. 
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3.4. Nanoparticles preparation and drug encapsulation 
Two methods were employed for nanoparticles formation 
depending upon the modification degree of the polymer. For 100 % 
modified polymers (PAALM-1, PMLA-Et100, PMLA-Bu100), which were 
hydrophobic polymers soluble in dicloromethane (DCM), the emulsion 
solvent evaporation method was applied. Briefly, 20 mg of polymer were 
dissolved in 1 mL of DCM, added to 10 mL of 0.2-2 % PVA 
(Mw~2000/14000) aqueous solution (Table 3.2) and emulsified with a tip 
probe sonicator (Bandelin, Berlin, Germany, Sonoplus, 200W) operating 
with intermittent pulses at 50 % of amplitude during 45 seconds. 
Emulsion was then dispersed in 20 mL of water and DCM was 
evaporated under reduced pressure in a rotary evaporator. 
Nanoparticles were recovered from the aqueous suspension by 
centrifugation; washed 3 times with distilled water to eliminate the 
emulsifier excess and freeze-dried for storage. 
The precipitation dialysis method was applied for nanoparticle 
formation when partially modified PMLA were used (PAALM-Lx, 
PAALM-Fx, coPMLA-Et50H50, coPMLA-Bu50H50, coPMLA-PrSRxHy and 
coPGGA-PrSRxHy). In this case, to a solution of 2.5-10 mg·mL-1 of 
copolymer in DMSO, NMP, acetone or methanol (Table 3.3), 1 mL of 
water was added dropwise under magnetic stirring. The mixture was 
dialyzed against distilled water for 24 h using a cellulose membrane with 
a molecular weight cut-off of 8 kDa. NPs formed inside the bag were 
recovered by freeze-drying. Particle morphology was monitored by 
scanning electron microscopy (SEM) and their average hydrodynamic 
diameters and surface charge were determined by dynamic light 
scattering (DLS) and ζ-potential measurements, respectively.  
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For drug loading, 10-30 % (w/w) of drug was added to the initial 
organic polymer solution used either in the emulsion solvent 
evaporation or in the precipitation dialysis method (Tables 3.2 and 3.3). 
In the case of DOX addition of triethylamine (TEA) previous to 
emulsification was necessary to render the drug solubilized in DCM in 
the emulsion solvent evaporation method. In the case of PAALM-L and 
PAALM-F derivatives, methanol was used as cosolvent for drug 
encapsulation and was removed by rotaevaporation to avoid drug losses 
during dialysis. Precipitation dialysis procedure was used for TEO and 
CBZ encapsulation but using drug-saturated water for the dialysis 
process to reduce losses during dialysis.  
 
Table 3.3. Conditions for nanoparticle formation and drug encapsulation with the 
precipitation-dialysis method.
Derivative Solvent [Poly]a Drugb [Drug]ic Chapter
coPMLA-Et50H50
coPMLA-Bu50H50
DMSO 1 %
TMZ, 
DOX
10 % 5.
coPAALM-Lx
coPAALM-Fx
DMSO,
Methanol,
Acetone
0.5, 1 %
TMZ, 
DOX
30 % 6.
coPMLA-PrSRxHy
coPGGA-PrSRxHy
DMSO
NMP
0.25 %
1 %
TEO, 
CBZ
20 % 8.
a Polymer concentration: % (w/v).
b Encapsulated drug.
c Drug concentration in the organic solution related to the polymer (w/w).
 
 
Drug content was determined by dissolving 5 mg of drug-loaded 
nanoparticles either in DMSO, methanol or DCM and quantifying drug 
concentration by UV-vis spectrophotometry. Drug concentration was 
calculated from a calibration curve using known amounts of free drug as 
standards. Absorbance of drugs was measured at the following wave 
lengths: TMZ (330 nm), DOX (480 nm), TEO (275 nm) and CBZ (220 nm). 
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Encapsulation efficiency (EE) was calculated on the basis of the 
following formula:  
%  EE  =  _____________  · 100[ Drug ]final
[ Drug ]initial , 
where [Drug]final = drug concentration in the nanoparticles (w/w) and 
[Drug]initial = drug concentration in the initial organic solution related to 
the content of polymer (w/w).  
 
3.5. Drug loaded films 
Drug-loaded films (coPMLA-PrSRxHy and coPGGA-PrSRxHy) were 
prepared by casting. Briefly, 1 mL of 2 % polymer solution in CHCl3 and 
0.5 mL of 0.4 % CBZ solution in CHCl3 were mixed and slowly 
evaporated on a Teflon cast (20 % w/w CBZ/polymer). TEO loaded 
films were not possible to make because there was not a common solvent 
for polymers and drug. DSC analysis was performed on drug-loaded 
films to determine the crystalline state of the drug in the films.  
 
3.6. In vitro drug release 
In vitro drug release was evaluated by the dialysis method. Briefly, 
10 mg of freeze-dried drug-loaded nanoparticles were resuspended in    
1 mL of citrate buffer at pH 5.0 or phosphate buffer either pH 6.8 or 7.4 
(Table 3.4), and transferred into a dialysis tube with 8 kDa molecular 
weight cut-off. The tube was then immersed into 20 mL of buffer and left 
at 37 °C under slight stirring. 0.5 mL aliquots of the releasing medium 
were taken at scheduled times and the drawn volume replaced by fresh 
buffer. Drug concentration was determined by high performance liquid 
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chromatography (HPLC) at 330 and 480 nm for TMZ and DOX, 
respectively, using known amounts of free drugs as standards. Since 
TMZ is hydrolytically labile, its degradation product 5-aminoimidazole-
4-carboxamide (AIC) absorbing at 254 nm was also accounted. 
In vitro DOX release from PMLA/DOX conjugates was evaluated 
also as function of pH and ionic strength. Briefly, 10 mg of freeze-dried 
PMLA/DOX ionic complex particles were resuspended in 1 mL of buffer 
at either pH 5.0, 150 mM NaCl ionic strength, and at pH 7.4, 75, 150 or 
300 mM NaCl ionic strengths (Table 3.4). 2 mL aliquots of the releasing 
medium were taken at scheduled times and the drawn volume replaced 
by fresh buffer. Drug concentration was determined by UV-vis 
spectroscopy at 480 nm and cumulative drug release was calculated as a 
function of time. 
Theophylline and Carbamazepine concentrations were also 
determined by UV spectroscopy at 220 and 275 nm for CBZ and TEO, 
respectively. Cumulative drug release was calculated as a function of 
time.  
 
Table 3.4. Buffer conditions for in vitro drug release assays. 
Derivative Buffer pH Ionic strength 
PAALM-1 Phosphate 6.8, 7.4  
PMLA-Et100 
co PMLA-Et50H50 
PMLA-Bu100 
co PMLA-Bu50H50 
Phosphate 7.4  
coPAALM-Lx 
coPAALM-Fx 
Phosphate 7.4  
PMLA/DOX- 
Citrate 
Phosphate 
5.0 
7.4 
150 mM 
75, 150, 300 mM 
coPMLA-PrSRxHy 
coPGGA-PrSRxHy 
Phosphate 7.4  
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3.7. Cell lines and culture media 
Cell lines used in citotoxicity studies were primary human glioma 
U-87 MG and T98G, human invasive breast carcinoma MDA-MB-231 
and MDA-MB-468, and human brain metastatic lung cancer CRL-5904, 
obtained from American Type Culture Collection (ATCC, Manassas, VA, 
USA). U-87 MG and T98G cells were cultured in MEM media 
supplemented with the following ingredients (final concentrations): 10 % 
fetal bovine serum, 1 % MEM NEAA, 1 mM sodium pyruvate and 2 mM 
L-glutamine. For MDA-MB-231 and MDA-MB-468, Leibovitz’s L-15 
medium with 10 % final concentration fetal bovine serum was used, and 
for CRL-5904, RPMI 1640 (ATCC) medium was used. Cells were seeded 
at 104 cells per well (0.1 mL) in 96-well flat-bottomed plates and 
incubated overnight at 37 °C in humid atmosphere with 5 % CO2  for    
U-87 MG, T98G and CRL-5904 and without CO2 for MDA-MB-231 and 
MDA-MB-468 cell lines. 
 
3.8. Cytotoxicity tests and nanoparticles cellular uptake 
Cytotoxicity studies were performed on cells incubated for 1, 12, 
24 and 72 hours with freshly prepared nanoparticles suspensions, 
previously filtered on a 0.45 μm sterile filter, at increasing concentrations 
of polymer ranging from 1 to 1000 μg·mL-1, medium was replaced every 
48 h (Table 3.5). After the scheduled incubation time, the medium was 
removed and the cellular viability was estimated. For drug-loaded 
nanoparticles cell viability was measured on day 2 for DOX-loaded 
nanoparticles and day 7 for TMZ-loaded nanoparticles. Cell viability was 
assessed using the CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay kit (Promega, USA). In this assay the yellow [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt] (MTS) is bioreduced by cells into formazan 
that is soluble in the culture medium with a maximum absorbance at 490  
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nm. This reaction only takes place when mitochondrial reductase 
enzymes are active, and therefore the conversion and the Abs490 from the 
96-well plates can be directly related to cells viability.140 Viability of 
untreated cells was taken as 100 %.   
DOX uptake was investigated by fluorescent microscopy with cells 
prepared and treated as described above. After 2 h of incubation with 
DOX-loaded nanoparticles, cells were fixed with 4 % paraformaldehyde 
at room temperature for 10 min, cells nuclei were counter stained with 
4',6-diamidino-2-phenylindole (DAPI). The fluorescence from DOX was 
observed and free drug was used as positive control. For all experiments 
the constant concentration of DOX was 3 µM. 
 
3.9. Measurements 
DLS- Dynamic light scattering for particle hydrodynamical size 
and ζ-potential measurements were performed with a ZetaSizer NS 
(Malvern Instruments, UK) with particles suspended in deionized water. 
Displayed values are the average of ten readings. 
DSC- Differential scanning calorimetry profiles were recorded 
using a Perkin-Elmer Pyris-1 (Perkin-Elmer, USA) under nitrogen flow. 
Thermograms were obtained from 2-4 mg samples at heating and 
cooling rates of 10 °C min-1 to determine crystallinity state and 20 °C 
min-1 to determine polymers Tg. Indium and zinc were used as standards 
for calibration.  
Fluorescence microscopy- Cell fluorescence was accounted by 
using an inverted fluorescence microscope (Leica, Germany) at 40X 
magnification, exposure time set to 25 ms and provided with an 
appropriate filter set. 
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FT-IR- Fourier transform infrared spectras were acquired in a 
Perkin-Elmer Frontier FT-IR Spectrometer (Perkin-Elmer, USA)  
provided with a universal attenuated total reflectance (ATR) sampling 
accessory. Each run accumulated 4 scans. 
GPC- For gel permeation chromatography a Waters 515 HPLC 
pump equipped with a Waters 410 Differential Refractometer detector 
and a Waters Styragel HR 5E column (7.8 x 300 mm) (Waters, USA) was 
used. Solvent consisting of 0.05 M sodium trifluoroacetate in 
hexafluoroisopropanol at 0.5 mL·min-1 flow rate was applied. 
Chromatograms were calibrated against poly(methyl methacrylate) 
standards (Varian, USA).  
HPLC- High performance liquid chromatography was carried out 
with a Waters 600 system consisting of Waters 996 photodiode array 
detector (Waters, USA)  and an Inertsil ODS-3V column (5 µm, 4.6x250 
mm) (GL Sciences, USA) at an elution rate of 1 mL·min-1. Mobil phase for 
TMZ quantification was a mixture of methanol and 0.5 % aqueous acetic 
acid (10:90); and for DOX, a mixture of 0.02 M sodium hydrogen 
phosphate and acetonitrile (60:40). Drug concentrations were calculated 
with a calibration curve obtained from known amounts of free drugs as 
standards. 
NMR- 1H NMR spectras were recorded on a Bruker AMX-300 
(Bruker, Germany) instrument from samples immersed in D2O or 
dissolved in DMSO-d6, CDCl3 or methanol-d4 containing minor amounts 
of trifluoroacetic acid. Spectra where recorded at 25 °C operating at 300.1 
MHz, 128 scans were acquired with 32 k data points and relaxations of   
2 s. 13C NMR spectras were taken from deuterated acetone solutions with 
64 k data points and 5-10 x 103 scans with relaxation delays of 2 s.  
SEM- Scanning electron microscopy images were taken with a 
field-emission JEOL JSM-7001F instrument (JEOL, Japan) from 
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platinum/palladium coated (PMLA/DOX conjugates) and uncoated 
samples.  
TGA- Thermogravimetric analysis measurements were performed 
with a Perkin-Elmer TGA-6 thermobalance (Perkin-Elmer, USA) under 
nitrogen flow of 20 mL·min-1 from 10-15 mg samples at a heating rate of 
10 °C min-1. 
UV-vis-  Absorbance measurements were performed using a UV-
visible spectrophotometer CECIL CE 2021 (CECIL, UK) with 4 nm 
bandwidth. Samples were dissolved in DCM, methanol or DMSO using 
HPLC grade solvents. Drug concentrations were calculated with a 
calibration curve obtained from known amounts of free drugs as 
standards. 
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4 
 
Poly(Methyl Malate) Nanoparticles:  
Formation, Degradation and  
Encapsulation of Anticancer Drugs 
  
 
 
Aim and Scope  
The use of poly(β,L-malic acid) for biomedical applications has shown to 
be advantageous for its properties as biodegradability, non-immunogenecity, 
and bioresorbability. Nevertheless, because PMLA water-solubility, a chemical 
modification of the material might be done if a solid particulate drug delivery 
system is desired.  
Recently, the hydrophobization of PMLA has been done by the 
methylation of the polymer with diazomethane. This poly(α-methyl-β,L-malate) 
has been used for the formulation of erythromycin-loaded microparticles by the 
emulsion solvent evaporation technique. 
In this chapter we study the capability of poly(α-methyl-β,L-malate) for 
the formulation of hydrophobic nanoparticles and the encapsulation of 
anticancer drugs, which could have potential for crossing the blood brain barrier 
for brain cancer treatment. 
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Abstract 
PMLA nanoparticles with diameters of 150–250 nm are prepared, 
and their hydrolytic degradation is studied under physiological 
conditions. Degradation occurs by hydrolysis of the side chain methyl 
ester followed by cleavage of the main-chain ester group with methanol 
and L-malic acid as the final degradation products. No alteration of the 
cell viability is found after 1 h of incubation, but toxicity increases 
significantly after 3 d, probably due to the noxious effect of the released 
methanol. Anticancer drugs Temozolomide and Doxorubicin are 
encapsulated in the NPs with 20–40 % efficiency, and their release is 
monitored using in vitro assays. Temozolomide is fully liberated within 
several hours, whereas Doxorubicin is steadily released from the 
particles over a period of 1 month.  
 
1 μm
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4.1. Introduction 
Biodegradable polymers and their copolymers are the preferred 
materials for the manufacture of a variety of devices that are nowadays 
widely applied in medicine and pharmacology.19 One of their attractive 
potential uses is in the formulation of drug delivery systems (DDS) for 
parenteral administration.5 DDS systems based on polymer particles, 
either nanoparticles or microparticles, are clearly advantageous because 
(i) particle size and surface can be engineered to achieve passive or active 
drug targeting, (ii) drugs can be incorporated without chemical reaction, 
(iii) drug activity is optimally preserved and (iv) formulation can be 
delivered trough different routes of administration.80 In these systems 
polymer plays an essential role in the therapeutic function, because in 
addition to act as carrier, the system may be properly designed to control 
the drug delivery rate or its selective release at a specific site of action.6 
The application of DDS in chemotherapy has spread out rapidly in 
the last decades because their use allows to increasing drug 
concentration at a specific site and reducing systemic toxicity. Thus, DDS 
based on biopolymers or biodegradable synthetic polymers allow 
repeated treatment of patients without deposition and storage diseases. 
This has stimulated the modification of naturally occurring biopolymers 
and the development of new synthetic biodegradable polymers.20,21 
Synthetic poly(lactide-co-glycolide) (PLGA) derivatives have been the 
center focus of a great amount of research in the last decades due to their 
advantages respect to other systems.7
 
Nevertheless, PLGA micro- and 
nanoparticles (NP) devices still retain a number of drawbacks mainly 
related to their releasing pattern that largely limit their applications. 
New options based on biopolymers able to meet specific requirements 
are therefore being currently searched. In this regard, poly(β-L-malic 
acid) (PMLA) (Scheme 4.1) and its derivatives constitute a family of 
promising candidates.  
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PMLA is a water-soluble, biodegradable, bioabsorbable, and non-
immunogenic polyester141
 
that can be produced either by chemical 
synthesis20,142
 
or by fermentation of certain microorganisms.141
 
The 
properties and functionality of PMLA are adjustable by chemical 
derivatization.51
 
In fact, the carboxylic side group of PMLA can be 
modified to modulate the overall hydrophobicity of the polymer or to 
introduce bioactive ligands.50
 
Recently, we have reported the 
methylation of PMLA by diazomethane51
 
to create hydrophobic PMLA 
methyl esters suitable for the formulation of drug delivery 
microparticles.48
 
 
In cancer therapy, the treatment of tumor cells must proceed with 
minimal side effects to normal cells and nontoxic drug formulations 
should be applied.80
 
The use of polymeric DDS in such therapy is 
increasing in popularity since they are less immunogenic than viral 
vectors.50
 
Furthermore, DDS based on NPs offer clear advantages 
compared to microparticles for their potential ability to cross cell 
membranes. Once the polymer is selected, generation of NPs with the 
desired size and encapsulation efficiency are the foremost requirements 
to fulfill DDS design.  
In this work, we wish to report the preparation of NPs from 
poly(α-methyl-β-L-malate) (PAALM-1), their in vitro degradation under 
physiological conditions, and their capacity for encapsulation and 
delivery of drugs to treat brain cancer. A major factor limiting 
intracranial therapeutic levels of systemically administered active agents 
is the restriction of permeability imposed by the blood brain barrier 
(BBB).143
 
Temozolomide (TMZ) is widely recognized as one of the most 
effective antineoplastic agents for glial tumor, in great part due to its 
ability to cross the BBB. Some detrimental side effects have been 
observed however upon its prolonged systemic administration because 
high dosages have to be given in order to achieve the required 
therapeutic effect.144
 
A platform based on PMLA for the design of a water 
soluble nanoconjugate for brain tumor treatment has been described.59
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This nanoconjugate is known to cross the brain tumor barrier (BTB) by 
transcytosis using an attached antibody that binds to transferrin 
receptor. A similar nanobioconjugate based on PMLA for the delivery of 
TMZ has been recently published.62
 
 
 
 
Scheme 4.1. Repeating unit of PMLA (R=H) and its methyl ester PAALM-1 (R=CH3). 
 
4.2. Results and discussion 
4.2.1. Synthesis and characterization of PAALM-1 
PMLA was methylated to 100 % degree with diazomethane in dry 
acetone. This reaction allowed us to obtaining a complete esterification of 
the carboxylic side groups of PMLA without significant reduction in 
molecular weight. PAALM-1 precipitated from the reaction medium and 
was purified by repeated dissolution-precipitation in chloroform/ether. 
The final PAALM-1 was NMR spectroscopically pure and its weight-
average molecular weight and polydispersity determined by GPC were 
33 kDa and 1.4, respectively.  
 
4.2.2. Nanoparticles formation and characterization 
Spherical nanoparticles were obtained by the emulsion-
evaporation method using three emulsifiers at four different concen-
trations. We were also able to obtain NPs without using emulsifier by 
fast evaporation of the organic phase under reduced pressure; under 
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such conditions particle could be formed before coalescence of the 
disperse phase occurred. The overall appearance of the obtained 
nanospheres is shown in the SEM pictures of Figure 4.1. Light scattering 
measurements indicated that they have diameters with average values 
ranging between 100 and 350 nm, the smallest ones being those prepared 
in the absence of emulsifier, and a satisfactory polydispersity.  
 
 
Figure 4.1. SEM micrographs of PAALM-1 nanoparticles prepared using different 
emulsifiers, a) PVA-2 kDa, b) PVA-14 kDa, c) PMLA and d) without emulsifier. 
 
As it is seen in Figure 4.2, all samples show a unimodal 
distribution of sizes when analyzed by light scattering. The effect of 
emulsifier concentration on the size distribution profiles were not 
significant, which can be attributed to the governing effect of the solvent 
evaporation process. On the contrary, the influence of the applied 
sonication time was clearly noticeable. As demonstrated in Figure 4.2, 
size distribution profiles were displaced to the left and became narrower 
with increasing sonication time indicating that particles became smaller 
Chapter 4                
65 
 
and less polydisperse in size. Variation in particle size as a function of 
sonication time is plotted in Figure 4.3 showing that the particle diameter 
decreases with time approaching asymptotically to a value close to 220 
nm when an emulsifier was used for preparation and around 175 nm in 
the absence of emulsifier. According to the previous work carried out on 
NPs preparation using this method,120
 
such effect appears because the 
size of dispersed drops decreases with sonication time approaching to a 
minimum critical size, which is determined by the relative phase 
viscosities, interfacial tension between the phases and the magnitude of 
the emulsion generating force. In our case, where a rapid organic phase 
evaporation occurs and mean particle size is not affected by increasing 
emulsifier concentrations, it seems that it is emulsion droplet size 
(related to sonication time) rather than emulsion stability (related to 
emulsifier concentration) which determines the final particle size. This is 
fully consistent with the fact that NPs could be obtained in the absence of 
emulsifier and also with the different effect that emulsifier concentration 
and sonication times exerted on particle size. Particles sonicated for 45 s 
were chosen for the subsequent assays since their size differences are 
minimum. The characteristics of these NPs are compared in Table 4.1. 
 
 
Figure 4.2. Particle size distribution as a function of sonication time for particles 
prepared with and without emulsifier, as indicated.  
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 The ζ-potentials of the particles have average values between –20 
and – 34 mV with the highest negative value observed for NPs that were 
prepared without using emulsifier. As the ζ-potential is related to surface 
charges, it directly affects particle’s suspension stability. Usually a          ζ-
potential higher than 25 mV (positive or negative) is taken as the 
minimum to maintain the system in a stable disperse state. Our results 
indicate that NPs prepared using PVA as emulsifier do not reach such 
value whereas those prepared without emulsifier will be able to form 
well stable dispersions.  
 
 
Figure 4.3.  Decrease of mean particle diameter with sonication time. Error bars stand 
for standard deviations. 
 
 
Table 4.1. Mean diameter, size polydispersity index (Pd.I.) and ζ-potential of 
nanoparticles used for degradation. 
Nanoparticle Emulsifier 
Diameter  
(nm) 
Pd.I. 
ζ-potential 
(mV) 
NP-PVA2 PVA 2kD 222 0.033 -23.3 
NP-PVA14 PVA 14kD 231 0.193 -20.6 
NP-PMLA PMLA 238 0.063 -25.7 
NP - 207 0.236 -33.9 
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4.2.3. Hydrolytic Degradation 
The hydrolytic degradation rate of PAALM-1, both in powder 
form and as NPs, was comparatively estimated by following the 
evolution of the molecular weight with incubation time (Figure 4.4). 
PAALM-1 NPs showed a degradation rate lower than the powder. After 
18 weeks of incubation, when the powder appeared completely 
degraded, the polymer in the NPs still retained between 25 and 75 % of 
its original molecular weight depending on the procedure applied for 
emulsification. A problem associated to the use of emulsifier is its 
binding on the particles surface. Since emulsifier stays at the oil/water 
interface during solvent evaporation, it presumably remains attached to 
the surface of the particle altering thereby the surface composition and 
consequently the degradation rate. The occurrence of irreversible 
binding of PVA on particle surface of PLGA at the water/DCM 
interphase has been reported by several authors,127,145
 
and the slow 
degradation rate observed for such particles was related to the relatively 
low digestibility of the PVA coating.146
 
As it is shown in Figure 4.4, NPs 
prepared either without emulsifier or with PMLA emulsifier, degraded 
much faster than those prepared using PVA, which strongly supports 
that also in our case, PVA attached to NPs surface acts as a hydrolysis 
protecting coat. Nevertheless, what it is really worthy to note is that 
PAALM-1 NPs degrade considerably faster than those made of poly(α-
benzyl β-malate), which has been reported to undergo only 40 % of 
molecular weight reduction after 20 weeks of incubation.5
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Figure 4.4. Hydrolytic degradation of PAALM-1 powder and nanoparticles in PBS 
pH 7.4 at 37 °C. Nanoparticles were prepared using three different emulsifiers or 
without emulsifier.  
 
Hydrolytic degradation mechanism of PAALM-1 was studied in 
deuterated water at 60 °C by NMR analysis of the incubating medium 
using powder samples (Figure 4.5a). At the physiological temperature of 
37 °C, hydrolysis rate was so low that signals arising from degraded 
products were almost undetectable in the first months of incubation. 
Conversely, a singlet signal corresponding to methanol, which is 
released in the hydrolysis of the ester side group, started to be observed 
after only 1 week of incubation at 60 °C. This signal increased 
continuously with time until complete hydrolysis of the 
methoxycarbonyl group. Conversely, the signal corresponding to the 
methyl group attached to the polymer chain appeared after 3 weeks 
indicating the presence of soluble chain fragments in the supernatant. 
This solubilized material may be oligomers or partially side chain 
hydrolyzed PAALM-1 long fragments. As the polymer began to be water 
soluble, the hydrolysis rate increased so the spectra recorded after 5 
weeks of incubation showed signals corresponding to a mixture of 
degradation compounds including methanol, malic acid, and more or 
less methylated oligomers.  
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A similar NMR analysis carried out with PAALM-1 NPs revealed 
that the degradation mechanism was essentially the same as observed 
with powder but with noticeable differences in the timing of signal 
appearance. 1H NMR spectra recorded at increasing incubation times 
from the supernatant of the NPs made with PMLA as emulsifier or 
without emulsifier (not shown), were very similar to the case of the 
powder. On the basis of the collected NMR and GPC data, and in 
agreement with previous results reported by us on partially methylated 
PMLA,48
 
the basic mechanism that can be outlined for the hydrolytic 
degradation of PMLA is depicted in Scheme 4.2.  
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Scheme 4.2. Hydrolytic degradation mechanism of PAALM-1 at 37 °C.   
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4.2.4. Cytotoxicity 
For its potential use as a biomaterial it was mandatory to evaluate 
the toxicity of NPs made of fully methylated PMLA. Thus, an in vitro 
study of PAALM-1 NPs cytotoxicity on human glioma cell lines U-87 
MG and T98G, and invasive human breast carcinoma cell lines MDA-
MB-231 and MDAMB-468, was performed. Cellular viability was 
measured as a function of polymer concentration using the MTT test for 
contact times of 1, 12, 24, and 72 h between polymer and cells. As it is 
expected, results obtained for all cell lines indicated that the percentage 
of viability decreased when contact time and concentration of polymer 
increased (Figure 4.6). The effect of the NPs on cell viability depended 
also on cell line type so that glioma U-87MG and breast cancer MDA-
MB-231 cells were more affected than glioma T98G cells and breast 
cancer MDA-MB-468 cells.  
Toxicity caused by physical damage due to membrane disruption 
may be neglected since NPs effect on cell viability is not manifested in 
the time scale of 1 h. In a way similar to that observed for partial 
hydrolyzed PAALM-1 derivatives,47
 
it is highly probable that the low 
toxicity observed was due to the effect of methanol that is released 
during polymer degradation. Both methanol and L-malic acid are 
generated in the hydrolysis of PAALM-1 but whereas L-malic acid is 
converted into water and carbon dioxide in the tricarboxylic acid cycle, 
methanol is known to adversely affect the living cells. Similar results 
have been reported for NPs made of other PMLA derivatives, where 
cytotoxicity was also related to the degradation products generated in 
the cell culture media.21
 
Nevertheless, the toxicity observed for exposure 
times over 12 h may be considered negligible, because in DDS 
applications residence times for NPs in the human body will be only a 
few hours before they are cleared from blood through the renal system.  
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Figure 4.6. Cell viability, of human glioma cell lines U-87 MG and T98G and invasive 
breast carcinoma cell lines MDA-MB-231 and MDA-MB-468 after different contact 
times between polymer and cells as a function of polymer concentration.  
 
4.2.5. Drug Encapsulation and in vitro Release 
TMZ and DOX encapsulation was made in PAALM-1 without 
using emulsifiers in order to avoid exhaustive washing and minimize 
drug losses. Although both drugs were encapsulated by the same 
method, DOX was encapsulated with a higher efficiency than TMZ 
(Table 4.2), due to the higher solubility of TMZ in water or the poor 
solvent compatibility between the drug and the polymer. Both drugs 
display a remarkable affinity for polar solvents which causes a diffusion 
of these compounds from the organic phase to the aqueous phase during 
emulsion’s generation. In the case of DOX this phenomena could be 
reduced by the addition of TEA to modify DOX solubility and increase 
its encapsulation efficiency.  
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The releasing profiles of TMZ from PAALM-1 NPs obtained at 
different pH are shown in Figure 4.7. The analysis of TMZ release under 
physiological conditions is complex because above pH = 7.0 it undergoes 
fast hydrolysis yielding AIC together with the methyldiazonium ion, 
which is the chemotherapeutically active molecule.147,148
 
For a correct 
evaluation of the in vitro TMZ release, it will be therefore necessary to 
quantify the delivery of both compounds. A releasing assay carried out 
at pH 6.8 revealed that a significant decomposition took place even at 
this pH. Nevertheless, there is meaningful differences in the AIC release 
profiles generated at pH 7.4 and 6.8, which clearly indicate that the 
formation of AIC follows the release and decomposition of TMZ from 
the particles. The release of TMZ seems to be independent of pH, but its 
half-life time appeared to be longer at pH 6.8, as it was expected. Thus, 
firstly TMZ was delivered from PAALM-1 NPs and then it decomposed 
forming AIC with the consequent release of the methyldiazonium ion.  
 
Under physiological conditions the release of DOX followed a 
much lower rate than TMZ. Whereas only a few hours were required for 
a complete release of TMZ the complete liberation of DOX needed more 
than 1 month (Figure 4.8). Since the releasing profile of DOX follows 
more or less closely the degradation profile of PAALM-1, it can be 
reasonably concluded that the delivery of this drug is governed by the 
hydrolysis of the polymer. On the contrary, the fast release of TMZ must 
happen by diffusion during the first stages of the NPs degradation. The 
different chemical nature of TMZ and DOX account for the remarkable 
differences they display in their releasing from PAALM-1 NPs.  
Table 4.2. PAALM-1 nanoparticles encapsulation of TMZ and DOX. 
 Drug content %a EE %b 
TMZ 2.18 ± 0.17 21.75 ± 1.7 
DOX 4.20 ± 0.62 42.06 ± 6.2 
a Percentage of drug contained  in the  nanoparticles upon encapsulation (w/w).   
b Percentage of the drug that is encapsulated. 
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Figure 4.7. Profiles of TMZ in vitro release from PAALM-1 nanoparticles and 
formation of AIC from released TMZ at pH 7.4 and pH 6.8. 
 
 
 
 
Figure 4.8. DOX in vitro release from PAALM-1 nanoparticles at pH 7.4. 
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4.3. Conclusions 
Fully methylated polymalic acid obtained by methylation of fungal 
PMLA is a biodegradable polyester that can be used to produce 
nanospheres with an average diameter of around 200 nm and ζ-potential 
of –20 to –35 mV depending of the kind of emulsifier used in the 
preparation. PAALM-1 NPs prepared using polyvinylalcohol as 
emulsifier degraded slower than without emulsifier indicating that PVA 
acts as a hydrolysis protecting coat. In aqueous buffer particles 
hydrolyze releasing methanol followed by main chain ester bond 
cleavage. DOX and TMZ can be encapsulated in the NPs and released 
upon incubation under physiological conditions. TMZ was released 
within a few hours with subsequent hydrolytic pH-dependent activation 
resulting in AIC, while DOX was released in a time scale of days. These 
differences agree with the different chemical nature of both drugs. The 
particles described (in the absence of loaded TMZ or DOX) did not show 
a sign of toxicity after a few hours of administration but cell viability is 
significantly altered after days of contact. Although PAALM-1 NPs are 
suitable for either short or long time DDSs depending on the chemical 
nature of the drug, long residence times are expected to result in 
undesired side effects.  
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5 
 
Nanoparticles of Esterified Polymalic Acid for  
Controlled Anticancer Drug Release 
 
 
 
Aim and Scope  
Cancer treatment with nanovehicles has increased since the elucidation of 
the enhanced permeation effect by cancerous tumors. This phenomenon allows 
the passive accumulation of nanosystems without a targeting receptor for a 
specific spatial delivery. 
Nanoparticle formation and anticancer drugs encapsulation has been 
achieved with poly(α-methyl-β,L-malate), but a certain degree of cytotoxicity to 
prolonged exposure times was related to the methanol released during the 
hydrolytic degradation of the material. 
The search of less cytotoxic PMLA derivatives impels this study, where 
PMLA is modified by esterification with short alkyl chains. The evaluation, of 
the synthesized derivatives, as nanoparticulate drug delivery systems of 
anticancer drugs is carried out. 
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Abstract 
Esterification of microbial polymalic acid was performed with 
either ethanol or 1-butanol to obtain polymalates conjugates capable to 
form nanoparticles for drug encapsulation and release. Degradation of 
these nanoconjugates upon incubation under physiological conditions 
took place by cleavage of the ester groups of both main and side chains 
with release of malic acid and the corresponding alcohol as unique 
degradation products. Fully and partially esterified polymers were used 
to obtain nanoparticles in the range of 100-350 nm by precipitation 
dialysis and emulsion solvent evaporation techniques. The anticancer 
drugs Temozolomide and Doxorubicin were encapsulated in 
nanoparticles with efficiency between 17 and 37 %, respectively. In vitro 
drug release essays showed that Temozolomide was almost completely 
discharged in a few hours while Doxorubicin was steadily released along 
several days. Cell cytotoxicity and cellular uptake of nanoparticles was 
assessed with MDA-MB468 and U87-MG cell lines. Unloaded 
nanoparticles did not display cytotoxicity while drug-loaded ones 
showed remarkable effectiveness against cancer cells. Nanoparticles 
made of partially ethylated polymalic acid were those that showed the 
highest cellular uptake. 
 
DOX 
fluorescence
Cell nucleus 
stain
DOX in Cells
1 μm
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5.1. Introduction 
Nowadays, biodegradation and bioassimilation are indispensable 
qualities of any polymer intended for temporal applications in human 
therapy.18 Accordingly biodegradable and safe polymers are the 
preferred materials for the manufacture of many devices that are today 
used in medicine and pharmacology.19 Such requirements have 
stimulated efforts towards both the modification of naturally occurring 
biopolymers and the synthesis of new polymers with biodegradable and 
biocompatible properties.20,21 In this regard, poly(β,L-malic acid) (PMLA) 
and its derivatives constitute a family of promising candidates. PMLA is 
a poly(β-hydroxy propionate) derivative with a carboxylic group 
stereoregularly attached to the α-carbon of the repeating unit (Scheme 
5.1). The polymer is water-soluble, nontoxic, biodegradable, 
bioresorbable and non-immunogenic.141,149 PMLA can be produced by 
either chemical synthesis20,142 or by biosynthesis.24 Degradation of PMLA 
produces easily metabolizable L-malic acid.26 At difference from most 
common biodegradable polyesters such as polylactides, polyalkanoates 
or polycaprolactone, PMLA is a functional polymer whose properties are 
adjustable trough chemical modification of the pendant carboxylic side 
group;51 not only the overall hydrophobicity of the polymer may be 
controlled by partial esterification but also bioactive ligands may be 
incorporated by reaction with appropriate agents.50 
 
O
HOOC O
 
Scheme 5.1. Chemical formula of poly(β,L-malic) acid.  
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The application of drug delivery systems (DDS) in chemotherapy 
has spread out rapidly in these last years since their use reduces systemic 
toxicity and allows to increase drug concentration at the specific site. 
Although cancer cells are more vulnerable than normal cells to the effect 
of chemotherapy agents, drugs are nonselective and can affect normal 
tissues. The use of polymeric DDS in cancer therapy is increasing in 
popularity because they are less immunogenic than protein-based 
vectors, and allow repetitive administration without acute or chronic 
host immune response.62 Furthermore DDS systems based on polymer 
particles, either nanoparticles or microparticles, are clearly advantageous 
by several reasons: a) particle size and surface can be engineered for 
passive or active drug targeting, b) drugs can be incorporated without 
chemical reaction, c) drug activity is optimally preserved during 
transportation to the site of action, and d) different routes of 
administration are optional for drug delivering.2,6,80,116,117 
PMLA and its derivatives have been used either as platform in the 
synthesis of nanoparticles for drug delivery18,21,53,56,95,150 or as backbone 
in macromolecular conjugates bearing several functionalities to treat 
human brain and breast tumors in mouse models.50,59,151,152 It was 
concluded from these investigations that PMLA is a very suitable 
polymer for building efficient drug delivery systems. Recently we 
reported on methylated PMLA nanoparticles and showed that the cell 
toxicity of this system increased significantly after long time periods of 
incubation due to the noxious effect of the released methanol. In this 
work we report on other esters of PMLA, which are expected to display 
less cytotoxicity. These new esters are obtained by partial or total 
esterification of PMLA with ethanol or 1-butanol, and the nanoparticles 
made from them are explored for their suitability as DDS for the 
anticancer drugs Temozolomide and Doxorubicin. 
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5.2. Experimental 
5.2.1. PMLA esterification with ethanol and 1-butanol 
Esterification of PMLA was performed at room temperature with 
PMLA dissolved in the alcohol of choice and using 
dicyclohexylcarbodiimide (DCC) for activation of the carboxylic side 
group. Briefly, to 1 mmol of PMLA in 3 mL of either ethanol or 1-
butanol, 0.5 or 1.0 mmol of DCC dissolved in 2 mL of the same alcohol, 
according to the desired esterification degree, were added dropwise 
under stirring and the reaction was left to proceed for 2 h. Exhaustive 
removal of dicyclohexylurea (DCU) was achieved by successive dialysis 
of the reaction solution against methanol for 24 h and water for 6 h using 
a cellulose membrane of 8 kDa cutoff. The resulting polyesters were 
lyophilized for recovery and storage and their conversion degree and 
purity ascertained by 1H NMR.  
 
5.3. Results and discussion 
5.3.1 Synthesis and characterization 
Ethyl and butyl PMLA esters with esterification degrees of 
approximately 50 % and fully esterified were obtained by reaction of 
PMLA with ethanol and 1-butanol, respectively, using 
dicyclohexylcarbodiimide as activator (Scheme 5.2). Esterification results 
are summarized in Table 5.1. 
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O
HOOC O
ROH, DCC
O
ROOC O
O
HOOC O
H2O, DCU
PMLA coPMLA-RxHy
x y
 
Derivative  R  x/y  
coPMLA-Et50H50  Et  50/50 
PMLA-Et100  Et  100/0  
coPMLA-Bu50H50  Bu  50/50  
PMLA-Bu100  Bu  100/0  
Scheme 5.2. Esterification reaction of PMLA.  
 
The esterification degree was controlled by adjusting the added 
amount of DCC so that conversions close to the used DCC/PMLA molar 
ratios were obtained in both cases. Reaction yields were around 50-70 % 
with higher values afforded in the esterification with ethanol. Product 
losses during polymer isolation and purification are the most probable 
reasons accounting for such relatively low yields. Molecular weights of 
esterified products were found to be higher than that of PMLA and they 
show a logical increasing correlation with the values that should be 
expected from ethyl and butyl grafting for the attained conversions. 
However, the experimental values are slightly lower than the theoretical 
ones when individually compared, and polydispersity increased 
noticeably. Such results seem to indicate therefore that some degradation 
must take place during esterification, an event that apparently was more 
significant when the butyl group was introduced. Nevertheless, the 
esterified polymers were spectroscopically pure giving 1H NMR spectra 
in full agreement with the expected constitution and without showing 
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any sign of chain end groups (see appendix 1, Fig. A1.1-A1.4); 
apparently low molecular weight species eventually generated by 
degradation were removed along the treatments applied for isolation 
and purification with the subsequent lowering of yields, as observed. 
The reason of determining glass transition temperatures will be 
explained forward, but we can observe that the insertion of ethyl and 
butyl groups have a significant effect lowering Tg, showing a bigger 
effect with increasing number and length of the alkyl grafted chains, so 
100 % esterified PMLA presented lower Tg than their respective 
copolymers (Table 5.1). 
 
5.3.2. Hydrolytic degradation 
Hydrolytic degradation assays were carried under physiological 
conditions (pH 7.4, 37 °C), and also in a slightly acidic medium (pH 5.0, 
37 °C) intended to simulate the occurring environment inside of mature 
lysosomes. Results obtained by GPC for the incubated PMLA-Et100 and 
PMLA-Bu100 samples are compared in Figure 5.1. These polyesters after 
degradation produced monomodal GPC chromatograms with single 
peaks and values almost steadily decreasing with time following a 
steeper slope for the ethyl than for the butyl derivative as well as for the 
acidic than for the neutral solutions. Large differences were found 
between the two extreme cases; whereas the Mw of PMLA-Bu100 
incubated at pH 7.4 decayed less than 10 % of the original value, a 
decreasing near 50 % was observed for PMLA-Et100 incubated at pH 5.0. 
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Figure 5.1. Evolution of the molecular weight of PMLA-Et100 and PMLA-Bu100 
incubated in aqueous buffer at pH 7.4 and 5.0 at 37 °C.  
 
Degradation of coPMLA-Et50H50 and coPMLA-Bu50H50 followed a 
more complex pattern. Bimodal or trimodal GPC chromatograms 
indicative of the occurrence of populations with different molecular 
weights were invariably registered from the residues left by these 
copolyesters upon incubation (Figure 5.2). To understand these results it 
is necessary to make clear that chains with low esterification degree are 
water soluble and they therefore escape the GPC analysis.  
Chromatograms were deconvoluted using Peakfit software to monitor 
the two main peak distributions with time (Figure A1.5). Taking into 
account the evolution of the two-deconvoluted peaks allows inferring 
that the one appearing at shorter retention times must represent the 
original polymer chains, while the second one with a much lower 
molecular weight must correspond to oligomeric products coming from 
the parent chain with a relatively high degree of esterification. The 
change in signal intensity of the low Mw chains between the third and 
fourth week of incubation suggests the occurrence firstly of significant 
cleavage of the initial polymer to generate oligomers and then the 
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degradation of these oligomers taking place at higher rate than that of 
the remaining higher molecular weight chains. 
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Figure 5.2. GPC chromatograms of: a) coPMLA-Et50H50 and b) coPMLA-Bu50H50, after 
incubation in aqueous buffer at pH 7.4 for the indicated times. 
 
1H NMR was employed for getting insight the degradation 
mechanism by identifying and monitoring the soluble products that are 
generated upon incubation of the polymers.  Degradation spectra of 
PMLA-Et100 are presented in Figure 5.3. Results obtained with PMLA-
Bu100 (Figure A1.6) were almost identical indicating that the same 
degradation mechanism must operate in both systems. The first 
detectable NMR signals appeared after three weeks of incubation and 
they corresponded to the alcohol (ethanol or 1-butanol) released from the 
hydrolysis of the lateral chain ester group. Differences between the two 
polymers started to be appreciated after week 8th. At this time, the 
spectrum recorded from the PMLA-Et100 degradation medium showed 
the signals characteristic of the ethyloxycarbonyl group while those of 
the butyloxycarbonyl group did not appear in the incubation medium of 
PMLA-Bu100 until week 13th.  These results are a clear indication of the 
faster degradation and/or easier solubilization that takes place in 
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PMLA-Et100 compared to PMLA-Bu100. Signals corresponding to PMLA 
oligomers, partially esterified polymer and free malic acid are present in 
both samples after week 13th but displaying higher intensity in the case 
of the ethyl derivative. After twenty weeks of incubation of PMLA-Et100, 
ethanol and free malic acid were the only products detected in the 
incubation medium of PMLA-Et100.  In the degradation of PMLA-Bu100, 
signals corresponding to the butyloxycarbonyl group were still 
observable at week 25th according to the higher reluctance of this group 
to be hydrolyzed.  
Degradation of copolymers proceeded following a pattern similar 
to homopolymers but at higher rates since their unmodified carboxylic 
units confer them a marked hydrophilicity. 1H NMR spectra of coPMLA-
Et50H50 incubated at pH 7.4 and 37 ºC for three months are presented in 
Figure 5.4. Degradation started after only a week of incubation as it is 
revealed by the spectrum recorded at that time from the incubation 
medium. Signals indicative of the presence of ethanol, malic acid and 
oligomeric species are detected in the spectrum recorded from the 
supernatant after just a week of incubation. After two weeks, signals 
arising from terminal groups increased whereas those arising from the 
main chain diminished, which is taken as an unequivocal indication of 
the occurrence of main chain breaking with generation of oligomers. 
These oligomers still contain unhydrolysed malate units as it is revealed 
by the presence of signals arising from ethyl and butyl side groups. At 
the third week signals from free alcohol and malic acid increased in 
intensity, while those from the alkyl esters and oligomers became weaker 
as it is expected to result from the progressive hydrolysis of the lateral 
and main chain ester bonds. After week 6th, the only observable signals 
are those arising from malic acid and the alcohol, which are obviously 
the final products of degradation. Note that the weakening observed of 
signals for the alcohols over time is due to partial evaporation of these 
volatile compounds. A similar mechanism was concluded that must be 
operating in the degradation of coPMLA-Bu50H50 (Figure A1.7). 
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Figure 5.3. 1H NMR spectra of the degradation media over time for PMLA-Et100 at 
pH 7.4. 
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Figure 5.4. 1H NMR spectra of the degradation media over time for coPMLA-Et50H50 
at pH 7.4. 
 
5.3.3. Nanoparticle formation 
Given the potential application intended for these polyesters as 
DDS, their capability to form nanoparticles was assessed. Due to 
differences in polarity between fully and partially esterified PMLAs, two 
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different methods were employed for nanoparticle formation. The 
emulsion solvent-evaporation method was preferred for the most 
hydrophobic homopolymers (PMLA-Et100 and PMLA-Bu100), whereas for 
the copolymers coPMLA-Et50H50 and coPMLA-Bu50H50, which are 
amphiphilic polymers, the precipitation dialysis method was instead 
employed. According to what is largely experienced in the self-assembly 
of polymers, formation of nanoparticles composed of an inner 
hydrophobic core and an outer shell made of hydrophilic groups should 
be expected.84 
Dynamic light scattering (DLS) measurements (size distribution 
profiles in Figure A1.8) revealed that particles of nanometric size with 
average hydrodynamic diameters in the 250-350 nm range were obtained 
for the homopolymers by using the emulsion-evaporation method (Table 
5.2). Much smaller particles with average diameters between 100 and 200 
nm were obtained from the copolymers by precipitation dialysis method. 
Moreover, SEM observations revealed significant morphological 
differences among them. As shown in Figure 5.5, nanoparticles with 
pretty defined spherical shape were observed for all the polymers except 
for PMLA-Bu100 (Figure 5.5b). In this case the particles displayed a much 
larger size than that determined by DLS and their shapes were not well 
outlined. This is interpreted as the result of the coalescence probably 
occurring upon deposition of the particles on the support used for 
sample preparation. Such particular behavior displayed by PMLA-Bu100 
is in agreement with its relative low Tg (Table 5.1) and its homogeneous 
constitution. The combination of these two factors could render sticky 
particles prone to coalesce when in contact with each other. Some signs 
of a similar behavior are also detected for PMLA-Et100 in Figure 5.5a 
although in this case the particles still retain their spherical shape. Given 
the unsatisfactory behavior of PMLA-Bu100 particles, they were 
discarded in subsequent drug encapsulation and release assays. 
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5.3.4. Drug encapsulation and in vitro release 
For encapsulation of Temozolomide and Doxorubicin in the 
nanoparticles, the same procedure as for nanoparticle formation was 
applied but with the drug added to the initial polymer solution. Results 
obtained for esterified PMLA excluding PMLA-Bu100, are presented in 
Table 5.2 for the two drugs. Encapsulation efficiencies (EE) in the 13-38 % 
and 17-37 % ranges were achieved for TMZ and DOX, respectively. It is 
remarkable that EE values are very similar for both drugs encapsulated 
in PMLA-Et100, and that higher values were attained when the emulsion 
method was used. Low encapsulation efficiencies and drug contents 
obtained for copolymers could be explained by drug loses taking place 
during solvent removal by dialysis for nanoparticle formation. The 
higher content obtained for DOX compared to TMZ in the partially 
esterified PMLA particles is probably due to the capability of this 
cationic drug to form ionic complexes with the carboxylic groups  
remaining present in the copolymer, in a similar manner as it has been 
reported to occur in other polyelectrolyte systems.103 Limited drug 
loading and burst drug release are features usually associated to 
encapsulation and delivery in nanoparticles due to their small available 
volume and large surface area.116 
Drug release was measured under close to physiological 
conditions, i.e. at pH 7.4 and 37 °C. It should be taken into account that 
TMZ is susceptible of degradation in water at pH 7 with generation of 
AIC; the half-life time of TMZ under such conditions is 2 h.148 Both 
compounds must be monitored therefore in order to evaluate the actual 
release of TMZ. In Figure 5.6 it is shown that the maximum TMZ release 
took place between 2 and 4 h of incubation with a cumulative release of 
60 % of the content in the case of coPMLA-Et50H50. Later the TMZ 
concentration peak decreased drastically due to its decomposition 
whereas the AIC concentration increased to reach a constant level after 
24 h. It is worthy to note that polymer nanoparticles still released TMZ 
after 24 h of incubation. Comparison of the releasing profiles for the 
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three polymers revealed that most of the drug was delivered within the 
first few hours of incubation, and that the release was faster as the 
hydrophilicity of the polymer increased. In fact, traces of TMZ releasing 
from PMLA-Et100 nanoparticles were detected even after 48 h of 
incubation (Figure 5.6). Such high retention and resistance against 
hydrolysis of TMZ loaded in these particles is probably due to the higher 
hydrophobic character of ethyl polymalate. 
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Figure 5.6. Temozolomide release from polymer nanoparticles at pH 7.4 and     37 °C. 
 
 DOX was released much slowly that TMZ following a 
continuously increasing profile that after several days reaches a constant 
value (Figure 5.7). coPMLA-Bu50H50 shows the fastest release while 
PMLA-Et100 shows the slowest one. It is also remarkable that release 
differences among the polymers in the case of DOX are larger than for 
TMZ.   
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Figure 5.7. Doxorubicin release from polymer nanoparticles at pH7.4 and 37 °C.  
 
5.3.5. Cell viability and nanoparticles cellular uptake  
Cytotoxic tests were performed with unloaded and loaded drug 
nanoparticles on cell lines U87-MG and MDA-MB468; U87-MG cells are 
used as an in vitro model of human glioblastoma, while MDA-MB468 is 
a cell line for breast carcinoma cells. Both are extensively used to 
investigate the cytotoxic effect of chemotherapeutic drugs towards 
cancer cells. Cytotoxicities of unloaded nanoparticles were practically 
negligible, since at the tested concentrations cell viability remained 
above 94 %, except for PMLA-H50Bu50 which caused decays to 90 % 
viability for MDA-MB468 cell line at higher concentrations (Figure 5.8). 
The cytotoxicity of these derivatives (ethyl and butyl polymalates) 
results to be significantly lower than that observed for methyl 
polymalate which cell viability decayed to less than 80 % after 24 hour of 
exposure of the cells to the nanoparticles. The higher toxicity displayed 
by the methyl derivative was attributed to the action of methanol 
released during polymer degradation.153 
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Figure 5.8. Cytotoxicity test of unloaded and drug-loaded nanoparticles and free 
drugs on U-87-MG and MDA-MB468 cell lines. a, b), Doxorubicin treatment and        
c, d), Temozolomide treatment. 
 
In toxicology, half maximal effective concentration (EC50) refers to 
the concentration of a drug where 50 % of its maximal effect is observed 
or where 50% of the population exhibits a response, after a specified 
exposure time, in our case 50% of viability after 2 or 7 days depending 
on cell line, after been exposed 24 h to the treatment. Cytotoxicity 
response on cell lines is plotted in Figure 5.8, as a function of drug 
concentration, and EC50 values are summarized in Table 5.3. In general 
loaded nanoparticles need more concentration to exert the same effect 
than the free drugs, with coPMLA-Et50H50/drug showing the closest 
behavior to free drugs. Second in response are PMLA-Et100 nanoparticles 
except for U87-MG cell line with DOX, in which coPMLA-Bu50H50/DOX 
presented lower concentrations for EC50. The most remarkable case is 
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observed for MDA-MB468 cell line treated with TMZ and TMZ-NPs, in 
which free TMZ showed ineffectiveness at all concentrations, while TMZ 
loaded nanoparticles reach EC50 between 100-200 μM TMZ 
concentrations. This difference can be due to two different phenomena, 
first to a more extended TMZ presence in the media since free TMZ has a 
half life of 2 h in aqueous media, and second, to NP internalization by 
cells and TMZ release in the cytosol making the cells more sensitive to 
the drug.  
  
 
To evaluate the cellular uptake and trafficking of DOX loaded 
nanoparticles in U87-MG cells, we performed microscopic studies based 
on red autofluorescence of DOX (Figure 9). DOX loaded coPMLA-Et50H50 
nanoparticles showed the most intense auto-fluorescence compared to 
the other samples; this auto-fluorescence is localized in the cytoplasm 
and cell nucleus, while cells treated with free-DOX demonstrated 
significantly less auto-fluorescence and only inside the nucleus. Loaded 
nanoparticles from coPMLA-Bu50H50 and PMLA-Et100 showed a limited 
internalization what is consistent with cytotoxicity results. The effective 
protection of TMZ against degradation, the slow release of DOX, the low 
citotoxicity and the effective internalization mainly of coPMLA-Et50H50 
Table 5.3. Cytotoxicity EC50 values for free and encapsulated drugs in 
polymer nanoparticles. 
 TMZ  DOX 
 
 
U87-MG 
(μM) 
MDA 
MB468 
(μM) 
 
 
U87-MG 
(μM) 
MDA 
MB468 
(μM) 
Free drug 37 > 400  1 0.08 
PMLA-Et100/Drug 133 130  30 0.8 
PMLA- Et50H50/Drug 50 105  1 0.2 
PMLA- Bu50H50/Drug 260 200  10 10 
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nanoparticles, make this derivative a potential material for the 
encapsulation and delivery of drugs for cancer treatment. 
 
Red channel DAPI stain Red channel + DAPI stain
Untreatedcells
DOX
coPMLA‐Et50H50
coPMLA‐Bu50H50
PMLA‐Et100
 
Figure 5.9. Fluorescence microscopy of U87-MG cells incubated with free DOX and 
DOX-loaded nanoparticles. DOX autofluorescence in the red channel. 
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5.4. Conclusions 
 Microbial polymalic acid both fully and partially esterified with 
ethanol or butanol are easily hydrolysable polyesters than can be 
employed for building nanoparticles suitable for drug encapsulation as 
drug delivery systems. The final degradation products of these polymers 
are the innocuous corresponding alcohol and easily metabolyzable malic 
acid. Nanoparticles diameters oscillate from 100 to 350 nm depending on 
the polymer and on the methodology used for particle formation and 
encapsulation. DOX and TMZ can be encapsulated in these nanoparticles 
and released upon incubation under physiological conditions. Most of 
the TMZ was released within a few hours with subsequent hydrolytic 
degradation into AIC, while DOX was steadily released in a time scale of 
days. Furthermore TMZ encapsulation afforded protection to the drug 
against hydrolytic decomposition. Drug-unloaded nanoparticles were 
not cytotoxic for the tested cell lines, whereas drug-loaded nanoparticles 
were cytotoxic for cancer cell lines. In the case of MDA MB468 cells, drug 
loaded particles were highly efficient, while free TMZ did not show a 
measurable effect. The most efficient polymer nanoparticles were 
coPMLA-Et50H50 which showed better internalization of DOX by cells 
than the free drug.  
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6 
 
Modification of Microbial Polymalic Acid  
with Hydrophobic Amino Acids for  
Drug Releasing Nanoparticles 
 
 
Aim and Scope  
As a promising material for the design of drug delivery systems; PMLA 
and its derivatives have been used as platform of nanocarriers or as a constituent 
in macromolecular conjugates for drug delivery. The capability of PMLA to 
form nanoparticles and encapsulate active substances has been proved by two 
different methods. 
Particles differ in terms of drug loading capacity, particle and drug 
stability, drug release rate, targeted delivery ability and toxicity. As we increase 
the diversity of materials we also augment the possibility and range of 
application of the systems. 
This chapter treats about the use of bioorganic molecules, amino acids, for 
modification/hydrophobization of PMLA for nanoparticle generation. This kind 
of modification/functionalization has been used before in DDS for 
hydrophobization or to confer membranolytic properties to the systems. 
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Abstract 
Microbial poly(β,L-malic acid) was modified with either L-leucine 
ethyl ester (L) or L-phenylalanine methyl ester (F) to produce 
amphiphilic copolymers. The degradation of these copolymers in 
aqueous buffer took place under physiological conditions in a few weeks 
by hydrolysis of the side chain ester group followed by cleavage of the 
main chain with releasing of soluble oligomers and L-malic acid. 
Spherical nanoparticles with diameters ranging between 70 and 230 nm 
were prepared from these copolymers by the dialysis-precipitation 
method. No alteration of the cell viability was observed after 24 h of 
incubation of these nanoparticles in different cell lines provided that 
concentrations were maintained below 0.125 % (w/v). Anticancer drugs 
Temozolomide and Doxorubicin were encapsulated in nanoparticles 
with 15-30 % efficiency. Drug release from the nanoparticles in aqueous 
buffer was monitored in vitro; Temozolomide was released within 
several hours whereas Doxorubicin took several weeks to be completely 
liberated. 
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6.1. Introduction 
Contemporary cancer therapy is in urgent need of increasing the 
treatment efficiency. Although cancer cells are more vulnerable than 
normal cells to the effect of chemotherapy agents, drugs are nonselective 
and unavoidably affect normal tissues. Research is now focused on 
killing cancer cells using more specific targeting because toxicity of 
normal cells is the main constrain for dose and frequency, both being 
critical important factors in determining the efficiency of the cancer 
chemotherapy treatment.119 In the last decades, drug delivery systems 
(DDS) based on biodegradable polymeric nanoparticles (NPs) have 
received great attention as effective carrying devices. Nowadays, 
biodegradation is considered a prerequisite for any high molecular 
weight material which is to be introduced in a living body for a limited 
period of time.18 
Nanoparticles for drug delivery include numerous architectural 
designs in terms of size, shape, and materials. Particles differ in terms of 
drug loading capacity, particle and drug stability, drug release rate, and 
targeted delivery ability.119  A variety of polymers have been tested and 
proved to deliver the drug to a target site thus increasing the therapeutic 
benefit while minimizing side effects.6 Polymer based delivery systems 
are usually preferred because they are less immunogenic than protein-
based ones, and they allow repetitive treatments without acute or 
chronic host immune response, which is a major requirement for the 
effective cancer treatment.62 
Poly(β,L-malic acid) (PMLA), a biologically produced polyester, 
has a great potential in biomedicine because its excellent 
biodegradability and biocompatibility. PMLA is readily biodegraded 
producing easily metabolizable L-malic acid.26 Unlike other 
biodegradable polymers, PMLA can be chemically modified through 
derivatization of the carboxylic side groups to change and modulate its 
properties.95 PMLA and its derivatives have been used as platform in the 
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synthesis of nanocarriers for drug delivery,21,53,56,153 or as a constituent in 
macromolecular conjugates bearing several functionalities to treat 
human brain and breast tumors in mouse models.50,59,151 In all of these 
investigations it has been concluded that PMLA is a promising building 
block for the design of efficient drug delivery systems.49  
Unmodified PMLA is highly hydrophilic and readily soluble in 
water due to its carboxylic polyfunctionality. Grafting of hydrophobic 
amino acids or peptides on hydrophilic polymers has been done to give 
an amphiphilic character to the polymer so it could form NPs,84 or to 
introduce a membranolytic shell which helps DDS to escape from 
endosomes to cytoplasm.59 In this work, with the aim of inducing 
amphiphilic character, PMLA has been subjected to partial amidation 
with alkyl esters of L-leucine (L) (PAALM-L) and L-phenylalanine (F) 
(PAALM-F). The partially amidated polyesters were used for preparing 
self-assembled nanoparticles and the suitability of these as drug delivery 
systems has been examined.  
 
6.2. Experimental 
6.2.1. Synthesis of poly(β,L-malic acid)-graft-AA  
PMLA was conjugated with L-leucine ethyl ester or                      
L-phenylalanine methyl ester, by activation of the carboxylic side groups 
with dicyclohexylcarbodiimide (DCC) (Scheme 6.1). Briefly, 1 mmol of 
PMLA was dissolved in 4 mL of acetone at room temperature (RT) and 
the solution cooled in an ice bath. The amino acid used for grafting and 
DCC in 1 mL of acetone were added dropwise. The amino acid and DCC 
amounts depended on the conversion degree that was desired (Table 
6.1). Reaction was left to proceed under stirring for 1 h at 4 °C and then 
for 23 h at RT, after which the reaction mixture was cooled in the freezer 
and the precipitated dicyclohexylurea (DCU) removed by filtration. To 
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remove DCU traces remaining in solution, the filtrated polymer solution 
was dialyzed against methanol for 24 h using a cellulose membrane with 
a cutoff of 8 kDa. The modified PMLA was recovered from the dialyzed 
solution by adding water and subsequent freeze-drying.  
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Scheme 6.1. Amidation reaction of PMLA using DCC as activating agent. 
 
6.3. Results and discussion 
6.3.1. Amino acid grafting on PMLA 
PAALM-L and PAALM-F copolymers nominally containing 30, 60 
and 90 % of amidated units were obtained at yields in the 55-65 % range 
by reaction of PMLA with the esterified amino acids L-leucine and         
L-phenylalanine using DCC as carboxylic group activator (Table 6.1). 
Conversions attained were precisely assessed by 1H NMR (Figure 6.1) 
and the GPC analysis showed that the initial polymer did not undergo 
significant reduction in the molecular weight. All copolymers are soluble 
in dimethylsulfoxide, acetone and HFIP but non-soluble in diethyl ether 
and water. Only the copolymers amidated at 90 % were soluble in 
chloroform. 
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Figure 6.1. 1H NMR spectra of: A) PAALM-L60 and B) PAALM-F60. (*) Peak of 
water.  
 
Unfortunately, the 13C NMR spectra recorded from these 
copolymers did not provide the information required to carry out a 
statistical analysis of the chain microstructure. Nevertheless, the 
evolution of the signal arising from different carbons of the amino acid 
moiety units (a, a’) with changes in composition revealed that the 
distribution of amidated and free-carboxylic units along the copolymer 
chain must be essentially at random. As it is illustrated in Figure 6.2, this 
signal evolves from an essentially single peak for the 90 % amidated 
PMLA to a doublet for both the 30 and 60 % amidated copolymers with 
relative peak intensities changing according to composition. The 
observed splitting is interpreted as due to the presence of dyads made of 
amidated-amidated (LL or FF) and amidated-non-amidated (LM/ML or 
MF/FM) units, which is an indication of a random microstructure. 
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Figure 6.2. 13C NMR spectra of the amino acid region corresponding to aCH2 of  
PAALM-L (A) and  non protonated aromatic carbon of PAALM-F (B) of copolymers 
with different conversion degrees. 
 
6.3.2. Hydrolytic degradation 
The hydrolytic degradation of the copolyesters was performed 
under physiological conditions (pH 7.4, 37 ºC), and the process was 
followed by GPC of the residue and by 1H NMR of the released 
products. According to expectations, GPC results showed that 
degradation rate decreased with the increasing amidation degree of the 
copolyester and results were similar for both Leu and Phe derivatives. 
As it is shown in Figure 6.3, the 30 % amidated copolyesters become 
fully degraded after four weeks of incubation whereas for the 90 % 
amidated copolymers, the reduction in molecular weight was less than 
30 % after six weeks of treatment. 
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Figure 6.3. Molecular weight reduction of PAALM-L and PAALM-F copolyesters as 
a function of incubation time in PBS, pH 7.4 at 37 ºC. 
 
The copolyesters PAALM-L60 and PAALM-F60, which are those 
with a more equilibrated compositions, were used to carry out the 
analysis of the released products by NMR and results are shown in 
Figure 6.4. Samples were incubated at 37 °C in deuterated water, and 1H 
NMR signals arising from degradation soluble products were monitored.  
In the case of PAALM-L, the spectra clearly revealed the presence of 
ethanol in the solution just after two weeks of incubation as well as of 
free malic acid at the seventh week. In addition, signals from leucine 
methyl groups and from the polyester main chain were also detectable 
suggesting either oligomer solubilization or partial polymer 
solubilization. As expected, all signals increase in intensity at longer 
incubation times except those arising from oligomers which show a 
progressive diminution. For PAALM-F the hydrolysis proceeded 
similarly with methanol being the first product detected in the mother 
solution, and with signals arising from the degraded main chain 
products coming out after twenty weeks of incubation. 
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Figure 6.4. Evolution of the 1H NMR spectra recorded from the water mother 
solution of the incubation of  PAALM-L60 at 37 °C with time.   
 
These NMR results supported by others previously obtained by us 
in the hydrolytic degradation of alkyl esters of PMLA suggest the 
hydrolytic mechanism for the copolyesters PAALM-L and PAALM-P 
depicted in Scheme 6.2. Hydrolysis starts with the cleavage of the amino 
acid ester groups with releasing of the corresponding alcohol, and 
continues with the splitting of the main chain at the ester linkages 
between non-amidated units with generation of oligomeric fragments 
and malic acid. Oligomers become solubilized or not depending on their 
amidation degree, and finally the hydrolysis of the main chain is 
completed with releasing of malic acid and free L-leucine or                     
L-phenylalanine.  
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Scheme 6.2. Hydrolytic degradation mechanism of PAALM-L. 
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6.3.3. Nanoparticles formation 
Spheric nanoparticles were prepared from copolymers PAALM-L 
and PAALM-F by applying the precipitation-dialysis method. An 
exploratory study of the influence of preparation conditions and 
copolymer conversion on the characteristics of the resulting 
nanoparticles was performed. Solutions at two different polymer 
concentrations (0.5 and 1.0 % w/v) in acetone, DMSO and methanol 
were tested. It was found that NPs were formed under all assayed 
conditions with a mean hydrodynamic diameter ranging between 70 and 
230 nm (Table 6.2) depending on both the procedure applied and 
copolymer chosen. Firstly, the nanoparticle forming capability of 
copolymers with varying composition was examined, and results 
obtained with the PAALM-F series are illustrated in Figure 6.5. As it 
could be anticipated,[15] the morphology of the formed NPs varied with 
the ratio of hydrophobic to hydrophilic counterparts. 
 
 
Figure 6.5. Nanoparticles of PAALM-F copolymers with different amidation degrees 
obtained from a 1.0 % (w/w) DMSO solution: a) PAALM-F30, b) PAALM-F60, and  
c) PAALM-F90. Scale bar: 1 µm. 
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Table 6.2. Mean hydrodynamic diameter of PAALM-L and PAALM-F nanoparticles obtained by the
precipitation-dialysis method under different conditions.
PAALM-L PAALM-F
Conva 30 60 90 30 60 90
Concb 1.0 0.5 1.0 1.0 1.0 0.5 1.0 1.0
DMSO 110±35 66±29 141±24 95±13 123±29 113±34 159±54 104±18
Methanol 126±27 76±38 199±36 109±31 145±18 137±37 222±42 - c
Acetone 173±20 156±33 227±19 139±12 180±24 180±41 231±22 147±35
a Degree of amidation (%).
b Initial concentration of the polymer solution (% w/v).
c Not measured in MeOH due to non-solubility of the copolymer in this solvent.
 
 
NPs prepared from 60 % amidated copolymers produced well 
defined nanospheres essentially exempted of amorphous material. On 
the other hand, solvent was the factor mainly deciding the nanoparticle 
size, the minimum values and dispersities being obtained with DMSO. 
This effect is well illustrated in Figure 6.6 for the case of PAALM-L 
copolymers. Results were very similar for the two series although 
particle sizes were much smaller when they were made from leucine 
amidated copolymers.  
 
 
Figure 6.6. Nanospheres of PAALM-L60 prepared from 1 % (w/w) solution in 
different solvents: a) DMSO, b) methanol, and c) acetone. Scale bar: 1 µm. 
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6.3.4. Nanoparticle cytotoxicity 
For its potential use as a biomaterial it was mandatory to evaluate 
the toxicity of nanoparticles. Thus, an in vitro study of PAALM-L60 and 
PAALM-F60 nanoparticles cytotoxicity on primary human glioma cell 
lines U-87MG, human non-small cell lung cancer, (metastatic in brain), 
CRL-5904, and invasive human breast carcinoma cell line MDA-MB-468, 
was performed. All cell lines presented a similar pattern with cell 
viability remaining near 100 % after 24 h of exposure to NPs in 
concentrations lower than 125 µg·mL-1. At higher concentrations there is 
a significant reduction in cell viability (Figure 6.7). Such concentration 
dependent cytotoxicity is related to the binding of polymer to 
membrane, followed by copolymer intrusion and irreversible membrane 
reorganization followed by a lytic event. Interactions between the 
copolymer hydrophobic microdomains and lipid bilayer membranes 
would explain membrane binding of the copolymers with subsequent 
membrane disruption.154 
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Figure 6.7. Cell viability of U-87-MG, CRL-5904 and MDA-MB-468 after 24 h of 
contact between polymer NPs of PAALM-L60 and PAALM-F60 and cells as a 
function of polymer concentration.  
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Ding and coworkers59 observed that an increase in hydrophobicity 
and/or elimination of negative charges resulted in membranolytic 
activity of PMLA copolymers. They also found that the density of 
substituents on the polymer chain have an effect on membranolytic 
activity, observing a maximum efficacy at 40-60 % of substituents. The 
viability drop of U87MG after treatment with 0.5 % (w/v) of PAALM-L 
and PAALM-F60, could be also observed by optical microscopy and 
related with a significant change in cell morphology, which is more 
drastic after a treatment with 1 % (w/v) of NPs (Figure 6.8). 
 
PAALM-L
Control                                 0.5μg/mL                       1μg/mL
PAALM-F
 
Figure 6.8. Cell morphology of cultured cells after 24 h incubation at 37 ºC for U-
87MG cell line in the presence of nanoparticles of PAALM-L60 (top) and PAALM-
F60 (bottom). 
 
6.3.5. Drug encapsulation and in vitro release 
PAALM-L60 and PAALM-F60 nanoparticles were chosen for 
studying the Temozolomide and Doxorubicin encapsulation and 
releasing. Drugs were encapsulated by the precipitation dialysis method, 
using methanol as the common solvent for both, drugs and polymer. The 
two copolymers showed a very similar behavior, with an entrapment 
Modification of PMLA with hydrophobic AA 
 
113 
 
around 5 % (w/w) of TMZ and 8 % (w/w) for DOX. Although drug 
contents in the NPs could be considered acceptable, the encapsulation 
efficiency was low; DOX was entrapped about 28 % of its initial 
concentration and TMZ only around the half of such value (Table 6.3).  
The higher encapsulation efficiency for DOX can be explained by the fact 
that this compound could form ionic complexes with anionic 
polyelectrolytes.103 Compared to our results obtained in the 
encapsulation of these drugs in poly(methyl malate) (PAALM-1) 
nanoparticles, encapsulated contents were doubled in the present case, 
which is likely due to the possibility of using a common solvent for both 
drug and polymer. 
 
 
Cumulative Temozolomide release profiles from PAALM-L60 and 
PAALM-F60 nanospheres are presented in Figure 6.9. Since TMZ 
undergoes fast hydrolysis above pH 7.0 yielding AIC together with the 
methyldiazonium ion, which is the chemotherapeutically active 
molecule,147,148 the analysis of the release profile under physiological 
conditions is complex. Thus, for a correct evaluation of in vitro TMZ 
release, it will be therefore necessary to quantify the delivery of both 
compounds, TMZ and AIC. The releasing profiles are very similar for the 
two copolymers, reaching almost 60 % of TMZ release after 3 hours of 
incubation and displaying a progressive decay concomitant to its 
hydrolytic degradation, after which TMZ was not longer detectable. 
Simultaneously, AIC concentration increased rapidly from the third hour 
Table 6.3. Drug content and encapsulation efficiency of Temozolomide and 
Doxorubicin in PAALM-L60 and PAALM-F60 nanoparticles.  
 TMZ  DOX 
 % Conta % E.E.b  % Cont.a % E.E.b 
PAALM-L60 4.9 ± 1.5 16.4 ± 5.1  8.5 ± 1.2 28.5 ± 4.2  
PAALM-F60 4.2 ± 0.8  14.2 ± 6.2   8.4 ± 0.6 28.0 ± 2.1  
 
a Percentage (w/w) of drug contained in the nanoparticles upon encapsulation. 
b Percentage of initial drug that is encapsulated. 
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to the ninth, and more slowly afterwards. After 24 h of incubation, 
released TMZ was completely degraded. These results suggest that TMZ 
was firstly released form nanoparticles and then decomposed in the 
medium forming AIC with the consequent release of the 
methyldiazonium ion. A similar pattern of behavior was observed for 
the TMZ releasing from poly(methyl malate) nanoparticles.153  
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Figure 6.9. Profiles of TMZ in vitro release from PAALM-L60 and PAALM-F60 
nanoparticles and formation of AIC from released TMZ at pH 7.4. 
 
The release of DOX from PAALM-L60 and PAALM-F60 followed a 
similar profile in the two systems (Figure 6.10). The profiles were much 
simpler and revealed a much slower delivery rate than for TMZ; while 
only a few hours were required for the complete liberation of TMZ, the 
complete release of DOX took more than ten days. Such a comparative 
delay is likely to be due to the ionic interaction taking place between 
DOX and the free carboxylic groups present in the copolymers. Recently 
a similar behavior for the release of DOX from poly(γ-glutamic acid) 
particles has been reported[19], and it has been shown that DOX release 
was highly pH dependant; they found that at pH 2.2, which is below 
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PGGA pKa, the release reaches 60 % after 180 h of incubation whereas at 
pH 7.4 it was below 20 % after such time, a behavior very close to that 
observed in this work. 
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Figure 6.10. DOX in vitro release from PAALM-L60 and PAALM-F60 nanoparticles at 
pH 7.4. 
 
6.4. Conclusions 
Microbial polymalic acid partially amidated (30-90 %) with 
hydrophobic L-leucine (L) and L-phenylalanine (F) amino acid esters can 
be used to produce nanospheres with an average diameter ranging 
between 70 and 230 nm, depending on the kind of amino acid and the 
solvent used for preparation. The amino acid ester-grafted copolyesters 
are readily hydrolyzed in water at physiological conditions in times of 
weeks at a rate that decreases with the increasing degree of amidation. 
DOX and TMZ can be encapsulated in these nanoparticles and released 
upon incubation under physiological conditions. TMZ was released 
within a few hours with subsequent hydrolytic pH-dependent 
conversion into AIC, while DOX was steadily released in a time scale of 
days. The particles described did not show a sign of toxicity during the 
24 hours of administration provided that NPs concentration is kept 
below 0.125 mg·mL-1. 
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Poly(β,L-Malic Acid)/Doxorubicin Ionic Complex:  
a pH-Dependent Delivery System 
  
 
Aim and scope  
The main drawback of anticancer chemotherapeutics is its high toxicity 
to both, cancer and healthy cells and tissues, especially Doxorubicin which can 
cause heart diseases. A strategy for improving therapeutic efficacy and limiting 
DOX toxicity has been to encapsulate the drug in carriers. In most of the drug 
delivery systems, drug is covalently attached or dissolved in the polymer matrix. 
But, for the case of polyelectrolytes, like PMLA, they are able to bind to an 
oppositely charged drug by electrostatic interactions forming a drug-polymer 
ents its ponic interactions are an effective way to bind a drug to a polymer; these 
Ionic interactions are an effective way to bind a drug to a polymer; these 
interactions and therefore the formation of the ionic complex are pH dependant. 
As a result, drug-polymer ionic complexes are suitable candidates for drug 
delivery pH responsive systems. This chapter analyzes the capability of 
complexation between DOX and biotechnologically produced PMLA, for the 
generation of a pH-dependent drug delivery system. 
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Abstract 
Poly(β,L-malic acid) (PMLA) was made to interact with the cationic 
anticancer drug doxorubicin (DOX) in aqueous solution to form ionic 
complexes with different compositions and an efficiency near to 100%. 
The PMLA/DOX complexes were characterized by spectroscopy, 
thermal analysis, and scanning electron microscopy. According to their 
composition, the PMLA/DOX complexes spontaneously self-assembled 
into spherical micro or nanoparticles with negative surface charge. 
Hydrolytic degradation of PMLA/DOX complexes took place by 
cleavage of the main chain ester bond and simultaneous release of the 
drug. In vitro drug release studies revealed that DOX delivery from the 
complexes was favored by acidic pH and high ionic strength. 
 
DOX
PMLA
Self‐assembled
microparticleDOX release
Malic acid
Stacked
DOX
PMLA/DOX 
ionic complex
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7.1. Introduction 
Biopolymer particles have found important applications as drug 
delivery systems and constitute an ideal option for encapsulating drugs 
since their activity, solubility, cell permeability and stability can be tuned 
by using polymers with appropriate chemical and physical 
properties.80,103 Poly(β,L-malic acid) (PMLA) is a water-soluble, 
biodegradable, bioabsorbable and non-immunogenic polyester141 that 
can be produced by either chemical synthesis20,142 or by fermentation of 
certain microorganisms.24 The properties and functionality of PMLA are 
adjustable by chemical derivatization; in fact PMLA has been esterified 
in different degrees to modulate the overall hydrophobicity of the 
polymer47,95,153 or to introduce bioactive ligands.50 PMLA ionizes readily 
in water (pKa ~ 3.5) giving rise to a highly soluble polycarboxylate;24 
under these conditions it is able to be readily coupled with cationic 
compounds by stable ionic interactions.  
Doxorubicin (DOX) is an anthracycline antibiotic that has been 
used for over 30 years as a potent chemotherapeutic antineoplastic agent 
to treat a wide spectrum of human cancers, especially breast cancer and 
lymphoma.137 However, its therapeutic efficacy is limited because DOX 
long-term clinical use is compromised by the toxicity common to 
anthracycline drugs. Although encapsulation of DOX in lipid micelles 
has been used to overcome such shortcomings,155,156 several essential 
attributes like drug release timing are difficult to control. New 
alternatives, like pH dependent release, are emerging with the purpose 
of optimizing the therapeutic action of DOX.157-159  
The release of the drug in the free form from delivery systems is a 
prerequisite for the activity of most of the antitumor active agents. To 
attain a high antitumor activity along with a satisfactory cell-specificity, 
the characteristics of the polymer as well as the type of linkage between 
drug and carrier have to be properly chosen.138 Chemical conjugation of 
DOX to poly(aspartic acid) has been done but it was revealed that was 
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actually the unconjugated DOX in the micelle which exerted the 
therapeutic effect.160 Conjugation via acid-cleavable hydrazone bond has 
also been explored.134,159 Other alternatives investigated has been the 
physical entrapment of DOX by nanoparticles150,153 or micelles,161 which 
offers advantages such as easy preparation and low cost but also suffers 
disadvantages such as limited drug loading and difficulty in drug 
release control.  
Ionic interaction is an effective way to bind a drug to a polymer.162 
Such association is possible between polyelectrolytes and charged drugs 
and is termed as polymer/drug complexation.103 The pH changes 
occurring within the body can address the response of the complex to a 
certain tissue or cellular compartment.163,164 Carboxylic polymers, as it is 
the case of PMLA, are suitable candidates for pH responsive systems. 
These polyelectrolytes usually ionize in the 3 to 10 pH range to render 
polyanions able to bind substantial amounts of cationic drugs owing to 
their high negative charge density. DOX complexation with various 
polymeric systems like poly(acrylic acid),165 poly(γ-glutamic acid)103 and 
dextran sulfate137 has been earlier reported. In this work we studied the 
complexation between DOX and microbially produced PMLA, as an easy 
and clean option for DOX encapsulation and pH-dependent release. To 
our knowledge it is the first time that polymalic acid is used as 
polyelectrolyte for direct coupling with a therapeutic drug. The well 
demonstrated capacity of PMLA to be bioassimilated along with its 
excellent hydrodegradability and biodegradability confer to this kind of 
complexes an exceptional interest for building pH-dependent drug 
delivery systems.  
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7.2. Experimental  
7.2.1. PMLA/Doxorubicin ionic complexes synthesis 
Ionic complexes of PMLA with DOX with different molar ratios 
were obtained by a simple and clean method. Briefly, to 1 mmol of 
PMLA dissolved in 4 mL of milli-Q water, pH ~ 6.0 (final pH  ~ 4), 0.1, 
0.25 or 0.5 mmol of DOX dissolved in 2 mL of the same solvent were 
added dropwise under magnetic stirring, and left to react overnight in 
the dark to prevent DOX photodegradation. Non-attached DOX was 
removed by extensive dialysis against deionized water for 48 h using a 
cellulose membrane of 8 kDa molecular weight cut-off. The PMLA/DOX 
ionic complexes precipitated from solution and were lyophilized for 
recovery and storage. The complexation degree attained was determined 
by 1H NMR. 
 
7.3. Results and discussion 
7.3.1. Synthesis and characterization 
Poly(β,L-malic acid) (PMLA) ionizes readily in water giving rise to 
a highly soluble polyanion. The pKa of biologically produced PMLA has 
been determined to take values within the 3.4-3.6 range so it is 
extensively charged under physiological conditions.24 On the other hand, 
DOX is a positively charged amphoteric drug containing one protonable 
amino group in the sugar moiety with a pKa=8.6 and two deprotonable 
phenolic groups in the aglycone part of the molecule; thus an 
equilibrium exists between the positively charged, negatively charged 
and neutral species of DOX depending on pH. In the 0-6 pH range, the 
amino group in DOX is protonated as NH3+ which makes possible its 
electrostatic binding to negatively charged PMLA;103 in fact, non-
stoichiometric ionic complexes with polymer/drug molar ratios of 10:1, 
4:1 and 2:1 were successfully obtained by precipitation upon mixing the 
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two components in an aqueous medium that was initially set at pH 4.0 
(Scheme 7.1). Complexes precipitated from the solution displacing the 
equilibrium towards their continuous formation. 
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Scheme 7.1. Non-stoichiometric ionic complex PMLA/DOX.  
 
The complexes were formed with high efficiency for whichever 
composition with more than 90 % of the added drug becoming ionically 
coupled to PMLA (Table 7.1). Such loading efficiency was up to three 
times higher than that attained in the physical entrapment of DOX in 
esterified PMLA derivatives using the emulsion-evaporation153 or 
precipitation-dialysis methods.150 The partial charge neutralization 
taking place upon complexation resulted in the instantaneous 
precipitation of a reddish product in the form of particles. For 
PMLA/DOX-(10:1) and PMLA/DOX-(4:1), particles remained in a 
colloidal suspension, while those made of PMLA/DOX-(2:1) tend to 
aggregate and settle down onto the bottom of the container.  
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Table 7.1. Coupling reaction characterization.
Feed Ratio
mol:mol
Complex 
Composition
(mol:mol)
Efficiency 
(%)
Yield 
(%)
Mw
(g mol-1)
PMLA - - - - 32,000
PMLA/DOX-(10:1) 1:0.10 1:0.09 99 85.7 29,300
PMLA/DOX-(4:1) 1:0.25 1:0.23 92 83.3 29,800
PMLA/DOX-(2:1) 1:0.50 1:0.46 92 80.5 29,600
 
 
 Since aqueous PMLA/DOX mixtures evolve with immediate 
precipitation of the complex, the occurrence of interactions between the 
two components in solution is difficult to investigate. To approximate 
the question 1H NMR spectra were taken from aqueous solutions of 
malic acid/DOX mixtures over a wide range of composition ratios, and 
compared to the spectra of the pure components. No differences were 
detected for any composition, which can be taken as indicative of 
complete absence of specific interaction between MLA and DOX in 
aqueous solution (1H NMR spectra shown in the Support Information, 
appendix 2, Figure A2.1). 
 Conversely the formation of the ionic PMLA/DOX complex in 
the solid state could be ascertained by infrared spectroscopy. The FT-IR 
profiles registered from the 2:1 complex and from its components, both 
separately and physically mixed are compared in Figure 7.1, and 
characteristic absorption bands are listed in Table 7.2. Main changes 
detected in the spectrum of the ionic complex compared to that 
registered from the physical mixture or PMLA and DOX are the 
disappearance of the 3528 and 1521 cm-1 bands, as well as the decrease in 
intensity of the 869 and 802 cm-1 bands; all these bands are associated to 
the DOX NH bond vibrations (stretching, bending or wagging), and their 
absence indicates that the DOX amine group must be directly involved 
in the association of the drug with the polyacid, most probably through 
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ionic interaction. Similar changes in the DOX infrared spectrum were 
reported in the work of Kayal and Ramanujan,166 in which they 
demonstrated the attachment of DOX to PVA coated iron oxide 
nanoparticles via amine-hydroxyl interactions. In order to support our 
interpretation the solid product resulting from evaporating an aqueous 
solution containing equimolar amounts of malic acid and DOX was also 
examined by FTIR. The spectrum from the compound showed also a 
large decreasing of the 1521 cm-1 DOX band according to what should be 
expected for the interaction of the amine group of DOX with the 
carboxylic group of malic acid (Figure A2.2).  
 
Table 7.2. FT-IR of PMLA and DOX, their physical mixture (2:1), and their ionic 
complex (2:1). 
Absorption bands (cm-1)  Assignment 
PMLA DOX PMLA+DOX PMLA/DOX   
 3528 3528   ν(O-H) free 
 3316 3316   ν(H-O) bonded 
 3160-2300 3160-2300   ν(NH3+) 
 2897 2897   ν(C-H) 
1730 1730 1730 1730  ν(C=O)a 
 1615 1615 1615  ν(C=O)b 
 1580 1580 1580  ν (C=C) 
 1521 1521   δ(N-H) 
 1413 1413 1413  δ(CH) 
 1283,989 1283,989 1283,989  ν(C-O-C) 
1157   1157  ν(O-C-C) 
 1071 1071 1071  ν(C-O) 
1044 
    ν(C-O), 
 ν(Cα-Cβ) 
 869/802 869/802 869  ω(N-H) 
 
a Band from ketone in DOX. 
b Bands from quinone carbonil associated by intramolecular hydrogen bonds. 
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Figure 7.1.  FTIR spectra of the PMLA/DOX-(2:1) complex, the PMLA+DOX (2:1) 
physical mixture, DOX, and PMLA. 
 
The amount of drug bound to the polymer was quantified by 
NMR spectroscopy. The 1H NMR spectra of complexes and their 
components are compared in Figure 7.2. Calculations for drug content 
were done using the signal at 1.55 ppm arising from the methyl group 
attached to the pyrano moiety in DOX and the signal located at 5.6-5.9 
ppm, which arises from the PMLA main chain CHα and one CH of DOX. 
The PMLA/DOX molar ratios in the complexes as determined by this 
method are listed in Table 7.1, which were found to be very close to the 
feed. 
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Figure 7.2. 1H NMR spectra of PMLA, DOX and PMLA/DOX ionic complexes. 
 
7.3.2. Thermal characterization 
A DSC analysis of the complexes was carried out in order to 
appraise their thermal behavior. The DSC traces of PMLA, DOX, their 
physical mixture with a 2:1 ratio, and the ionic PMLA/DOX-(2:1) 
complex are compared in Figure 7.3. The DSC trace of PMLA displayed a 
wide melting peak at 210-215 °C, indicative of the semicrystalline nature 
of this polymer, and the trace of DOX presented a well-defined melting 
peak at 231 °C characteristic of highly crystalline material. Conversely 
the trace registered from the PMLA+DOX physical mixture is essentially 
similar to that of PMLA with the melting peak broadened and displaced 
downwards due to the presence of DOX, which presumably was 
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dispersed in molten PMLA. On the contrary, the heat exchange 
detectable in the trace of the PMLA/DOX-(2:1) complex was almost 
imperceptible indicating that crystallinity of PMLA was largely 
suppressed due to the ionic interaction taking place between the drug 
and the polymer. Furthermore, the total absence of the characteristic 
DOX melting peak on the complex may be taken as demonstrative of 
that no pure DOX precipitated separately during complexation. 
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Figure 7.3. DSC traces of the PMLA/DOX-(2:1) complex, the PMLA+DOX-(2:1) 
physical mixture, PMLA and DOX. 
 
The thermal stability of DOX/PMLA complexes was evaluated by 
thermogravimetry. The TGA traces of the complexes and their 
components are compared in Figure 7.4. The initial weight loss of about 
5 % seen on the TGA traces of samples containing PMLA is attributed to 
their moisture content. More than 90 % of weight loss of PMLA occurred 
over the 200-250 °C range, which is consistent with the degradation 
signal that is observed by DSC overlapping the melting of the polymer. 
On the other hand, DOX degradation was found to happen along three 
steps that started at 237, 320 and 400 °C, respectively, and that entailed a 
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total weight loss of 50 % of the initial mass. The complexes also 
presented a degradation in three steps but at lower onset temperatures 
and entailing smaller weight losses and that are depending on 
composition. Remaining weights after heating at 800 °C were 20, 27 and 
38 %, for 10:1, 4:1 and 2:1 PMLA/DOX complexes respectively. In the 
three cases thee second degradation step happened about 325 °C with a 
weight loss corresponding to the DOX degradation second step.  
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Figure 7.4. DSC traces of the PMLA/DOX-(2:1) complex, the PMLA+DOX-(2:1) 
physical mixture, PMLA and DOX. 
 
7.3.3. Particle formation and characterization 
Particles formed during drug-polymer complexation were 
examined by scanning electron microscopy. Since the ionic complexes 
are amphiphilic they are expected to self-assemble in water to form 
spherical particles, presumably with the hydrophobic DOX-coupled 
PMLA units integrating the inner particle core and the remaining ionized 
polymer segments preferentially located near to the surface. In fact, 
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individually dispersed microspheres for 10:1 and 4:1 complexes and 
aggregated nanospheres for 2:1 complex were observed (Figure 7.5).  
 
 
Figure 7.5. SEM micrographs of PMLA/DOX complex particles. a) PMLA/DOX-
(10:1), b) PMLA/DOX-(4:1), and c) PMLA/DOX-(2:1).  
 
The hydrodynamic average diameter of microparticles determined 
by DLS was around 1.5 µm while in nanospheres it was ten times 
smaller, i.e. 150 nm approximately. The result is comparable to that 
reported for the chemical conjugation of DOX with poly(α-aspartic acid) 
which changed the initial hydrophilic units of the polyacid into 
hydrophobic blocks by ionic coupling with the drug. The coupled DOX 
will self-assembly to form a hydrophobic micelle core.160 A somewhat 
simple model illustrating the possible structure of the particles is 
depicted in Figure 7.6. The role of the ionic interactions as the main 
cohesive forces operating in the particles was evidenced by appraising 
the effect that the ionic strength exerts on their stability. In fact, 
decomposition of the complex with subsequent liberation of DOX to the 
medium took place in particles suspended in NaCl aqueous solution as 
soon as the salt concentration came up around 0.1M (Figure 7.7). 
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Figure 7.6. Schematic model of the interaction mechanisms operating in the 
PMLA/DOX particle formation and drug loading and release. 
 
The surface charge of the particles, reflected by their ζ potential, 
had approximately the same negative value for the three complexes 
confirming the outer location of the non-coupled carboxylic groups 
(Table 7.3). These values are significantly lower than that reported for 
neat PMLA.167 Although positively charged particles are preferred for 
cell uptake, it is known that negative particles are also able to undergo 
endocytosis by adsorption at the positively charge cell sites.168 In fact a 
combination of factors including size, shape and surface chemistry is 
actually governing cellular uptake. Regarding the zeta potential, it is 
accepted that particles may be internalized if values of ζ are within the 
range of tens of -mV and + mV.169 
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Table 7.3. PMLA/DOX ionic complex particles characterization.
Particles State
Sizea
(nm) Pd.I.
b
ζ potential 
(mV)
PMLA Solution -22.9 ± 1.7
PMLA/DOX-(10:1) micro Suspension 1613 0.544 -26.0 ± 5.1
PMLA/DOX-(4:1) micro Suspension 1496 0.447 -28.0 ± 4.8
PMLA/DOX-(2:1) nano Aggregate/Precipitation 150 0.114 -26.9 ± 4.0
a Hydrodynamical average diameter.
b Polydispersity index of particle size.
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Figure 7.7. Normalized absorbance of DOX released from PMLA/DOX complexes as 
a function of NaCl concentration. 
 
7.3.4. Hydrolytic degradation mechanism 
The hydrolytic degradation of the complexes was followed by 1H 
NMR analysis of the products released to the incubating medium (Figure 
7.8). The supernatant of PMLA/DOX-(10:1) incubated at pH 7.4 and      
37 ºC showed signals arising from the methylene groups of PMLA after 3 
days of incubation which are attributed to the presence of partially 
solubilized large size oligomers. The presence of short oligomers was 
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later evidenced by the appearance of a signal at 2.90 ppm arising from 
the β-CH2 of the PMLA end-chain unit. The intensity of this signal 
increased continuously along the two first weeks of incubation to be 
finally replaced by the 2.70 ppm methylene signal from free malic acid. 
Weak signals characteristic of DOX were detected from the third day of 
incubation (Figure 7.8a) but their intensity remained essentially 
unchanged due to the instability of this compound in the incubating 
medium. In fact it has been reported that DOX in aged aqueous solution 
tends to form clusters with water included between the stacked aromatic 
sheets which are excluded from solution in form of gel.170,171 We have 
experimentally checked this behavior by NMR and results have been 
included in the Annex section as Figure A2.3. The NMR analysis of 
PMLA/DOX-(2:1) incubated under similar conditions afforded the same 
signal changing pattern but with lower peak intensity and a delay of one 
week in the appearance of new signals, in agreement with what should 
be expected from its lower content in non-complexed PMLA residues.  
The 1H NMR spectra recorded from the incubation medium at pH 
5.0 were more difficult to analyze due to the fact that the signals of the 
citric acid used for pH buffering overlapped with the methylene signals 
of the free malic acid and terminal malate units. Nevertheless, a close 
inspection of the spectra shown in Figure 7.8b revealed that they 
followed an evolution pattern similar to that observed at pH 7.4 but at a 
higher rate. Degradation of PMLA/DOX-(10:1) at pH 5.0 clearly showed 
signals from terminal β-CH2 of the PMLA chain after 3 days of 
incubation, and at difference with what happened at pH 7.4, signals 
arising from the CH end groups were also detected at this time (Figure 
7.8b). 1H NMR spectra recorded at different pH for PMLA/DOX-(2:1) 
showed slighter differences than for PMLA/DOX-(10:1). Although less 
soluble products and a lower rate of disappearance of the main chain 
signals were observed in this case, DOX signals started to be observed 
for both complexes at the third day of incubation. 
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Figure 7.8. 1H NMR spectra of the degradation media of ionic complexes 
PMLA/DOX-(10:1) and PMLA/DOX-(2:1) at different pHs: a) 7.4 and b) 5.0. D = 
DOX, * solvent traces.  
 
7.3.5. In vitro drug release 
It is known that pH and ionic strength play a key role in the 
liberation of drugs that are immobilized to a polymer matrix by ionic 
coupling interactions. Drug release from PMLA/DOX complexes was 
assessed as a function of releasing media conditions concerning pH and 
ionic strength. The physiological pH 5.0 and 7.4 were assayed; pH 5 
emulates inside mature lysosome environment whereas pH 7.4 imitates 
plasma conditions. The cumulative DOX releasing profiles observed for 
the three studied complexes as a function of time are comparatively 
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plotted in Figure 7.9a for the two assayed pH values. DOX release 
appeared to be markedly pH dependent since at pH 5 the delivery rate 
was four times faster than at pH 7.4 regardless complex composition. In 
fact, the cumulative amount of DOX released after 25 days of incubation 
at pH 5 was 35-40 % of the initial load whereas at pH 7.4 it hardly 
reached 15 %. Furthermore, the cumulative release at pH 7.4 tends to a 
stabilized on a plateau while at pH 5 the release rate was almost constant 
along the whole incubation time. A moderate burst is noticed at either 
pH and at any ionic strength. The small fraction of DOX initially 
delivered at high rate would be that located nearly the surface. The 
release of inner located drug will be somewhat depending on polymer 
degradation and its delivery rate is expected to decay. Both H-bonding 
PMLA/DOX interactions and π-π stacking DOX/DOX interactions 
would be responsible for the further delayed or even incomplete drug 
release observed in these complexes.  
The pH dependence observed for the PMLA/DOX complexes is 
certainly a relevant result since drug release during blood transport 
would be prevented whereas drug discharge would take place at the 
target compartment where the pH is expected to be around 5.0. Tumor 
tissue has an extracellular pH of 6.5-7.2, slightly lower than the 7.4 value 
present in normal tissues, whereas inside the lysosomes, where the 
microparticles would access via phagocytosis, the pH is 4.5-5.0. 
Furthermore the hydrolytic enzymes therein present could enhance 
polymer degradation and therefore drug release. Since residence times of 
a few hours should be expected for a carrier in the blood stream, DOX 
losses from microparticles made of PMLA/DOX complexes are expected 
to be negligible during transport. This is a highly appreciated advantage 
for cytotoxic drugs like DOX, although only an efficient delivery at the 
site of action will allow to taking full benefit.103 
 
Chapter 7 
134 
 
0 10 20 30
0.0
0.1
0.2
0.3
0.4
0.5
 pH 5 - (10:1)
 pH 5 - (4:1)
 pH 5 - (2:1)
 pH 7.4 - (10:1)
 pH 7.4 - (4:1)
 pH 7.4 - (2:1)
C
um
m
ul
at
iv
e 
re
le
as
e 
(n
or
m
al
iz
ed
)
Days
a)
0 10 20 30
0.0
0.1
0.2
  75 mM - (10:1)
150 mM - (10:1)
300 mM - (10:1)
  75 mM - (4:1)
150 mM - (4:1)
300 mM - (4:1)
  75 mM - (2:1)
150 mM - (2:1)
300 mM - (2:1)
C
um
m
ul
at
iv
e 
re
le
as
e 
(n
or
m
al
iz
ed
)
Days
b)
 
Figure 7.9. Doxorubicin release from PMLA/DOX ionic complexes as a function of 
pH (a) and ionic strength at pH 7.4 (b).  
 
Regarding compositions it was observed that release rate 
differences between complexes at pH 5 were small, whereas they were 
significant at pH 7.4. Apparently the DOX release rate is dependent on 
the complex composition provided that incubation is performed under 
neutral conditions. Probably such a different behavior is related to the 
effect of pH on degradation rate of PMLA. Also the effect of the ionic 
strength on DOX release was studied at pH 7.4 for I values of 75, 150 and 
300 mM (Figure 7.9b). A clearly enhancing effect of the ionic strength on 
the DOX release rate was observed for the three complexes, although in 
not so much extent as for pH changes. The maximum release rate 
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observed at pH 7.4 was for the PMLA/DOX (10:1) complex at 300 mM 
ionic strength; the drug accumulated in the incubation medium after 26 
days of residence was 17 % of the initial loaded amount. 
The release kinetics of DOX physically entrapped in nanoparticles 
made of PMLA derivatives has been recently studied.150,153 DOX release 
rates at pH 7.4 from PMLA/DOX complexes measured in this work are 
proven to be up to three times slower than the release reported for 
physical entrapped DOX (Table 7.4). On the other hand, in the work of 
Manocha et al. on the ionic complex made of poly(γ-glutamic acid) and 
DOX,103 the release of the drug was reported to take place initially 
following a profile similar to that reported for physically entrapped 
systems but reaching a plateau at the end of the incubation period. This 
is according to expectations since release of the physically entrapped 
drug is mainly depending on diffusion/degradation factors whereas the 
releasing from ionically coupled systems, as it is the case of 
polyacid/DOX complexes, is largely determined by the environment 
conditions required to cleave the ionic link between the drug and the 
polymer. 
Table 7.4. Comparative of DOX release by different PMLA-based delivery systems.
Method of 
encapsulation
DOX content 
(w/w %)
Release at  
24 / 240 h (%)
Reference
PMLA/DOX (10:1) Simple mix -
precipitation
29.7 ± 2.4 2.7 / 8.3 This work
PMLA/DOX (4:1) Simple mix -
precipitation
107.6 ± 1.9 2.1 / 7.1 This work
PMLA/DOX (2:1) Simple mix -
precipitation
234.0 ± 3.1 2.0 / 5.4 This work
PGGA Simple mix -
precipitation
99.0 ± 0.06 8.5 / ~18 Manocha et al., 20102
PAALM-1 Emulsion - solvent 
evaporation
4.2 ± 0.6 14.3 / 27.4 Lanz et al., 20119
PAALM-L60 Precipitation -
dialysis
8.5 ± 1.2 5.2 / 30.2 Lanz et al., 201219
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7.4. Conclusions 
Result presented in this work show that the biopolymer PMLA can 
be used as a carrier for targeted delivery of DOX, a hydrophobic drug 
widely used in cancer therapy. In aqueous solution ionized PMLA 
interacted efficiently with DOX to form stable ionic complexes. The 
complexes tend to self-assemble in micro or nanospheres according to 
their polymer/drug ratio. These particles underwent hydrolysis at a rate 
that was dependent on pH and complex composition. The ability of 
PMLA/DOX complex particles to operate as a pH-sensitive drug 
delivery system has been evidenced. The DOX release rate from the 
complexes was enhanced by decreasing pH and, in less degree, by 
increasing the ionic strength of the medium. Furthermore the release rate 
could be modulated by adjusting the composition of the complexes. It 
can be concluded therefore that PMLA/DOX complexes afford a good 
potential for drug delivery in cancer therapy. 
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Modification of Microbial Polyglutamic and 
Polymalic Acids Via Click Chemistry:     
Nanoparticle Formation and Drug Encapsulation 
  
 
Aim and Scope  
Advances in drug delivery systems and in the understanding of cellular 
and molecular biology have provoked an increasing need for new materials with 
better defined structures or functionalities; however, the preparation of such 
materials imposes major synthetic challenges. 
Click chemistry provides alternatives to conventional strategies used for 
post-polymerization modification; a two step functionalization of PMLA is 
possible under the mild conditions used in modern click conjugation strategies. 
Thiol-ene chemistry is a metal catalyst-free approach, and has been 
demonstrated to be a powerful and versatile method for site specific 
functionalization. 
In this section, we studied aliphatic long chains grafting through thiol-
ene click reactions, in order to obtain aliphatic comb-like polymers for 
nanoparticle formation and drugs encapsulation; as a first approach to a 
multifunctional modification. 
Modification of microbial polymers by click reaction 
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Abstract 
Comb-like polymers were obtained by esterification of the 
carboxylic side groups of microbial poly(β,L-malic acid) (PMLA) and 
poly(γ,DL-glutamic acid) (PGGA) by grafting aliphatic long chains 
trough a two steps method involving UV-initiated thiol-ene click 
reactions. Amphiphilic derivatives were capable to form self-assembled 
nanoparticles in the range of 80-240 nm of diameter. Incubation under 
physiological conditions leads to the hydrolysis of the polymers, by the 
cleavage of the lateral ester bonds and later scission of the main 
polyester or polyamide chain. The model drugs, Theophylline and 
Carbamazepine were encapsulated with efficiencies up to 38.0 % with 
much better results for the later. Drug release from nanoparticles 
incubated under physiological conditions occurred with a burst effect 
and complete discharge of the drug in 24 h. Release profiles from drug-
loaded films suggest that drug release is driven by a diffusion process. 
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8.1. Introduction 
Biodegradable polymers are currently of great interest for their use 
in temporal biomedical applications like chirurgical sutures and drug 
delivery systems. Among them, biopolymers of natural occurrence, or 
biotechnologically produced polymers stand out because they must be 
bioassimilable and biocompatible since they are produced from 
bioorganic molecules.80,141,172  Polyamides and polyesters, like poly(γ-
glutamic acid) (PGGA) and poly(β,L-malic acid) (PMLA) respectively, 
are produced by fermentation with bacteria and fungi, respectively, and 
are excellent candidates as biodegradable materials for medical 
applications. 
PGGA is one of the three poly(amino acid)s present in nature that 
can be produced by several species of bacteria of the genus Bacillus, 
classified as GRAS (Generally Regarded As Safe) by the US Food and 
Drug Administration.88 PGGA is a water-soluble polyamide that 
degrades into glutamic acid which is an essential substance to 
humans.82,173 The outstanding biodegradability and biocompatibility of 
poly(amino acid)s have attracted considerable attention and have made 
them object of much attention for their potential utilization in the fields 
of drug delivery system (DDS), tissue engineering, and other biomedical 
applications.174,175 PGGA and its derivatives are considered promising 
materials that distinguish by being able to display functional properties 
due to the presence of the carboxylic side group attached to the 
polyamide main chain. 
PMLA is naturally produced by myxomicetes and filamentous 
fungi. It is a water soluble polyester very prone to undergo hydrolysis.24 
PMLA is also a promising building block for the design of efficient drug 
delivery systems because its excellent biodegradability and 
biocompatibility and because its degradation produces easily 
metabolized L-malic acid.26 PMLA and its derivatives have been used as 
platform in the synthesis of nanocarriers for drug delivery18,48,53,56 or as a 
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constituent in macromolecular conjugates bearing several functionalities 
to treat human brain and breast tumors in mouse models.50,176  
Nowadays, biodegradation and bioresorption of any high 
molecular weight material for biomedical applications is considered as a 
prerequisite for its use in human therapy.18 This has stimulated the 
modification of naturally occurring biopolymers and the development of 
new synthetic ones.20,21 Both PGGA and PMLA bear pendant carboxylic 
groups which make their derivatization feasible for the modulation of 
polymer hydrophobicity and properties 51,77 and for the introduction of 
bioactive ligands required for the stable association with drugs and 
proper release.78,167  
The concept of postpolymerization functionalization strategies 
introduces techniques based on click chemistry.104 Click chemistry 
embraces a number of simple, modular, and highly specific chemical 
reactions featuring high yields under mild conditions.111 In this context, 
thiol-ene chemistry has most of the attributes of click chemistry. 
Furthermore, it is a metal catalyst-free approach that has been proved to 
be in both, its radical and base/nucleophilic forms, a powerful and 
versatile method for site specific functionalization as well as a 
conjugation tool convenient for a wide range of applications, including 
polymer functionalization, dendrimer synthesis and 
nanoimprinting.107,177 There are several features associated with the thiol-
ene reaction that makes it particularly attractive, facile and versatile 
process; i) it results in a stable linkage, ii) it exhibits minimal cross-
reactivity with other functional groups, iii) reaction arrives close to 
completion, iv) resulting products are free of appreciable amounts of 
impurities and v) it proceeds under mild conditions.108  
In this work we take benefit from the functionality of PGGA and 
PMLA for the construction of amphiphilic comb-like polymers for their 
application as DDS. Amphiphilic block or graft copolymers consisting of 
hydrophilic and hydrophobic segments are capable of self-assembling in 
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aqueous solutions to form micro or nanoparticles.53,86 DDS based on 
polymer particles are clearly advantageous because: a) particle size and 
surface can be engineered to achieve passive or active drug targeting, b) 
drugs can be incorporated without chemical reaction, c) drug activity is 
optimally preserved during its transportation to the site of action, d) site-
specific targeting can be achieved by attaching targeting ligands, e) 
formulation can be delivered trough different routes of administration 
and f) controlled drug release can be achieved.2,80,116,117  
We present a two-step modification of PGGA and PMLA as a first 
approach for PGGA and PMLA functionalization through thiol-ene 
reactions. In the first step the allyl group is introduced by direct 
esterification, which leads to a double-bond functionalized polymer with 
potential for orthogonal, specific and multifunctional modification.178 In 
the second step aliphatic long chains are grafted in order to obtain the 
comb-like architecture required for nanoparticle formation and drug 
encapsulation. Drugs used for encapsulation and drug delivery assays 
were Theophylline and Carbamazepine which are considered as 
hydrophilic and hydrophobic drug models, respectively. 
 
8.2. Experimental 
8.2.1. Esterification reactions 
Esterification of PGGA with allyl bromide was carried out 
following the procedure described elsewhere for esterification of PGGA 
with alkyl-bromides.179 Briefly, NaHCO3 (525 mg) was added to a 
solution of 200 mg of PGGA in 20 mL of N-methylpyrrolidone (NMP) 
heated at 60 °C. Allyl bromide was slowly added in the necessary 
amount to reach the desired conversion. The reaction was left to proceed 
for 48 h and the esterified polymer was recovered by precipitation in 
diethyl ether, washed with acetone, and dried in vacuum for storage. 
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Esterification of PMLA with allyl alcohol was performed through 
activation of the carboxyl side group with DCC. Briefly, a mixture of 0.5 
or 0.75 mmol of DCC in 2 mL of allyl alcohol was added dropwise to a 
solution of 1 mmol of PMLA in 2 mL of allyl alcohol; the reaction was 
left to proceed for 3 h at room temperature under magnetic stirring. The 
final reaction mixture was subjected to dialysis against methanol for 48 h 
using an 8 kDa cut-off membrane. The allyl ester of PMLA was 
lyophilized for recovery and storage.  
 
8.2.2. Thiol-ene click reactions  
The 3-alkylthio-propyl PGGA and PMLA esters were prepared as 
follows:  To a 7.5 % (w/v) solution in NMP, at room temperature, of the 
allyl PGGA ester the corresponding 1-alkanothiol (1-octanethiol, 1-
dodecanethiol and 1-hexadecanethiol) was added in a 2:1 molar ratio 
respect to  double bond concentration, and then DMPA (4% respect to 
double bond) was added. The reaction mixture was placed under UV 
radiation (2 x Philips PL-S 11 W/10, 360 nm) and was irradiated for 24 h 
to reaction completion, reaction was followed by 1H NMR; the grafted 
PGGA was recovered by pouring the reaction mixture into ethanol. The 
final product was dried in vacuum for storage. The same procedure was 
applied for the preparation of the PMLA derivatives but starting from a 
1.5 % (w/v) of the allyl PMLA ester in DMSO.  
 
8.3. Results and discussion 
8.3.1. Comb-like polymers synthesis 
Comb-like copolymers from PGGA and PMLA were obtained by a 
two-step process (Scheme 8.1). First, polymers were allylated in different 
degrees using specific procedures for PGGA and PMLA according to the 
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different susceptibility that their main chains display towards 
hydrolysis. PGGA was esterified with allyl bromide under middle-basic 
conditions whereas allyl alcohol was used for esterifying PMLA with the 
concourse of DCC as carboxylic side groups activator. Esterification was 
achieved with good yields, around 90 % for PGGA and above 75 % for 
PMLA derivatives (Table 8.1).  
The resulting allylated copolymers were spectroscopycally pure as 
it was proved by 1H NMR. In fact the occurrence of the allylation of the 
polyacids was clearly evidenced by following the changes taking place in 
the 1H NMR spectra. For PGGA the signal of the allylic CH2 appearing at 
4.1 ppm in allyl bromide (Figure 8.1b, signal e) shifted 0.5 ppm 
downfield in coPGGA-AlxHy (Figure 8.1c, signal e').  In the case of PMLA, 
a similar displacement was observed for the allylic CH2 signal which 
moved 0.7 ppm downfield when the allyl alcohol entered in the PMLA 
as alcohyl group (signal e in Figure 8.2b compared to signal e’ in Figure 
8.2c). Molecular weight increases proportional to the modification 
degree, while copolymers polydispersities had similar values (Table 8.1).  
Grafting of three linear alkanothiols containing 8 (Oc), 12 (doD) 
and 16 (hxD) carbons length, on allyl functionalized polymers, was 
successfully achieved taking advantage of the high reactivity and 
specificity of the thiol-ene click reaction. DMPA was chosen as 
photoiniciator and UV radiation as activator; the reaction is known to 
take place as a free radical reaction initiated by decomposition of DMPA 
and to proceed with propagation to terminate by radical chain 
transfer.180 Conversion degrees for all copolymers was practically 100% 
  
Modification of microbial polymers by click reaction 
 
144 
 
O
O
C
O
O
H
n
H
O
O
O
C
x
O
O
+
R
H
S
+
hv
,  
R
T
O
O
C
x
O
O
S
b1
)
b2
)
R
D
C
C
O
O
C
O
O
H
y
O
O
C
O
O
H
y
D
M
S
O
H N
C
O
O
H
n
H
O
H N
C
O
O
+
R
H
S
+
hv
,  
R
T
a2
)
N
aH
C
O
3
N
M
P,
 6
0 
ºC
N
M
P
O
a1
)
H N
C
O
O
H
y
O
O
x H N
C
O
O
H N
C
O
O
H
y
O
O
x S
R
R
 =
C
H
2
C
H
3
7
C
H
2
C
H
3
11
C
H
2
C
H
3
15
H N
C
O
O
H N
C
O
O
H
y
O
O
x
O
O
C
x
O
O
O
O
C
O
O
H
y
P
G
G
A
co
P
G
G
A
-A
l xH
y
co
P
G
G
A-
Al
xH
y
co
PG
G
A
-P
rS
R
xH
y
PM
LA
co
PM
LA
-A
l xH
y
co
PM
LA
-A
l xH
y
co
P
M
LA
-P
rS
R
xH
y
 Sc
h
em
e 
8.
1.
 T
w
o-
st
ep
 g
ra
ft
in
g 
of
 a
lip
ha
ti
c 
lo
ng
 c
ha
in
s 
in
to
: a
) P
G
G
A
 a
nd
 b
) P
M
L
A
. 
Chapter 8 
 
145 
 
Table 8.1. Step 1: reaction conditions, conversion degrees, yields and molecular 
weights obtained for the different polymers. 
 Feed
a 
 
Esterification 
% 
Yield 
% 
 Mwb Db 
PGGA - - -  30,000  
coPGGA-Al25H75 1 : 0.25 26 88  30,600 2.9 
coPGGA-Al50H50 1 : 0.50 55 96  37,900 2.3 
coPGGA-Al75H25 1 : 0.75 73 92  44,200 2.6 
       
PMLA - - -  25,000 1.2 
coPMLA-Al50H50 1 : 0.50 48 79  27,300 2.8 
coPMLA-Al75H25 1 : 0.75 73 75  33,500 3.0 
 
a Molar ratio of: a) polymer:allyl bromide for PGGA; and b) polymer:DCC for PMLA reactions. 
b Weight-average molecular weight and dispersity estimated by GPC. 
 
 
as it could be assessed by 1H NMR which showed that signals arising 
from the double bound (5-6 ppm) had fully disappeared after reaction 
(Figure 8.1d and 8.2d), indicating that the totality of allyl groups 
hadbeen converted. Nevertheless, reactions yields were relatively lower 
than for the first step, i.e. between 60 and 80 % for PGGA and around 45 
% for PMLA derivatives (Table 8.2). Material looses could be due in part 
to photodegradation taking place by the prolonged exposition of the 
polymer to UV radiation. Shorter exposition times were assayed but 
reaction did not reach completeness. This degradation is also reflected in 
the molecular weight of the grafted copolymers which were found to be 
slightly lower than for their respective allylated precursors. 
Nevertheless, Mw values obtained for the three alkylated derivatives for 
each copolymer composition were consistent with the length of the 
alkylthiol chain length grafted in each case (Table 8.2). 
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Table 8.2. Step 2: Results of the thiol-ene click reaction on allylated PGGA 
and PMLA.  
Polymer Conversion 
% 
Yield 
% 
 Mw Pd. 
coPGGA-PrSOc25H75 100 61  25,200 2.5 
coPGGA-PrSdoD25H75 100 62  27,800 2.6 
coPGGA-PrShxD25H75 100 78  30,600 2.8 
      
coPGGA-PrSOc50H50 100 67  29,000 2.9 
coPGGA-PrSdoD50H50 100 74  31,800 2.3 
coPGGA-PrShxD50H50 100 64  33,200 2.3 
      
coPGGA-PrSOc75H25 100 60  30,300 2.6 
coPGGA-PrSdoD75H25 100 79  33,700 2.8 
coPGGA-PrShxD75H25 100 76  35,300 3.0 
 
 
     
coPMLA-PrSOc50H50 100 49  31,000 2.1 
coPMLA-PrSdoD50H50 100 49  32,100 2.2 
coPMLA-PrShxD50H50 100 50  33,400 2.4 
      
coPMLA-PrSOc75H25 100 51  33,100 2.0 
coPMLA-PrSdoD75H25 100 47  36,300 2.4 
coPMLA-PrShxD75H25 100 56  38,700 2.8 
 
 
8.3.2. Thermal characterization 
A DSC calorimetric study  was carried out in order to appraise the 
crystalline character of the grafted copolymers since previous works on 
comb-like polyacids had shown that in these polymers long linear alkyl 
side chains are able to crystallize in a phase separated from the another 
one constituted by the main chain.77,181,182 As it is observed in Figures 8.3 
and 8.4, only copolymers bearing -SR side chains with 16 carbon atoms 
display endothermal peaks characteristic of melting, no matter what 
copolymer is concerned or what is the attained esterification 
degree.Melting temperatures are near to 55 °C for all the semicrystalline 
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polymers here examined, which is much expected value for the melting 
of a crystalline paraffinic phase made of the alkyl chains of sixteen 
carbon atoms. These results are consistent with what has been reported 
for poly(α-alkyl-γ-glutamate)s which were found to be able to crystallize 
for  alkyl chains containing at least 14 carbon atoms.77 It can be 
concluded therefore from these results that the sulphur atom is unable to 
enter in the paraffinic crystal lattice and therefore the propylthio group is 
rejected from the crystallized paraffinic phase to remain in a disordered 
interphase connecting the crystallized side chains and the polypeptide or 
polyester main chains.  
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Figure 8.3. DSC profiles (first heating) of  coPGGA-PrSRxHy.  
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Figure 8.4. DSC profiles (first heating) of  coPMLA-PrSRxHy. 
 
8.3.3. Nanoparticles formation and characterization 
Partial modification of the hydrophilic polyacids by alkylation 
resulted in amphiphilic macromolecules capable to form self-assembled 
nanostructures. To take advantage of this character, for nanoparticle 
formation the precipitation dialysis method was applied to modified 
polyacids. More or less spherical nanoparticles were obtained for 
coPGGA-PrSR50H50, coPGGA-PrSR75H25, coPMLA-PrSR50H50 and 
coPMLA-PrSR75H25 (Figure 8.5 and 8.6), whereas coPGGA-PrSR25H75 
were not capable to form nanoparticles under the tested conditions. 
Average hydrodynamical diameters of these particles oscillated from 80 
to 240 nm (Table 8.3), with smaller sizes obtained for PGGA derivatives. 
PGGA with 50% of free carboxylic groups, coPGGA-PrSR50H50, rendered 
smaller particles for longer grafted aliphatic chains. In the case of the 
PMLA series, larger particles were those prepared from derivative 
bearing side alkyl chains of intermediate length.  What it is common to 
all the series is that smallest particle sizes are invariably obtained for 
compounds in which the alkyl chains are crystallized if exception is 
made for the coPGGA-PrShxD75H25 where very close particle diameter 
were obtained for the three alkyl chain lengths.  
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Figure 8.5. SEM micrographs of modified PGGA nanoparticles: a) coPGGA-
PrSOc50H50, b) coPGGA-PrSdoD50H50, c) coPGGA-PrShxD50H50, d) coPGGA-
PrSOc75H25, e) coPGGA-PrSdoD75H25 and f) coPGGA-PrShxD75H25.  
 
 
Figure 8.6. SEM micrographs of modified PMLA nanoparticles: a) coPMLA-
PrSOc50H50, b) coPMLA-PrSdoD50H50, c) coPMLA-PrShxD50H50, d) coPMLA-
PrSOc75H25, e) coPMLA-PrSdoD75H25 and f) coPMLA-PrShxD75H25.  
 
Particle surface charge was estimated as the ζ-potential measured 
in distilled water; results are included in Table 8.3. As it was expected, 
all nanoparticles presented negative values due to the remaining free 
carboxylic units still present in all compounds from both PGGA and 
PMLA. On the basis of well-settled amphiphilic self-assembled particle  
  
Modification of microbial polymers by click reaction 
 
152 
 
 
T
ab
le
8.
3.
N
an
op
ar
tic
le
s
ch
ar
ac
te
ri
za
tio
n
of
th
e
di
ffe
re
nt
co
po
ly
m
er
s.
D
ru
g
co
nt
en
t
an
d
en
ca
ps
ul
at
io
n
ef
fi
ci
en
cy
ar
e
pr
es
en
te
d
fo
rC
ar
ba
m
az
ep
in
e
an
d
Th
eo
ph
yl
li
ne
.
C
B
Z
T
E
O
S
iz
e
(n
m
)
P
d
.I
.a
ζ-
p
ot
(m
V
)
C
on
t.
(%
)
E
.E
.
(%
)
C
on
t.
(%
)
E
E
(%
)
co
PG
G
A
-P
rS
O
c 5
0H
50
19
4
0.
40
8
-3
0.
2
3.
18
15
.9
0.
54
2.
7
co
PG
G
A
-P
rS
d
oD
50
H
50
15
7
0.
29
4
-3
3.
5
4.
15
20
.7
0.
65
3.
2
co
PG
G
A
-P
rS
hx
D
50
H
50
76
0.
15
5
-3
2.
1
7.
68
38
.4
1.
74
8.
7
co
PG
G
A
-P
rS
O
c 7
5H
25
13
8
0.
15
7
-2
9.
9
5.
36
26
.8
2.
70
13
.5
co
PG
G
A
-P
rS
d
oD
75
H
25
13
5
0.
16
0
-2
8.
4
3.
38
16
.9
1.
99
9.
9
co
PG
G
A
-P
rS
hx
D
75
H
25
14
4
0.
20
3
-2
8.
5
1.
85
9.
2
1.
61
8.
0
co
PM
L
A
-P
rS
O
c 5
0H
50
19
7
0.
38
3
-4
0.
6
5.
8
29
.0
4.
1
20
.5
co
PM
L
A
-P
rS
d
oD
50
H
50
23
6
0.
54
4
-3
2.
3
6.
4
32
.0
3.
8
19
.0
co
PM
L
A
-P
rS
hx
D
50
H
50
17
0
0.
33
5
-2
9.
0
6.
9
34
.5
2.
8
13
.9
co
PM
L
A
-P
rS
O
c 7
5H
25
20
6
0.
34
3
-3
5.
3
5.
9
29
.5
1.
7
8.
5
co
PM
L
A
-P
rS
d
oD
75
H
25
23
9
0.
48
6
-2
4.
8
5.
7
28
.5
1.
1
5.
5
co
PM
L
A
-P
rS
hx
D
75
H
25
15
1
0.
34
8
-1
2.
7
4.
9
24
.5
1.
4
7.
0
a
D
is
p
er
si
ty
in
d
ex
of
p
ar
tic
le
si
ze
s.
 
 
Chapter 8 
 
153 
 
structure concept it can be reasonably assumed that the carboxylic 
grafted chains are hidden in the inner part to form a core-shell structure. 
The trend observed for the ζ-potential values along the series and even 
within each series deserves comments. In first place it must be remarked 
that higher values and differences observed for the PMLA derivatives 
can be due to the greater ability of the more flexible polymalate chain to 
be sterically accommodated in the particle as a response to environment 
interactions. When different conversions are compared the negative 
charge decreases with increasing conversion degree, which is in 
accordance with what should be expected for the variation in the 
negative hydrophilic/neutral hydrophobic ratio. Lastly it is also 
remarkable that in PMLA derivatives the minimum ζ-potential values 
correspond to compositions in which the alkyl side chains are 
crystallized.  
 
8.3.4. Hydrolytic degradation 
The hydrolytic degradation of the nanoparticles was examined 
upon incubation under physiological conditions, pH 7.4 and 37 °C 
(Figure 8.7). Degradation rate was determined by following the 
molecular weight reduction as a function of incubation time. As it was 
expected the susceptibility of nanoparticles to hydrolysis decreased for 
higher conversion degrees and longer alkyl side chain lengths. Both 
factors, modification degree and lateral chain length, are directly related 
to the material hydrophobicity, and therefore with the sensitiveness to 
hydrolysis of the copolymers. PMLA copolymer derivatives displayed a 
much higher rate of hydrolysis than those of PGGA because the higher 
lability of the main chain ester bond compared to the amide bond of 
PGGA. The degradation profiles depicted in Figure 8.7 show that after 12 
weeks of incubation coPGGA-PrSOc50H50 retained about 60 % of its 
original molecular weight, while coPGGA-PrShxD50H50 remained above 
80 %. Conversely, in PMLA derivatives, the coPMLA-PrSOc50H50 
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molecular weight fell down to 35 % of its original value while for 
coPMLA-PrShxD50H50 it remained above 70 %. Polymers with 75 % of 
their units modified, hydrolytic degradation is slight, only coPGGA-
PrSOc75H25 and coPMLA-PrSOc75H25 showed a considerable molecular 
weight reduction, nevertheless those with longer side chains left over 
more than 90 % of the original molecular weight. 
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Figure 8.7. Evolution of the molecular weight of copolymers incubated under 
physiological conditions a) coPGGA-PrSRxHy and b) coPMLA-PrSRxHy. 
 
Hydrolytic degradation mechanism was studied with the support 
of 1H NMR analysis of the soluble products released to the aqueous 
medium upon incubation. According to the results found in the 
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degradation rate assays, copolymers modified at lower conversion 
degrees with shorter alkyl side chains degraded considerably faster and 
PGGA series were more resistant than the PMLA ones. Nevertheless the 
degradation mechanism seems to be common to all of them. Since 
coPGGA-PrSOc50H50 and coPMLA-PrSOc50H50 are the most degraded 
samples and their degradation products are water-soluble, they were 
chosen to describe the degradation mechanism operating in the PGGA 
and PMLA copolyesters series, respectively. 
In the degradation of coPGGA-PrSOc50H50, first observable signals 
appeared after one month of incubation. They were assigned to protons 
attached to the main chain carbons of glutamyl residues and to the 
protons contained in the alkylthioalkanol chains indicating the 
hydrolysis of the side ester group with the subsequent solubilization of 
fragments enriched in free carboxylic groups. In the second month of 
degradation, signals from the polymer terminal groups became 
observable, revealing that hydrolysis of the amide bonds from the main 
chain has started. From the third month ahead, signals got intensified, 
and those from the main chain displayed much better resolution. The 
progressive degradation of the main chain was evidenced by a clear 
increase of terminal groups signals. The occurrence of free glutamic acid 
in the aqueous medium could not be ascertained because its signals, if 
present, overlapped with those arising from both polymer and oligomer 
species (Figure 8.8).  
For PMLA derivatives the mechanism was found to be similar 
although degradation happened in shorter time. In this case, first signals 
appearing just after one week of incubation corresponded to the protons 
of free malic acid together with those arising from the hydrolyzed lateral 
chain, indicating that hydrolysis of ester groups, both the  main chain 
and the side chain, took place at the same time. Along the two first 
months of incubation no signals corresponding to terminal groups or to 
main chain methylene units were observed, this confirms that until the 
side chain hydrolysis occur, the copolymers are insoluble, then the fast 
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monomer PMLA cleavage occurs. Spectras became simplified and 
intensified with time so at the end of the incubation period, the only 
visible signals were those arising from free malic acid and the 
alkylthioalkanol (Figure 8.9).  
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Figure 8.8. Evolution of the 1H NMR spectrum taking from the aqueous medium of 
incubated coPGGA-PrSOc50H50 nanoparticles along time. 
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Figure 8.9. Evolution of the 1H NMR spectrum taking from the aqueous medium of 
incubated coPMLA-PrSOc50H50 nanoparticles along time. 
 
8.3.5. Drug encapsulation and in vitro release 
Encapsulated compounds were Carbamazepine (CBZ) and 
Theophylline (TEO); both of them used as models for hydrophobic and 
hydrophilic drugs, respectively, for encapsulation and releasing studies. 
The encapsulation method applied in this work made use of the 
precipitation dialysis method used for nanoparticle formation. The drug 
was added to the polymer solution prior to nanoparticle formation. 
Results are summarized in Table 8.3. CBZ appeared to be able to be 
encapsulated better than TEO displaying maximum encapsulation 
efficiency (EE) in coPMLA-PrShxD50H50 nanoparticles with 34 % of EE 
compared to only 20 % for TEO, while TEO only reaches 20 % with the 
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most hydrophilic polymer of all, coPMLA-PrSOc50H50. The low 
encapsulation efficiency of TEO may be because, during dialysis, drug 
losses are greater than in the case of CBZ due to their hydrophilicity. 
In vitro drug release assays were carried out under physiological 
conditions, pH 7.4 and 37 °C. Both drugs presented a burst release 
within the first hours of incubation, a fact that was accentuated for 
encapsulated TEO nanoparticles, which released between 60 and 80 % of 
the loaded drug in the first two hours of incubation.  On the contrary, 
CBZ loaded nanoparticles showed a more controlled release, with a 40 to 
60 % release of the loaded drug after 6 hours of incubation (Figure 8.10). 
Since nanoparticles of the same polymer are being compared it can be 
inferred that differences in drug release are largely determined by the 
hydrophobicity of the encapsulated compound. Given the obtained 
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Figure 8.10. Drug release profiles for coPMLA-PrSRxHy (top) and coPGGA-PrSRxHy 
(bottom) nanoparticles incubated under physiological conditions and loaded with 
Carbamazepine (a, a’) and Theophyline (b, b’). 
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encapsulation efficiency for CBZ and the more sustained release of this 
drug, it can be concluded that the derivatives examined in this work as 
well as the applied encapsulation method are more suitable for the 
design of DDS systems loaded with hydrophobic drugs.   
To understand the process that is behind the drug release from the 
nanoparticles CBZ loaded-films of both PGGA and PMLA copolymers 
were prepared and subjected to release assays. Films were analyzed by 
DSC and compared to the pure polymer and the physical blend to get 
insight of the state in which CBZ is in the film. The DSC trace of CBZ  
showed a characteristic melting peak around 180-190 °C, which it is also 
present in the traces from the physical blends but absent in the traces of 
the drug-loaded film, suggesting that the drug is well dispersed in the 
polymeric matrix (Figure 8.11). Although the release of the drug from the 
film took place at slower rates than for nanoparticles it was almost 
completely liberated in the first two days (Figure 8.12). It can be 
concluded therefore that drug release of CBZ from these materials is 
governed by a diffusion process since the degradation of the copolymers 
take place in much longer periods of time. Release rates were found to be 
faster for films made of copolymers with lower modification degrees and 
those modified with shorter aliphatic chains. Again drug release has to 
be related to the hydrophobicity of the material and the water 
penetration capability. Given the similitude of behavior with that 
observed for nanoparticles, the same diffusion process must govern drug 
release in both systems.  
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Figure 8.11. DSC traces of CBZ and a) polymer, b) physical blend polymer + CBZ and 
c) CBZ -loaded film. Top: coPGGA-PrSRxHy and bottom: coPMLA-PrSRxHy. 
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Figure 8.12. Carbamazapine release from drug-loaded films. a) coPMLA-PrSRxHy and 
b) coPGGA-PrSRxHy. 
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8.4. Conclusions 
Microbial polymalic and polyglutamic acids were modified by 
grafting aliphatic long chains through a two step process that makes use 
of thiol-ene click reactions. The prepared biodegradable polymers 
presented an amphiphilic character which drives their self-assembling in 
aqueous media into nanostructurated particles capable of drug 
encapsulation and suitable as drug delivery systems. Nanoparticles 
varied in size from 80 to 240 nm, the smaller ones being those prepared 
from PGGA derivatives. Hydrolytic degradation was found to be faster 
for PMLA than for PGGA derivatives as correspond to expected 
differences between polyesters and polyamides. Degradation happened 
by releasing the corresponding thioether alcohol and either malic or 
glutamic acid to the medium upon degradation. Model drugs TEO and 
CBZ were encapsulated in polymer nanoparticles with better efficiency 
for the hydrophobic drug CBZ than for the hydrophilic TEO. Both drugs 
were released upon incubation at pH 7.4 and 37 °C; with a burst release 
taking place in the first few hours and with almost complete release in 24 
h. The CBZ release profile obtained from drug-loaded films suggested 
that the drug is liberated through a mediated-diffusion process. 
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General Conclusions 
 
  
i. The biotechnological polymer poly(β,L-malic acid) (PMLA) was 
successfully modified, by direct esterification or amidation of its 
pendant carboxylic groups, under soft conditions without 
significant degradation. At the same time, PMLA and poly(γ-
glutamic acid) (PGGA) derivatization through click reaction was 
possible, opening a new window for orthogonal modification of 
PMLA and PGGA. Polymer modification led to a series of 
derivatives which showed significant changes in the original 
physicochemical properties. 
ii. PMLA esterification and amidation with organic compounds 
resulted in hydrophobic or amphiphilic polymers, depending on 
the attained conversion, which were capable of forming 
nanoparticles suitable for drug encapsulation and controlled 
release, either by emulsion solvent evaporation or precipitation 
dialysis techniques. Nanoparticles size varied between 70 to 350 
nm, smaller size being obtained for those prepared by 
precipitation dialysis.  
iii. Hydrolytic degradation of all esterified derivatives happened by 
hydrolysis of the lateral ester group followed by the  scission  of 
the main chain hidrolizable bonds, with subsequent release to the 
degradation medium of the grafted molecule and easily 
metabolizable malic acid or glutamic acid, as unique final 
products. Degradation occurred in a time scale of weeks, at a rate 
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that depended on the modification degree and on the 
hydrophobic character of the grafted molecules. Hydrolytic 
degradation was found to be faster for PMLA than for PGGA 
derivatives as correspond to expected differences between 
polyesters and polyamides. Furthermore, the presence of 
emulsifier on particles surface acted as a hydrolysis protecting 
coat.  
iv. Temozolomide (TMZ) and Doxorubicin (DOX) were 
encapsulated in modified PMLA by different methods.  Better 
efficiency was obtained for emulsion solvent evaporation over 
precipitation dialysis technique. However, the ionic coupling of 
DOX with pristine PMLA showed to be a highly effective and 
simple method for DOX loading, since ionized PMLA interacted 
efficiently with DOX to form stable ionic complexes. 
v. DOX and TMZ were encapsulated in PMLA derivatives 
nanoparticles and were released upon incubation under 
physiological conditions. TMZ encapsulation afforded protection 
to the drug against hydrolytic decomposition.  Release of TMZ 
took place within a few hours with subsequent hydrolytic pH-
dependent activation. DOX was released in a time scale of days, 
the delay thought to be caused by the intermolecular interactions 
of the drug with the unmodified carboxylic groups of the 
polymer as well as with other DOX molecules. 
vi. PMLA and DOX formed stable complexes which tend to self-
assemble in microparticles or nanoparticles according to their 
polymer/drug ratio. DOX release from these complexes resulted 
to be pH dependent, and in less degree, ionic strength reliant. 
This characteristic is of particular interest and can be used for site 
controlled drug delivery.  
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vii. Theophylline (THEO) and Carbamazepine (CBZ) were 
encapsulated in partially esterified PMLA and PGGA by 
precipitation dialysis method, with higher efficiency for the 
hydrophobic CBZ. The fast release from drug loaded 
nanoparticles and films made of long aliphatic chains PMLA and 
PGGA derivatives suggested the occurrence of a diffusion driven 
releasing process. 
viii. PMLA methyl derivative resulted in some cytotoxicity at long 
time exposure to cells from released methanol resulting from 
polymer degradation. Cellular toxicity of this derivative was 
overcome by the use of ethyl, butyl and aminoacyl coupled 
PMLA. Amino acids derivatives did not show sign of toxicity 
during 24 hours of administration provided that the 
concentration of nanoparticles was kept below 0.125 mg·mL-1 in 
the culture medium. 
ix. Drug-unloaded nanoparticles made of PMLA-Et and PMLA-Bu 
derivatives, were not cytotoxic for the tested cancer cell lines, 
whereas drug-loaded nanoparticles were toxic for the same cell 
lines. For MDA MB468 cells, TMZ loaded particles were highly 
efficient, while free TMZ did not show any relevant effect. 
Furthermore DOX loaded in nanoparticles made of copolymer 
coPMLA-Et50H50  showed better internalization by cells than free 
DOX.  
x. New comb–like polymers obtained through functionalization of 
pendant carboxylic groups of PMLA and PGGA, were able to be 
mildly elaborated using thiol-ene UV-mediated click reaction; 
demonstrating the applicability of a versatile technique for 
orthogonal and multifunctional modification of microbial 
polymers for the design of biodegradable drug delivery systems. 
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xi. The relative easy modification procedures, the degradability of 
the derivatives obtained, their capability to form nanoparticles 
and to encapsulate drugs, the low toxicity to cells and good 
response of cells to drug-loaded nanoparticles make 
biotechnological PMLA derivatives attractive materials for the 
design and development of biodegradable drug delivery 
systems, in particular with potential for the therapy of some 
diseases considered today challenging to pharmacological 
treatment. 
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Appendix 1 
Chapter 5 Support Information: 
Nanoparticles of Esterified Polymalic Acid for  
Controlled Anticancer Drug Release 
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Figure A1.1. 1H NMR spectrum of PMLA-Et100.    
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Figure A1.2. 1H NMR spectrum of of PMLA-Bu100.   
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Figure A1.3. 1H NMR spectrum of coPMLA-Et50H50. (*) DMSO and water solvent 
peaks.  
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Figure A1.4. 1H NMR spectrum of coPMLA-Bu50H50. (*) DMSO and water solvent 
peaks. 
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Figure A1.5. Deconvoluted GPC chromatograms of coPMLA-Et50H50  and coPMLA-
Bu50H50 after incubation  in aqueous buffer at pH 7.4 and 5.0 for the indicated times. 
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Figure A1.6. 1H NMR spectra of the degradation products over time for PMLA-Bu100. 
(*) impurity. 
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Figure A1.7. 1H NMR spectra of the degradation products over time for coPMLA-
Bu50H50.  
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Figure A1.8. Particle size distributions measured by light scattering, 
distributions based on intensity of PMLA esterified derivatives. 
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Appendix 2 
Chapter 7 Support Information: 
Poly(β,L-Malic Acid)/Doxorubicin Ionic Complex:  
a pH-Dependent Delivery System 
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Figure A2.2. FTIR spectra of malic acid, DOX and the residue recovery from evaporation of 
the aqueous solution of an equimolar mixture of the two compounds.  
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Figure A2.3. Evolution of 1H NMR signals of DOX incubated in phosphate buffer pH 7.4 
along time. 
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Figure A2.4. Figure 7.9a of the manuscript plotted at the same ordinate scale than Figure 7.9b 
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